

BMJ Open

Statin use and risk of liver cancer: an update meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005399
Article Type:	Research
Date Submitted by the Author:	04-Apr-2014
Complete List of Authors:	Shi, Meng; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Zheng, Huiling; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Gong, Wei; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Cui, Xiaobing; Nanfang Hospital, Southern Medical University, Department of Gastroenterology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Oncology
Keywords:	Gastrointestinal tumours < GASTROENTEROLOGY, Epidemiology < ONCOLOGY, Hepatobiliary tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

Peer Review Only

Statin use and risk of liver cancer: an update meta-analysis

Meng Shi¹, Huiling Zheng¹, Wei Gong¹ and Xiaobing Cui*

¹Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Avenue North, Guangzhou 510515, China

***Corresponding author:** Dr. Xiaobing Cui, Tel.: +86 13631312723, Fax: +86-20-87280770, E-mail: xbing119@gmail.com.

Running title: Meta-analysis: statin and liver cancer

Key words: *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*

Abstract

Objective: Statins are commonly prescribed cholesterol-lowering drugs. Preclinical studies suggest that statins may possess cancer preventive properties. The primary objective of this meta-analysis was to determine the association between statin use and risk of liver cancer.

Design: Meta-analysis.

Setting: International.

Participants: A comprehensive literature search of PubMed, BIOSIS Previews, Web of Science, EMBASE, and EBSCO was conducted through March 2014. The effect estimate was reported as pooled relative risk (RR) with 95% confidence intervals (CIs), using the random-effects model. The test of heterogeneity, publication bias and subgroup analyses were also performed.

Results: A total of 14 (3 RCT, 5 cohort, and 6 case-control) studies were qualified for the meta-analysis, involving 1,779,630 participants with 35,775 liver cancer cases. Our results indicated a significant risk reduction of liver cancer among all statin users ((RR 0.58, 95% CIs 0.51–0.67). The difference of study design, baseline risk and confounding adjustment can partly explained the significant heterogeneity found in the overall analysis ($I^2 = 59\%$, $P=0.002$). No evidence of publication bias was observed. Similar results were also found in the subgroup of lipophilic statin use (RR 0.57, 0.50–0.65; $I^2=40\%$, $P=0.13$) and higher cumulative dosage of statin use (RR 0.54, 0.38-0.77; $I^2=85\%$, $P<0.00001$).

Conclusions: This meta-analysis suggests that there is a significant inverse

1
2
3 association between statin use and risk of liver cancer, however, some confounders
4
5
6 might overestimate this preventive effect of statins.
7

8
9 **Key words:** *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*

10 11 **Strengths and limitations of this study**

12
13
14 Statins are commonly prescribed cholesterol-lowering drugs. In this comprehensive
15
16 meta-analysis, we demonstrate that the statin use is associated with a significant
17
18 reduction of liver cancer risk.
19

20
21 The difference of study design, baseline risk and confounding adjustment can partly
22
23 explained the significant heterogeneity found in the overall analysis.
24

25
26 Some confounders, such as adjust factor of original studies, and indication of statin
27
28 use, might overestimate the preventive effect of statins on liver cancer.
29

30
31 Further studies are needed to investigate the efficacy of statins in the prevention and
32
33 treatment of liver cancer.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and widely used to reduce the plasma cholesterol level and the risk of cardiovascular events.¹ Although there is a concern over their possible carcinogenicity raised in rodent studies,² preclinical studies indicate that statins have anticancer properties *in vitro* and *in vivo*, through inhibiting angiogenesis, inducing apoptosis, and suppressing tumor growth and metastasis.³⁻⁵ However, high concentrations are typically required to induce these effects, raising questions concerning the therapeutic relevance of statins with cancer.⁶ Meanwhile, there are inconsistent results from clinical studies aiming at determining whether statins indeed reduce the risk of cancer at regular daily doses for cardiovascular event prevention. Moreover, several meta-analyses have indicated that there was no association between statin use and the risk of overall cancer,⁷⁻¹⁰ or cancer of breast,¹¹ stomach,¹² or pancreas.¹³ There is only a modest association between the statin use and the risk of prostate cancer¹⁴ and colorectal cancer.¹⁵

In contrary to previously reported studies, several recent studies reported encouraging benefits for risk reduction of liver cancer among all statin users. Of note, in a previously reported meta-analysis of ten studies, Singh *et al.* found a significant inverse association between the statin use and the risk of hepatocellular carcinoma (HCC).¹⁶ Considering the recently published evidences, the present meta-analysis was designed to further evaluate the association between the statin use and the risk of liver cancer, by a comprehensive literature search and more subgroup analyses based on a

1
2
3
4 large population base. Our results demonstrated the benefits of reducing liver cancer
5
6 risk in statin users with regular daily doses for prevention of cardiovascular events,
7
8 which may have a significant translational potential in the clinic. However, some
9
10 confounders might overestimate this preventive effect of statins.
11
12

13 **MATERIALS AND METHODS**

14 ***Literature Search strategy***

15
16 This meta-analysis was conducted following the PRISMA guidelines.¹⁷

17
18
19 The systematic computerized search for eligible studies was performed on the
20
21 database of PubMed, BIOSIS Previews, Web of Science, EMBASE, and EBSCO,
22
23 covering all studies published from their inception to March 5, 2014. The following
24
25 terms were searched with both the subjects (MeSH terms) and text-word search
26
27 strategies: “(Statin OR HMG-CoA reductase inhibitors OR Atorvastatin OR
28
29 Cerivastatin OR Fluvastatin OR Lovastatin OR Pravastatin OR Rosuvastatin OR
30
31 Simvastatin) AND (Hepatocellular OR Hepatic OR Intrahepatic OR Interlobular OR
32
33 Liver) AND (Carcinoma OR Sarcomas OR Angiosarcoma OR Cancer OR Neoplasm).
34
35 Additionally, the relevant reviews and retrieved articles were searched manually for
36
37 more eligible studies.
38
39
40
41
42
43
44
45

46 ***Study selection***

47
48 The inclusion criteria were: (1) randomized controlled trial (RCTs), cohort studies or
49
50 case-control studies; (2) original studies that assessed the effect of statin use on the
51
52 risk of liver cancer, compared with placebo or no treatment; and (3) liver cancer cases
53
54 were identified according to the International Classification of Diseases codes (ICD).
55
56
57
58
59
60

1
2
3
4 The exclusion criteria were: (1) study design not meeting the inclusion criteria; (2)
5
6 studies without estimate of relative risk (risk ratio, RR) of liver cancer, or liver cancer
7
8 incidence by statin use status; or (3) studies with duplicated reports.
9

10 11 ***Data extraction***

12
13
14 Two independent investigators (M. Shi and X.B. Cui) extracted data from the eligible
15
16 studies using a predefined data collection form. The differences of data extraction
17
18 were resolved by consensus referring back to the original article. The extracted
19
20 information included: (1) Studies: first author, year of publication, study design,
21
22 location, patient populations, period, and follow-up; (2) Statins: type, dosage or
23
24 duration of statin use; (3) liver cancer: case identification, incidence by statin use
25
26 status, crude RR with 95% confidence intervals (CIs), adjusted RR reflecting the
27
28 greatest degree of control for potential confounders, and confounders for adjustment
29
30 (including variables for matching). When the RR were not available, the RR with 95%
31
32 CIs were calculated from the raw data provided.
33
34
35
36
37
38

39 We extracted different measurements of effect estimates from original studies, such as
40
41 Relative Risk, Odds Ratio, Hazard Ratio, and Observed/Expected ratio. In this
42
43 analysis, these different measurements were found to provide similar estimates of RR,
44
45 presumably due to the fact that the incidence of liver cancer was very low in most
46
47 studies.
48
49

50 51 ***Methodological quality assessment***

52
53
54 Of note, the included RCTs were pooled analyses or secondary analysis of other RCTs,
55
56 therefore, it is inappropriate to assess the methodological quality. The methodological
57
58
59
60

1
2
3
4 quality of cohort and case-control studies were assessed on the Newcastle-Ottawa
5
6 Scale,¹⁸ including eight items that were categorized three categories: selection (three
7
8 items, one star each), comparability (one item, up to two stars), and exposure/outcome
9
10 (three items, one star each). A “star” presents a “high” quality choice of each items.

11 12 13 ***Statistical analysis***

14
15
16 The overall meta-analysis was performed first, followed by the subgroup analyses,
17
18 based on study design, study location, confounding adjustment, and baseline risk of
19
20 liver cancer. Meanwhile, we conducted subgroup analyses based on studies which
21
22 reported different RR estimate for use of lipophilic statins and higher cumulative
23
24 dosage of statin, when appropriate data were available.

25
26
27 To take into account the heterogeneity and provide a more conservative estimate, the
28
29 inverse variance method was used to estimate the pooled RR and corresponding 95%
30
31 CIs, and data were pooled using a random effects model. Heterogeneity was assessed
32
33 using the Chi-squared statistic (P) together with the Higgins I-squared statistic (I^2).¹⁹
34
35 Test for subgroup differences was carried out to characterize possible sources of
36
37 statistical heterogeneity. Publication bias was assessed using the Begg’s test and the
38
39 Egger’s test.²⁰ A P -values of 0.10 was used to determine statistically significant.
40
41
42 Software Review Manager (RevMan 5.2, Copenhagen) and STATA (Stata 11.2, Texas)
43
44 were used for the statistical analysis.
45
46
47
48
49

50 51 **RESULTS**

52 53 ***Study selection***

54
55
56 **Figure 1** illustrates the process of study selection for the meta-analysis. Of the 1405
57
58
59
60

1
2
3
4 potentially relevant references identified by electric and hand search, 142 were
5
6 selected for full-text review after screening titles and abstracts. Finally, a total of 14
7
8 studies was included, with 3 RCTs,²¹⁻²³ 5 cohort studies,²⁴⁻²⁸ and 6 case-control
9
10 studies.²⁹⁻³⁴ Of note, one of the case-control studies was presented solely in abstract
11
12 form.²⁹ For the cohort study conducted by Friedman *et al.*,²⁵ in which the RR estimate
13
14 were reported separately for different gender (male and female), these two reports
15
16 were regarded as separate studies in our meta-analysis. Therefore, a total of fifteen
17
18 reports were included for the present meta-analysis.
19
20
21
22

23 ***Study characteristics***

24
25 **Table 1** summarizes the characteristics of qualified studies in this meta-analysis. The
26
27 14 studies, involving 1,779,630 participants with 35,775 liver cancer cases, were
28
29 published between 2005 and 2013. Except one RCT without identify information,²³
30
31 one cohort adopted ICD-10 C22,²⁴ all other studies identified liver cancer cases
32
33 according to the ICD-9 155.
34
35
36
37

38
39 The three “RCTs” in the present study were pooled analyses of other RCTs
40
41 (n=33),²¹⁻²³ which investigated statins therapy in cardiovascular event prevention and
42
43 reported the incidence of liver cancer as adverse event. The observational studies were
44
45 all conducted with the local or national health databases, the statin exposure were
46
47 identified by linkage to prescription databases, and the controls were matched mainly
48
49 by age, sex and index date. Two cohort studies were restricted to specified patients,
50
51 such as patients with HBV infection,²⁷ or HCV infection.²⁸ One case-control studies
52
53 was restricted to patients with diabetes mellitus.³⁰ Meanwhile, two observational
54
55
56
57
58
59
60

1
2
3 studies were restricted to older patients.^{26 31}

4
5
6 **Table 2** summarizes the data provided by the included studies. In two RCT^{22 23} and
7
8 one pre-matched cohort study,²⁶ in which the RR estimates were not provided by the
9
10 original studies, the RR with 95% CIs were calculated from the 2×2 tables defined by
11
12 the incidence of liver cancer and the statin use status. Other studies reported different
13
14 measurements of RR estimates with adjustment by potential confounders. Only
15
16 several observational studies adopted at least 4 important risk factor for adjustments,
17
18 such as HBV infection, HCV infection, cirrhosis, non-alcoholic fatty liver disease
19
20 (NAFLD), HCV treatment, HBV treatment or anti-diabetic medications.³⁵ Meanwhile,
21
22 only two studies adopted the cholesterol level for adjustments.^{26 34}
23
24
25
26
27

28 *Methodological quality*

29
30 For the cohort and case-control studies, the median of Newcastle-Ottawa Scale scores
31
32 was 7, with a range of 5 to 8 (**Supplementary Table 1**). These results indicated that
33
34 the observational studies were in a reasonable good quality.
35
36
37

38 *Overall meta-analysis*

39
40 **Figure 2** depicts the forest plot of RR estimate with 95% CIs from individual studies
41
42 and overall meta-analysis. In the overall meta-analysis, pooled results showed a
43
44 statistically significant decrease in the liver cancer risk among all statin users (RR
45
46 0.58, 95% CIs 0.51–0.67). Of note, a statistically significant heterogeneity was
47
48 observed ($I^2 = 59%$, $P=0.002$). The P -values of Begg's test and Egger's test were
49
50 0.921 and 0.716, respectively, both suggesting there were no evidence of publication
51
52 bias.
53
54
55
56
57
58
59
60

Subgroup analyses

We first performed preplanned subgroup analyses of studies based on study design, study location confounding adjustment, and baseline risk of liver cancer. (**Table 3**).

In RCTs, only a non-significant decrease of liver cancer risk among all statin users was found (RR 0.95, 0.62–1.44; $I^2=0\%$, $P=0.59$). Subgroup analyses of cohort studies found a greater decrease of liver cancer risk than the case-control studies among all statin users (RR 0.51, 0.44–0.58; $I^2=18\%$, $P=0.30$ and RR 0.63, 0.54–0.73; $I^2=46\%$, $P=0.10$, respectively). Test for subgroup differences ($I^2=79.9\%$, $P=0.007$) indicated the study design partly explained the heterogeneity in the overall analysis. (**Figure 2**)

Subgroup analysis of studies with higher baseline risk of liver cancer,^{26-28 31} defined as older patients, HBV or HCV infected patients, found a greater decrease of liver cancer risk (RR 0.52, 0.47-0.59; $I^2=16\%$, $P=0.31$) than the studies with general population and other population (RR 0.60, 0.49–0.75; $I^2=48\%$, $P=0.05$ and RR 0.72, 0.62–0.83; $I^2=0\%$, $P=0.34$, respectively). Test for subgroup differences ($I^2=82.7\%$, $P=0.003$) indicated that the difference in baseline risk of liver cancer can partly explained the heterogeneity in the overall analysis (**Supplementary Figure 1**).

Subgroup analysis of studies that adjusted adequately,^{21-23 29-32} which defined as RCTs or adjusted for at least 4 of 7 important confounders, found a less decrease of liver cancer risk among all statin users (RR 0.67, 0.55-0.83; $I^2=47\%$ $P=0.09$). Subgroup analysis of studies that adjusted inadequately found a greater decrease of liver cancer risk among all statin users (RR, 0.54, 0.47-0.62; $I^2=40\%$, $P=0.10$).^{24-28 33 34} Test for subgroup differences ($I^2=69.2\%$, $P=0.07$) indicated the confounding adjustment also

partly explained the heterogeneity in the overall analysis (**Supplementary Figure 2**).

Then, we conducted subgroup analyses based on studies use lipophilic statins and higher cumulative dosage of statin, when appropriate data were available.

Subgroup analysis based on study location found similar results in Western countries and Asian countries (RR 0.61, 0.49–0.76; $I^2 = 59\%$, $P=0.01$ and RR 0.55, 0.49–0.63; $I^2 = 26\%$, $P=0.23$, respectively). Test for subgroup differences ($I^2 = 0\%$, $P=0.47$) found no significant heterogeneity between these two subgroups (**Supplementary Figure 3**).

Subgroup analysis of studies with use of lipophilic statins, such as atorvastatin, fluvastatin, lovastatin, and simvastatin, was conducted based on the pharmacokinetic data.^{23 25 27 30-32} The pooled results indicated a significant decrease of liver cancer risk among users of lipophilic statins (RR 0.57, 0.50–0.65; $I^2 = 40\%$, $P=0.13$). (**Supplementary Figure 4**)

Subgroup analysis of studies with higher cumulative dosage of statin use, defined as cumulative defined daily dose (cDDD) > 180 or cumulative duration of statin use > 0.5 years, also found a significant decrease of liver cancer risk (RR 0.54, 0.38-0.77), but with a high degree of degree of heterogeneity ($I^2 = 85\%$, $P < 0.00001$). (**Supplementary Figure 5**)

DISCUSSION

This present meta-analysis represents the most comprehensive review to date on the relation between the statin use and the liver cancer risk, by including 14 studies (3 RCTs, 5 cohort studies, and 6 case-control studies) and involving 1,779,630

1
2
3
4 participants with 35,775 liver cancer cases. Overall, we found a significant inverse
5
6 association between statin use and risk of liver cancer (RR 0.58, 95% CIs 0.51–0.67),
7
8 when statins were taken at daily doses for cardiovascular event prevention. This result
9
10 was in line with the previous three meta-analyses that only included some of our
11
12 included studies: Singh *et al.* included 10 studies and suggested statin users were less
13
14 likely to develop HCC than statin nonusers (Odds Ratios 0.63, 95% CIs 0.52–0.76),¹⁶
15
16 Pradelli *et al.* and Zhang *et al.* included 5 and 7 observational studies and found a
17
18 summary RR of 0.58 (95% CIs 0.46–0.74) and 0.61 (95% CIs 0.49–0.76),
19
20 respectively.^{36 37}

21
22 The inverse association between the statin use and the liver cancer risk was seen
23
24 primarily in observational studies, and which was relative stronger in the cohort
25
26 studies than the case-control studies. Subgroup analysis of RCTs only found a
27
28 non-significant inverse association, mainly because of the RCTs included low risk
29
30 population (Cardiovascular disease patients rather than HBV /HCV infected patients).
31
32 Meanwhile, subgroup analysis of studies with higher baseline risk of liver cancer,
33
34 found a greater decrease of liver cancer risk than the studies with general population
35
36 and other population. These results all indicated that the protective effect of statins
37
38 might vary according to different baseline risk.

39
40 Subgroup analysis of adjusted adequately studies found a less decrease of liver cancer
41
42 risk than the adjusted inadequately studies, indicated the potential of overestimate the
43
44 preventive effect of statins by inadequately adjustment. On the other hand, there were
45
46 inverse association between use of non-statin lipid-lowering drugs and risk of the liver
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cancer.^{31 34} Meanwhile, some clinical studies demonstrated that higher serum total
4
5 cholesterol concentration was associated with decreased risk of liver cancer
6
7
8
9 (Supplementary Table 3).³⁸⁻⁴⁰ Unfortunately, the studies we included seldom adopt
10
11 these two factors for adjustment. These fact all indicated that the statin indication (e.g.
12
13 hyperlipidemia) might overestimate its chemopreventive effect.

14
15
16 We found similar results in Western countries and Asian countries, which were
17
18 different from the meta-analysis conducted by Singh *et al.* which concluded that the
19
20 inverse association of statins with HCC was stronger in the Asian population.
21
22 Considering we included four more studies, this difference might be caused by the
23
24 insufficient data in their meta-analysis.
25
26
27

28
29 The lipophilic properties of the statins are accompanied by an extensive first-pass
30
31 effect at the hepatic level.⁴¹ It is plausible that lipophilic statins will differ in their
32
33 liver cancer prevention qualities.⁴² However, subgroup analysis of studies with
34
35 lipophilic statins found similar results with a summary RR of 0.57 (95% CIs
36
37 0.50-0.65). In our study, there was a trend toward more reduction of liver cancer risk
38
39 with higher cumulative dosage of statin use (RR 0.54, 95% CIs 0.38–0.77), which
40
41 showed the potential of dose-response relationship.
42
43
44

45
46 Besides the previously described limitations, there were several other limitations
47
48 should be noted when interpreting our findings. First, a significant heterogeneity was
49
50 observed in the present meta-analysis ($I^2 = 59\%$, $P=0.002$), and the difference in study
51
52 design, baseline risk and confounding adjustment might explained the significant
53
54 heterogeneity. Results of other subgroup analyses, which pooling the data all studies
55
56
57
58
59
60

1
2
3
4 together, would also be limited by this heterogeneity. Second, other factors may affect
5
6 the estimate of RR for liver cancer. For example, the adherence to statin therapy is
7
8 known to be associated with healthy lifestyle, which might affect the cancer
9
10 outcome.⁴³ Such information is hard to be captured in databases or medical record in
11
12 the observational studies.⁴⁴ Third, five observational studies were conducted using the
13
14 Taiwanese National Health Insurance Research Database (NHIRD),^{27 28 31-33} though
15
16 they were not in the same period, there was still a potential that these studies
17
18 contained overlapping groups of patients. Although the confounding factors
19
20 mentioned above may have a limited effect on our overall results from the present
21
22 study, these factors should be considered in future studies aiming at confirming the
23
24 protective effects of statins on human cancer risk.
25
26
27
28
29

30
31 The strengths of our meta-analysis were as follows: First, we performed a much more
32
33 comprehensively search and more subgroup analyses, compared with the previous
34
35 meta-analyses; Second, the methodological quality of the included studies was
36
37 reasonable good; Third, publication bias, which due to the tendency of not publishing
38
39 small studies with null results, were not found in our meta-analysis.
40
41
42

43
44 Currently, physicians are less likely to prescribe statins for patients with chronic liver
45
46 disease, which are known risk factors of liver cancer, based on the concerns about the
47
48 statin-induced liver injury.²⁷ However, there were number of studies have
49
50 demonstrated the safe use, even salutary effects, of statins in patients with HCV
51
52 infection, HBV infection or NAFLD.^{27 28 45-47} Meanwhile, the risk of serious
53
54 statin-related liver injury appears to be no greater than the background incidence of
55
56
57
58
59
60

1
2
3
4 this rare event.⁴⁸ Therefore, considering their benefits for cardiovascular event
5
6 prevention and potential in liver cancer prevention, statins should not be denied to the
7
8 patients with chronic liver diseases.
9

10
11 Of note, preclinical studies have indicated that statins possess synergism with other
12
13 therapeutic agents *in vitro* and *in vivo* for liver cancer.^{49,50} Meanwhile, clinical studies
14
15 have also demonstrated that statins would prolong survival in patients with advanced
16
17 liver cancer (**Supplementary Table 4**).⁵¹⁻⁵⁴ Moreover, statin use might associate with
18
19 decrease of cancer recurrence risk in patients of HBV related HCC after curative
20
21 surgery.⁵⁵ Therefore, considerable interest exists in adjunctive therapy with statins for
22
23 liver cancer. In fact, there were several prospective, randomized, controlled trials
24
25 ongoing to determine the effectiveness of pravastatin in the treatment of liver cancer,
26
27 when used in combination with sorafenib (**Supplementary Table 5**).
28
29
30
31
32

33
34 In conclusion, our results suggest there is a significant inverse association between the
35
36 statin use and the risk of liver cancer, when statins are taken daily for cardiovascular
37
38 event prevention. However, some confounders might overestimate the preventive
39
40 effect. Further studies are needed to investigate the efficacy of statins in the
41
42 prevention and treatment of liver cancer.
43
44
45

46 **ACKNOWLEDGEMENT**

47
48 We thank Medjaden Bioscience Limited for assisting in the preparation of this
49
50 manuscript.
51
52

53 **REFERENCES:**

- 54
55
56 1. Baigent C, Keech A, Kearney PM, *et al*. Efficacy and safety of cholesterol-lowering treatment:
57 prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
58
59
60

- Lancet 2005;**366**(9493):1267-78.
2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;**275**(1):55-60.
 3. Demierre MF, Higgins PD, Gruber SB, *et al.* Statins and cancer prevention. Nat Rev Cancer 2005;**5**(12):930-42.
 4. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. J Cancer Res Ther 2012;**8**(2):176-83.
 5. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2012;**27**(11):1654-64.
 6. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 2011;**67**(4):729-39.
 7. Dale KM, Coleman CI, Henyan NN, *et al.* Statins and cancer risk: a meta-analysis. JAMA 2006;**295**(1):74-80.
 8. Browning DRL, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 2007;**120**(4):833-43.
 9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008;**44**(15):2122-32.
 10. Baigent C, Blackwell L, Emberson J, *et al.* Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;**376**(9753):1670-81.
 11. Bonovas S, Filioussi K, Tsavaris N, *et al.* Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;**23**(34):8606-12.
 12. Shimoyama S. Statins and gastric cancer risk. Hepatogastroenterology 2011;**58**(107-108):1057-61.
 13. Cui X, Xie Y, Chen M, *et al.* Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 2012;**23**(7):1099-111.
 14. Bansal D, Undela K, D'Cruz S, *et al.* Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. PLoS One 2012;**7**(10):e46691.
 15. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010;**59**(11):1572-85.
 16. Singh S, Singh PP, Singh AG, *et al.* Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. Gastroenterology 2013;**144**(2):323-32.
 17. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;**339**:b2535.
 18. GA Wells, B Shea, D O'Connell, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
 19. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. BMJ 2003;**327**(7414):557-60.
 20. METABIAS: Stata module to test for small-study effects in meta-analysis [program], 2009.
 21. Matsushita Y, Sugihara M, Kaburagi J, *et al.* Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf 2010;**19**(2):196-202.
 22. Emberson JR, Kearney PM, Blackwell L, *et al.* Lack of effect of lowering LDL cholesterol on cancer:

- meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;**7**(1):e29849.
23. Stein EA, Corsini A, Gimpelewicz CR, *et al.* Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract* 2006;**60**(9):1028-34.
24. Friis S, Poulsen AH, Johnsen SP, *et al.* Cancer risk among statin users: A population-based cohort study. *Int J Cancer* 2005;**114**(4):643-7.
25. Friedman GD, Flick ED, Udaltsova N, *et al.* Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. *Pharmacoepidemiol Drug Saf* 2008;**17**(1):27-36.
26. Marelli C, Gunnarsson C, Ross S, *et al.* Statins and Risk of Cancer A Retrospective Cohort Analysis of 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult Americans. *J Am Coll Cardiol* 2011;**58**(5):530-7.
27. Tsan YT, Lee CH, Wang JD, *et al.* Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. *J Clin Oncol* 2012;**30**(6):623-30.
28. Tsan YT, Lee CH, Ho WC, *et al.* Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. *J Clin Oncol* 2013;**31**(12):1514-21.
29. Khurana V, Saluja A, Caldito G, *et al.* Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: Half a million US veterans' study. *Gastroenterology* 2005;**128**(4, Suppl. 2):A714.
30. El-Serag HB, Johnson ML, Hachem C, *et al.* Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. *Gastroenterology* 2009;**136**(5):1601-8.
31. Chiu HF, Ho SC, Chen CC, *et al.* Statin use and the risk of liver cancer: a population-based case-control study. *Am J Gastroenterol* 2011;**106**(5):894-8.
32. Lai SW, Liao KF, Lai HC, *et al.* Statin use and risk of hepatocellular carcinoma. *Eur J Epidemiol* 2013;**28**(6):485-92.
33. Leung HW, Chan AL, Lo D, *et al.* Common cancer risk and statins: a population-based case-control study in a Chinese population. *Expert Opin Drug Saf* 2013;**12**(1):19-27.
34. Chaiteerakij R, Yang JD, Harmsen WS, *et al.* Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. *Hepatology* 2013;**57**(2):648-55.
35. Singh S, Singh PP, Roberts LR, *et al.* Chemopreventive strategies in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2014;**11**(1):45-54.
36. Pradelli D, Soranna D, Scotti L, *et al.* Statins and primary liver cancer: a meta-analysis of observational studies. *Eur J Cancer Prev* 2013;**22**(3):229-34.
37. Zhang H, Gao C, Fang L, *et al.* Statin use and risk of liver cancer: A meta-analysis of 7 studies involving more than 4.7 million patients. *World J Meta-Anal* 2013;**1**(3):130-7.
38. Ahn J, Lim U, Weinstein SJ, *et al.* Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2009;**18**(11):2814-21.
39. Iso H, Ikeda A, Inoue M, *et al.* Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. *Int J Cancer* 2009;**125**(11):2679-86.
40. Kitahara CM, de Gonzalez AB, Freedman ND, *et al.* Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea. *J Clin Oncol* 2011;**29**(12):1592-8.
41. Gazerro P, Proto MC, Gangemi G, *et al.* Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev* 2012;**64**(1):102-46.
42. Gronich N, Rennert G. Beyond aspirin - Cancer prevention with statins, metformin and

- bisphosphonates. *Nat Rev Clin Oncol* 2013;**10**(11):625-42.
43. Brookhart MA, Patrick AR, Dormuth C, *et al.* Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. *Am J Epidemiol* 2007;**166**(3):348-54.
44. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. *Expert Opin Drug Saf* 2010;**9**(4):603-21.
45. Lewis JH, Mortensen ME, Zweig S, *et al.* Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology* 2007;**46**(5):1453-63.
46. Nelson A, Torres DM, Morgan AE, *et al.* A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol* 2009;**43**(10):990-4.
47. Lewis JH. Clinical Perspective: Statins and the Liver-Harmful or Helpful? *Dig Dis Sci* 2012;**57**(7):1754-63.
48. Bader T. The myth of statin-induced hepatotoxicity. *Am J Gastroenterol* 2010;**105**(5):978-80.
49. Kim W, Yoon JH, Kim JR, *et al.* Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. *Cancer Chemother Pharmacol* 2009;**64**(3):497-507.
50. Polo MP, Crespo R, de Bravo MG. Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line. *Cell Biochem Funct* 2011;**29**(6):452-8.
51. Kawata S, Yamasaki E, Nagase T, *et al.* Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. *Br J Cancer* 2001;**84**(7):886-91.
52. Lersch C, Schmelz R, Erdmann J, *et al.* Treatment of HCC with pravastatin, octreotide, or gemcitabine - A critical evaluation. *Hepatogastroenterology* 2004;**51**(58):1099-103.
53. Graf H, Jungst C, Straub G, *et al.* Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. *Digestion* 2008;**78**(1):34-8.
54. Georgescu EF, Badulescu F, Dumitrescu D, *et al.* Lovastatin may enhance cytostatic effects of sorafenib in hepatic carcinoma. Primary results of a pilot study. *Hepatol Int* 2011;**5**(1):423.
55. Wu CY, Chen YJ, Ho HJ, *et al.* Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. *JAMA* 2012;**308**(18):1906-14.

FIGURE LEGENDS:

Figure 1. Flow chart of study selection in the present meta-analysis.

Figure 2. Overall meta-analysis of the statin use and the liver cancer risk.

Supplementary Figure 1. Subgroup analyses based on baseline risk of liver cancer.

Supplementary Figure 2. Subgroup analysis based on confounding adjustment.

Supplementary Figure 3. Subgroup analysis based on study location.

Supplementary Figure 4. Subgroup analyses of use of lipophilic statins.

Supplementary Figure 5. Subgroup analyses of higher cumulative dosage of statin

use.

Table 1. Study characteristics

Studies	Study design	Patient population	Study period	Cases defined	Follow-up	Statins type	Dosage/Duration of Statin use
Stein, 2006, USA ²³	RCT	Pooled analysis of 8 RCTs	-	NR	2.4 years (M)	F, 20–80 mg daily	2.4 years (M)
Matsushita, 2010, Japan ²¹	RCT	IPD analysis of 3 RCTs	-	ICD-9 155	≥4.7 years	P, 10-20 mg daily	≥4.7 years
Emberson, 2012, UK ²²	RCT	IPD analysis of 22 RCTs	-	ICD-9 155	5.1 years (Me)	A, F, L, P, R, S	5.1 years (Me)
Friis, 2005, North Jutland ²⁴	Cohort	General population (CPR)	1989-2002	ICD-10 C22	3.3 years (M)	Unspecified	≥2 Rx
Friedman, 2008, USA ²⁵	Cohort	General population (KPMCP)	1994-2003	ICD-9-CM 155	> 2 years	A, L, S (97.6%)	≥1 Rx
Marelli, 2011, USA ²⁶	Cohort	General older population (men ≥ 45 and women ≥ 55 years; GE Centricity)	1990-2009	ICD-9 155	4.6 years (M)	Unspecified	≥1 cDDD
Tsan, 2012, Taiwan ²⁷	Cohort	Patients with HBV infection (NHIRD)	1997-2008	ICD-9 155	9.9 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Tsan, 2013, Taiwan ²⁸	Cohort	Patients with HCV infection (NHIRD)	1999-2010	ICD-9 155	10.7 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Khurana, 2005, USA ²⁹	Case control	General population (VISN)	1997-2002	ICD-9 155	NR	Unspecified	≥1 Rx
El-Serag, 2009, USA ³⁰	Case control	Diabetes patients (VA)	1997-2002	ICD-9-CM 155	2.4 years (M)	A, C, F, L, P, and S	1.6 years (M)
Chiu, 2011, Taiwan ³¹	Case control	Older patients (≥ 50 years; NHIRD)	2005–2008	ICD-9-CM 155	NR	A, F, L, P, R, and S	≥ 1 cDDD
Lai, 2013, Taiwan ³²	Case control	General population (NHIRD)	2000-2009	ICD-9-CM 155	1.4 years (M)	A, F, L, P, R, and S	≥1 Rx
Leung, 2013, Taiwan ³³	Case control	General population (NHIRD)	2000-2008	ICD-9-CM 155	4.1 years (M)	Unspecified	> 0.5 years
Chaiteerakij, 2013, USA ³⁴	Case control	Hyperlipidemia patients (Mayo Clinic)	2000-2010	ICD-9-CM 155	>1 years	Unspecified	≥1 Rx

Patients population: IPD=Individual patient data, RCT = randomized controlled trials, CRP=the Central Population Register of Danish citizens, KPMCP=the Kaiser Permanente Medical Care Program in northern California, GE Centricity=the General Electric Centricity database, NHIRD=the Taiwanese National Health Insurance research database, VISN=Veterans Integrated Service Networks 16 Veteran Affairs database, VA=Veterans Affairs national databases, Mayo Clinic= Mayo Clinic (Rochester, MN), HBV = hepatitis B virus; Cases defined: ICD-9 or -10 =International Classification of Diseases, Ninth Revision or Tenth Revision, CM=Clinical Modification; Duration of follow-up: When the follow-up periods of statin user and nonuser were different, only the shorter one was showed, and all periods were transformed to years; Statin type: A=Atorvastatin, C=Cerivastatin, F=Fluvastatin, L=Lovastatin, P=Pravastatin, R=Rosuvastatin, S=Simvastatin, Non-statin= Non-statin cholesterol-lowering drug(s) only; Duration of statin use: M=Mean, Me=Median, ≥1 cDDD = more than 1 cumulative defined daily dose before the diagnosis of liver cancer, Rx=prescriptions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Study data

Studies	Intervention/ Cases		Control		Measurements of effect estimates	Crude RR with 95% CIs	Adjusted RR with 95% CIs	Confounders for adjustment
	No. of event/ No. of exposure	No. of total	No. of event/ No. of exposure	No. of total				
Stein, 2006, USA ²³	3	3512	4	3289	RR	0.70 (0.16-3.14)*	0.70 (0.16-3.14)*	Randomization
Matsushita, 2010, Japan ²¹	5	7375	7	6349	HR	NA	0.58 (0.18-1.84)	Randomization
Emberson, 2012, UK ²²	35	67258	33	67279	RR	1.06 (0.66, 1.71)*	1.06 (0.66, 1.71)*	Randomization
Friis, 2005, North Jutland ²⁴	1	12251	166	334754	OR	NA	1.16 (0.46-2.90)	1,2, 16, 21, 23
Friedman(Male), 2008, USA ²⁵	32	192598	NA	NA	HR	NA	0.49 (0.34-0.70)	16
Friedman(Female), 2008, USA ²⁵	10	169261	NA	NA	HR	NA	0.40 (0.21-0.75)	
Marelli, 2011, USA ²⁶	13	45857	24	45857	RR	0.31 (0.14-0.68)*	0.31 (0.14-0.68)*	1-5, 14, 16-18, 26, 27
Tsan, 2012, Taiwan ²⁷	58	2785	963	30628	HR	0.66 (0.51- 0.86)	0.47 (0.36-0.61)	1, 2, 7, 8, 11, 12
Tsan, 2013, Taiwan ²⁸	1378	35023	26505	225841	HR	0.42 (0.39-0.46)	0.53 (0.49-0.58)	1, 2, 7, 8, 11, 13
Khurana, 2005, USA ²⁹	NA	NA	NA	NA	OR	NA	0.52 (0.41- 0.67)	1, 11, 13
El-Serag, 2009, USA ³⁰	447	1303	2766	5212	OR	0.46 (0.40-0.52)	0.74 (0.64-0.87)	1-3, 6, 8, 9, 11-13, 21, 24, 28
Chiu, 2011, Taiwan ³¹	117	1166	195	1166	OR	0.53 (0.41-0.69)	0.62 (0.45-0.83)	1, 2, 8, 9, 11, 12, 20, 29
Lai, 2013, Taiwan ³²	255	3480	1635	13920	OR	0.61 (0.52-0.72)	0.71 (0.56-0.89)	1, 2, 8-13, 22, 24, 25
Leung, 2013, Taiwan ³³	26	424	6851	33781	HR	0.45 (0.30-0.67)	0.44 (0.28, 0.72)	1, 2, 11, 15, 20, 21, 23
Chaiteerakij, 2013, USA ³⁴	72	165	165	256	OR	NA	0.6 (0.4-0.9)	1-3, 8, 11, 17, 22, 28, 30


*=the RR was calculated based on raw data; Adjusted RR=RR adjusted for confounders; Confounders for adjustment: 1=age, 2=sex, 3=race, 4=BMI, 5=smoking status, 6=ethanol intake, 7=socioeconomic status, 8=cirrhosis, 9=alcoholic liver disease, 10=non-alcoholic fatty liver disease, 11=diabetes mellitus, 12=HBV infection, 13=HCV infection, 14=concomitant diagnoses (unspecified), 15=Charlson score, 16=calendar year, 17=cholesterol (total cholesterol, VLDL, LDL, or triglycerides), 18=prostate-specific antigen, 19=resection extent, 20=other lipid-lowering agents, 21=cardiovascular medications (aspirin, nonsteroidal anti-inflammatory medications, or angiotensin-converting enzymes inhibitors), 22=metformin or thiazolidinedione, 23=hormone-replacement therapy, 24=HCV treatment, 25=HBV treatment, 26=medications taken (unspecified), 27=the number of office visits, 28=propensity to use statins, 29=hospital stay, 30=biliary tract diseases

Table 3. Subgroup analyses of included studies

Subgroup	No. of studies (reports)	Summary RR (95% CIs)	Heterogeneity, I ²	Heterogeneity, P value	Test for subgroup differences, I ²	Test for subgroup differences, P value	
Study design	RCTs	3	0.95 (0.62-1.44)	0%	P=0.59	79.9%	P=0.007
	Cohort studies	5 (6)	0.51 (0.44-0.58)	18%	P=0.30		
	Case-control studies	6	0.63 (0.54-0.73)	46%	P=0.10		
Baseline risk of liver cancer	Higher baseline risk	4	0.52 (0.47, 0.59)	16%	P=0.31	82.7%	P=0.003
	General population	8 (9)	0.60 (0.49-0.75)	48%	P=0.05		
	Other population	2	0.72 (0.62-0.83)	0%	P=0.34		
Confounding adjustment	Adjusted adequately studies	6	0.67 (0.56-0.83);	47%	P=0.09	69.2%	P=0.07
	Adjusted inadequately studies	8 (9)	0.58 (0.51-0.66)	40%	P=0.10		
Study location	Western studies	8 (9)	0.61 (0.49-0.76)	59%	P=0.01	0%	P=0.49
	Asian studies	6	0.56 (0.49- 0.64)	38%	P=0.15		
Use of lipophilic statins		6 (7)	0.57 (0.50-0.65)	40%	P=0.13	-	-
Higher cumulative dosage of statin		8	0.54 (0.38- 0.77)	85%	P<0.0001	-	-


RR= relative risk; higher baseline risk: older patients, HBV or HCV infected patients. Confounding adjustment: Adjusted adequately means reported RR have been adjusted for at least 4 of 7 important factors: HBV infection, HCV infection, cirrhosis, NAFLD, HCV treatment, HBV treatment, Anti diabetic medications; Lipophilic statin use: use of atorvastatin, fluvastatin, lovastatin, or simvastatin; Higher cumulative dosage of statin use: > 180cumulative defined daily dose or Duration of statin use > 0.5 years before the diagnosis of liver cancer.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Flow chart of study selection in the present meta-analysis.
227x264mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Overall meta-analysis of the statin use and the liver cancer risk
152x118mm (300 x 300 DPI)


SUPPLEMENTARY FIGURES:




Supplementary Figure 1. Subgroup analyses based on baseline risk of liver cancer.




Supplementary Figure 2. Subgroup analysis based on confounding adjustment.



Supplementary Figure 3. Subgroup analysis based on study location.



Supplementary Figure 4. Subgroup analyses of use of lipophilic statins.



Supplementary Figure 5. Subgroup analyses of higher cumulative dosage of statin use.

SUPPLEMENTARY TABLES:

Supplementary Table 1. Assessment of methodological quality of the cohort and case-control studies according to the Newcastle–Ottawa Scale

Cohort Studies	Selection			Outcome of present at start of study	Comparability		Outcome		Total Score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure		Control for important factor	Assessment of outcome	Follow-up long enough	Adequacy of follow up	
Friis, 2005 ²⁴	☑	☑	☑	☑	☑	☑	-	☑	7
Friedman, 2008 ²⁵	☑	☑	☑	☑	☑	☑	-	☑	7
Marelli, 2011 ²⁶	☑	☑	☑	☑	☑	☑	☑	☑	8
Tsan, 2012 ²⁷	☑	☑	☑	☑	☑	☑	☑	☑	8
Tsan, 2013 ²⁸	☑	☑	☑	☑	☑	☑	☑	☑	8

Case-Control Studies	Selection			Definition of controls	Comparability		Exposure		Total Score
	Adequate definition of cases	Representativeness of cases	Selection of controls		Control for important factor	Ascertainment of Exposure	Same method for cases and controls	Non-response rate	
Khurana, 2005 ²⁹	-	☑	☑	☑	☑	☑	☑	-	6
El-Serag, 2009 ³⁰	-	☑	☑	☑	☑ ☑	☑	☑	-	7
Chiu, 2011 ³¹	-	☑	☑	☑	☑ ☑	☑	☑	-	7
Lai, 2013 ³²	-	☑	☑	☑	☑ ☑	☑	☑	-	7
Leung, 2013 ³³	☑	☑	☑	☑	☑	☑	☑	☑	8
Chaiteerakij, 2013 ³⁴	-	☑	-	☑	☑	☑	☑	-	5

Control for important factor: ☑ Reported relative risk have been adjusted for at least 4 of 7 important factors: HBV infection, HCV infection, cirrhosis, NAFLD, HCV treatment, HBV treatment, anti-diabetic medications; ☑ Study controls for any additional factor. Assessment of outcome: ☑ record linkage. Follow-up long enough: ☑ follow up period ≥ 4 years. Adequate definition of cases: ☑ The case is defined with independent validation. Non-response rate: ☑ Same rate for both groups.

Supplementary Table 2. Studies reporting RR for use of lipophilic statins and for higher cumulative dosage of statin use

Studies	Measurements of effect estimates	Statins type	Dosage/Duration of Statin use	Crude RR with 95% CIs	Adjusted RR with 95% CIs
Tsan, 2012, Taiwan ²⁷	HR	A, F, L, P, R, and S	>365 cDDD	0.50 (0.26-0.96)	0.34 (0.33-0.59)
	HR	Lipophilia statin	≥28 cDDD	0.65 (0.39-1.09)	0.44 (0.33-0.59)
Tsan, 2013, Taiwan ²⁸	HR	A, F, L, P, R, and S	>180 cDDD	NA	0.33 (0.25-0.42)
El-Serag, 2009, USA ³⁰	OR	Simvastatin	1.6 years (M)	0.47 (0.41- 0.54)	0.64 (0.55-0.75)
Chiu, 2011, Taiwan ³¹	OR	A, F, L, P, R, and S	>215.4 cDDD	0.47 (0.30-0.72)	0.63 (0.37-1.06)
	OR	Lipophilia statin	≥ 1 cDDD	0.56 (0.45-0.69)*	0.56 (0.45-0.69)*
Lai, 2013, Taiwan ³²	OR	Lipophilia statin	≥1 Rx	0.67 (0.57-0.79)*	0.67 (0.57-0.79)*

*= RR was calculated based on raw data; Adjusted RR=RR adjusted for confounders

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Supplementary Table 3. Published studies of the total cholesterol and the risk of liver cancer

Studies	Study design	cases/ participants	Follow-up	Reference (mg/dL)	Index (mg/dL)	Adjusted HR (95% CIs)		P for trend*	Confounders for adjustment
						Men	Women		
Iso, 2009, Japan ³⁹	Population-based cohort (JPHC Study)	125 /33,368	12.4 years	180–199	< 160	2.62 (1.44–4.76)	4.15 (1.70–10.16)	Men < 0.0001 Women < 0.0001	1-10
					160–179	1.04 (0.52–2.07)	1.99 (0.82–4.85)		
					180–199	1	1		
					200–219	0.56 (0.24–1.28)	1.09 (0.44–2.68)		
					200–239	0.49 (0.16–1.44)	0.41 (0.11–1.52)		
Ahn, 2009, Finland ³⁸	Placebo-controlled, double-blinded primary prevention trial in male smokers (ATBC)	191/29,093	18.0 years	< 203.9	< 203.9	1	-	P=0.0007	1-5, 11-17
					203.9-227.6	0.69 (0.46-1.05)	-		
					227.7-249.2	0.63 (0.41-0.97)	-		
					249.3-276.6	0.56 (0.36-0.88)	-		
					> 276.7	0.66 (0.43-1.01)	-		
Kitahara, 2011, Korea ⁴⁰	Prospective study of Korean men and women (Korean NHIC)	10,161/1,189,719	12.7 years	< 160	< 160	1	-	Men < 0.001 Women < 0.001	2-5, 13, 18
					160-179	0.69 (0.65-74)	0.63 (0.54-0.72)		
					180-199	0.62 (0.58-0.66)	0.50 (0.44-0.58)		
					200-239	0.48 (0.45-0.51)	0.37(0.32-0.42)		
					≥ 240	0.42 (0.38-0.45)	0.32 (0.27-0.39)		

JPHC Study= The Japan Public Health Center-based Prospective Study, ATBC=The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Korean NHIC= The Korean National Health Insurance Corporation Medical Evaluation. *Tests for linear trend were conducted by treating the total cholesterol as a continuous variable in the multivariable models. **Confounders for adjustment:** 1=age, 2=BMI, 3=smoking, 4=ethanol intake, 5= hypertension, 6=diabetes, 7=hyperlipidemia medication use, 8=total vegetable intake, 9=coffee intake, 10=public health center, 11=intervention, 12=level of education, 13=physical activity, 14=Saturates fat intake, 15=polyunsaturated fat intake, 16=total calorie, 17=serum HDL cholesterol, 18=fasting serum glucose.

Supplementary Table 4. Published trials of statin use in treatment of liver cancer

Studies	Study design	Patients population	Intervention	Control	Overall survival of intervention (months)	Overall survival of control (months)	Kaplan-Meier and log-rank test
Kawata, 2001, Japan ⁵¹	Prospective, randomized, open label study	Patients with advanced liver cancer after TAE procedure, n=83	Pravastatin 20-40 mg + 5-FU 200 mg QD, n=41	5-FU 200 mg QD, n=42	Median 18	Median 9	<i>P</i> = 0.006
Lersch, 2004, Germany ⁵²	Prospective study	Patients with advanced liver cancer, n=58	Pravastatin 40-80 mg QD, n=20	A: Octreotide, n=30; B: Gemcitabine, n=8	Median 7.2 (95% CIs 2.9-11.5)	A: Median 5 (95% CIs 2.2-7.8); B: Median 3.5 (95% CIs 2.2-4.9)	A: <i>P</i> = 0.09; B: <i>P</i> = 0.03
Graf, 2008, Germany ⁵³	Prospective, non-randomized, open label study	Patients with advanced liver cancer after TACE, n=183	Pravastatin 20-40 mg QD, n=52	No treatment, n=131	Median 20.9 (95% CIs 15.5-26.3)	Median 20.9 (95% CIs 15.5-26.3)	<i>P</i> = 0.003
Georgescu, 2011, Romania ⁵⁴	Prospective, randomized, open label study	Patients with advanced liver cancer, n=72	Lovastatin 40 mg + Sorafenib 400 mg QD, n=39	Sorafenib 400 mg QD, n=33	Mean 12.15±0.76	Mean 10.85±0.82	Non-significant

TAE = Transcatheter arterial embolization; TACE = Transarterial chemoembolization.

Supplementary Table 5. Ongoing clinical trials of statin use in treatment of liver cancer

Studies	Year	Location	Phase	Study design	Condition	Intervention	Control	Estimated Enrollment	Resist number	Status
ESTAHEP-2010	2011	Spain	II	Multicenter, prospective, randomized, double-blind, placebo-controlled study	Advanced liver cancer	Sorafenib 400 mg BID + Pravastatin 40 mg, QD	Sorafenib 400 mg BID + placebo QD	216	NCT01418729; EUCTR2010-024421-21-ES	Recruiting
PRODIGE 21	2011	France	II	Multicenter, prospective, randomized, open label study	Liver cancer with Child-Pugh B Cirrhosis	A: Sorafenib 400 mg BID; B: Pravastatin 40 mg, QD; C: Sorafenib 400 mg BID + Pravastatin 40 mg, QD	Best supportive care	160	NCT01357486	Recruiting
JOUVE PHRCK 2009	2013	France	III	prospective, randomized, open label study	Liver cancer with Child-Pugh A Cirrhosis	Sorafenib 800 mg BID + Pravastatin 40 mg, QD	Sorafenib 800 mg BID	474	NCT01903694; NCT01075555	Recruiting



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	no
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4-5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	6



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7, 19, 20
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8, Suppl. Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figure 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8-10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	11-13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	NA

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.
 For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
 Page 2 of 2

BMJ Open

Statin use and risk of liver cancer: an update meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005399.R1
Article Type:	Research
Date Submitted by the Author:	24-Jul-2014
Complete List of Authors:	Shi, Meng; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Zheng, Huiling; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Gong, Wei; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Nie, Biao; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Cui, Xiaobing; Nanfang Hospital, Southern Medical University, Department of Gastroenterology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Oncology
Keywords:	Gastrointestinal tumours < GASTROENTEROLOGY, Epidemiology < ONCOLOGY, Hepatobiliary tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

only

Statin use and risk of liver cancer: an update meta-analysis

Meng Shi¹, Huiling Zheng¹, Wei Gong¹, Biao Nie¹ and Xiaobing Cui^{1*}

¹Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Avenue North, Guangzhou 510515, China

***Corresponding author:** Dr. Xiaobing Cui, Tel.: +86-13631312723, Fax: +86-20-87280770, E-mail: xbing119@gmail.com.

Running title: Meta-analysis: statin and liver cancer

Key words: *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*

Abstract

Objective: Statins are commonly prescribed cholesterol-lowering drugs. Preclinical studies suggest that statins may possess cancer preventive properties. The primary objective of this meta-analysis was to determine the association between the statin use and the risk of liver cancer.

Design: Meta-analysis.

Setting: International.

Participants: A comprehensive literature search of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO and Cochrane Library was conducted through March 2014. The effect estimate was reported as pooled relative risk (RR) with 95% confidence intervals (CIs), using the random-effects model.

Results: A total of 12 studies (one individual patient data analysis of 22 randomized controlled trials, 5 cohorts, and 6 case-controls) were qualified for this meta-analysis, involving 5,640,313 participants including 35,756 liver cancer cases. Our results indicated a significant risk reduction of liver cancer among all statin users (RR 0.58, 95%CIs 0.51–0.67). The difference of the study designs can partly explained the significant heterogeneity found in the overall analysis ($I^2 = 65\%$, $P = 0.0006$). No evidence of publication bias was observed in this meta-analysis. Similar risk reductions were found in the subgroups analysis of Western and Asian countries, lipophilic and hydrophilia statins. There was a trend toward more risk reductions in subgroups with higher baseline risk, inadequate adjustment, and higher cumulative dosage of statin use.

1
2
3
4 **Conclusions:** This meta-analysis suggests that the statin is associated with a
5
6 significant risk reduction of liver cancer, when taken daily for cardiovascular event
7
8 prevention. However, this preventive effect might be overestimated due to the
9
10 exposure period, the indication and contraindication of statins, and other confounders.
11
12
13
14 Statins might be considered as an adjuvant in the treatment of liver cancer.

17 **Strengths and limitations of this study**

18
19
20 Statins are commonly prescribed as cholesterol-lowering drugs. In this comprehensive
21
22 meta-analysis, we demonstrate that the statin use is associated with a significant risk
23
24 reduction of liver cancer.
25
26

27
28 The difference of the study designs is the part reason that explained the significant
29
30 heterogeneity found in the overall analysis.
31

32
33 However, this preventive effect might be overestimated due to the exposure period,
34
35 the indication and contraindication of statins, and other confounders.
36

37
38 Statins might be considered as an adjuvant in the treatment of liver cancer.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and they are widely used to reduce the plasma cholesterol level and the risk of cardiovascular events.¹ Although there is a concern over their possible carcinogenicity raised in rodent studies,² preclinical studies indicate that statins have anticancer properties *in vitro* and *in vivo*, through inhibiting angiogenesis, inducing apoptosis, and suppressing tumor growth and metastasis.³⁻⁵

However, higher concentrations of statins are typically required to induce these effects, raising questions concerning the therapeutic relevance of statins on cancer.⁶

To date, clinical studies regarding the cancer incidence associated with statin administration have highlighted conflicting results. Moreover, a large number of meta-analyses have concluded that there was no association between statin use and risk of overall cancer,⁷⁻¹⁰ or cancer of breast¹¹, stomach,¹² or pancreas.¹³ There is only a modest protective effect of statins in prostate cancer¹⁴ and colorectal cancer.¹⁵

In contrary, recent studies reported encouraging results for risk reduction of liver cancer among all statin users. Previous meta-analysis, conducted by Singh *et al.* by including 10 studies, found that statin users were less likely to develop hepatocellular carcinoma (HCC) than statin non-users.¹⁶ However, Singh *et al.* included the ALERT, LIPS, and MEGA trials twice, by including three individual patient data (IPD) analysis of randomized controlled trials (RCTs).¹⁷⁻¹⁹ Meanwhile, some factors of stratification were not considered in their analyses, such as dose and timing of exposure to statins, and the selection of controls and confounders, which might limit

1
2
3 the evaluation of cancer risk.²⁰ Furthermore, the lipophilic statins are accompanied by
4
5 an extensive first-pass effect at the hepatic level.²¹ It is plausible that lipophilic statins
6
7 may have a better liver cancer preventive qualities than the hydrophilic ones.²²
8
9

10
11 Therefore, we performed this updated meta-analysis to assess the association between
12
13 the statin use and the risk of liver cancer, involving the recently published studies and
14
15 conducting more subgroup analyses based on the factors mentioned above. Our results
16
17 demonstrated that statin use was associated with an over 40% risk reduction in liver
18
19 cancer, which may have a significant translational potential in the clinical practice.
20
21
22 However, there were some confounders might overestimate this preventive effect of
23
24 statins.
25
26
27

28 **MATERIALS AND METHODS**

29 *Literature Search strategy*

30
31 This meta-analysis was conducted following the PRISMA guidelines.²³
32
33

34
35 The systematic computerized search for eligible studies were performed on the
36
37 database of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO, and
38
39 Cochrane Library, covering all studies published from their inception to March 5,
40
41 2014. The following terms were searched with both the subjects (MeSH terms) and
42
43 text-word search strategies: “(Statin OR HMG-CoA reductase inhibitors OR
44
45 Atorvastatin OR Cerivastatin OR Fluvastatin OR Lovastatin OR Pravastatin OR
46
47 Rosuvastatin OR Simvastatin) AND (Hepatocellular OR Hepatic OR Intrahepatic OR
48
49 Interlobular OR Liver) AND (Carcinoma OR Sarcomas OR Angiosarcoma OR Cancer
50
51 OR Neoplasm). Additionally, the relevant reviews and retrieved articles were searched
52
53
54
55
56
57
58
59
60

1
2
3
4 manually for more eligible studies.

5
6 In study searching, only the original researches, published in form of peer review
7
8 article or meeting abstract, were included. No language restrictions were imposed.
9
10
11 However, the studies we included were all published in English.
12

13 ***Study selection***

14
15 The inclusion criteria were: (1) randomized controlled trial (RCTs), cohort studies or
16
17 case-control studies; (2) original studies that assessed the effect of statin use on the
18
19 risk of liver cancer, compared with placebo or no treatment; (3) liver cancer cases
20
21 were identified according to the International Classification of Diseases codes (ICD);
22
23 and (4) studies with estimate of relative risk (risk ratio, RR) of liver cancer, or with
24
25 data sufficient to calculate it.
26
27
28
29

30
31 The exclusion criteria were: (1) study design not meeting the inclusion criteria; (2)
32
33 studies without estimate of RR, or without sufficient data to calculate it; or (3) studies
34
35 with duplicated or overlap reports.
36
37
38

39 ***Data extraction***

40
41 Two independent investigators (M. Shi and X.B. Cui) extracted data from the eligible
42
43 studies using a predefined data collection form. The differences of data extraction
44
45 were resolved by consensus referring back to the original article. The extracted
46
47 information included: (1) Studies: first author, year of publication, study design,
48
49 location, patient populations, period, and follow-up; (2) Statins: type, dosage or
50
51 duration of statin use; (3) liver cancer: case identification, number of liver cancer,
52
53 crude RR with 95% confidence intervals (CIs), adjusted RR reflecting the greatest
54
55
56
57
58
59
60

1
2
3
4 degree of control for confounders, and confounders for adjustment (including
5
6 variables for matching). When the RR were not available, the RR with 95% CIs were
7
8 calculated from the raw data in original studies.
9

10
11 We extracted different measurements of effect estimates from original studies, such as
12
13 Relative Risk (RR), Odds Ratio (OR), Hazard Ratio (HR), and Observed/Expected
14
15 ratio. Due to the fact that the incidence of liver cancer was low in all studies, these
16
17 different measurements can be used to provide similar estimates of RR.
18
19

20 21 ***Methodological quality assessment*** 22

23
24 Of note, the included RCT was pooled analysis of other RCTs, therefore, it is
25
26 inappropriate to assess the methodological quality. The methodological quality of
27
28 cohort and case-control studies were assessed on the Newcastle-Ottawa Scale,²⁴
29
30 including eight items that were categorized three categories: selection (four items, one
31
32 star each), comparability (one item, up to two stars), and exposure/outcome (three
33
34 items, one star each). A “star” presents a “high” quality choice of each item.
35
36
37
38

39 ***Statistical analysis*** 40

41
42 The overall meta-analysis was first performed, followed by the subgroup analyses,
43
44 based on study design, baseline risk of liver cancer, confounding adjustment, study
45
46 location, and pharmacokinetic. Meanwhile, we conducted subgroup analyses based on
47
48 studies which reported RR estimate for higher cumulative dosage of statin use, when
49
50 appropriate data were available.
51
52

53
54 To take into account the heterogeneity and provide a more conservative estimate, the
55
56 inverse variance method was used to estimate the pooled RR and corresponding 95%
57
58
59
60

1
2
3
4 CIs, and data were pooled using a random effects model. Heterogeneity was assessed
5
6 using the Chi-squared statistic (P) together with the Higgins I-squared statistic (I^2), a
7
8 P value <0.10 was considered statistically significant for heterogeneity; and an I^2
9
10 value $> 50\%$ was considered a measure of severe heterogeneity.²⁵

11
12
13
14 Publication bias was assessed using the Begg's test and the Egger's test.²⁶ Influence
15
16 analysis was performed to investigate the influence of a single study on the overall
17
18 meta-analysis estimate, by omitting one study in each turn. Test for interaction was
19
20 applied to identify the difference between pooled RR from subgroup analysis using
21
22 the method described by Altman and Bland.²⁷ All statistical tests were two-sided and
23
24 $P < 0.05$ was considered statistically significant, unless otherwise specified. Software
25
26 Review Manager (RevMan5.2, Copenhagen) and STATA (Stata 11.2, Texas) were
27
28 used for the statistical analysis.
29
30
31
32

33 34 **Results**

35 36 ***Study selection***

37
38
39 **Figure 1** illustrated the process of study selection for the meta-analysis. Of the 1424
40
41 potentially relevant references identified by electric and manual search, 142 were
42
43 selected for full-text review after screening titles and abstracts. Finally, a total of 12
44
45 studies were included, with one IPD analysis,¹⁹ five cohort studies,²⁸⁻³² and six
46
47 case-control studies.³³⁻³⁸ One case-control study was presented solely in abstract
48
49 form.³³
50
51
52

53
54 Of note, the cohort study conducted by Friedman *et al.* reported RR estimate
55
56 separately for different gender (male and female),²⁹ we considered these two reports
57
58
59
60

1
2
3
4 as separate studies. Therefore, a total of thirteen reports were included for the present
5
6 meta-analysis.
7

8 *Study characteristics*

9
10 **Table 1** summarized the characteristics of qualified studies in this meta-analysis. The
11
12 12 studies, involving 5,640,313 participants with 35,756 liver cancer cases, were
13
14 published between 2005 and 2013. The “RCT” in the present study was pooled
15
16 analysis of 22 clinical trials,¹⁹ which investigated statins therapy in cardiovascular
17
18 event prevention and reported the occurrence of liver cancer as adverse event. The
19
20 observational studies were conducted with the local or national health databases, the
21
22 statin exposure were identified by linkage to prescription databases, and the controls
23
24 were matched mainly by age, sex and index date. Except one cohort adopted ICD-10
25
26 C22,²⁸ all other studies identified liver cancer cases according to the ICD-9 155. Of
27
28 note, two cohorts were restricted to patients with HBV infection,³¹ and HCV
29
30 infection;³² one case-control only included patients with diabetes mellitus;³⁴ two
31
32 observational studies included patients aged at least 45 years.^{30 35}
33
34
35
36
37
38
39
40

41 **Table 2** summarized the data of the included studies. In the RCT¹⁹ and one cohort
42
43 study,³⁰ the RR with 95% CIs were calculated from the 2×2 tables defined by the
44
45 incidence of liver cancer and the statin use status. The observational studies reported
46
47 different measurements of RR estimates with adjustment by confounders. Several
48
49 observational studies adopted the important risk factors of liver cancer for
50
51 adjustments^{31 32 34-36}, such as HBV infection, HCV infection, cirrhosis, alcoholic liver
52
53 disease, or non-alcoholic fatty liver disease (NAFLD).³⁹ Of note, only two studies
54
55
56
57
58
59
60

1
2
3 adjusted for the cholesterol level,^{30 38} and no study adjusted for the metabolic
4
5
6 syndrome, which might also influence the risk of liver cancer.³⁹
7

8 9 *Methodological quality*

10
11 For the cohort and case-control studies, the median score was 7 on the
12
13 Newcastle-Ottawa Scale, with a range of 5 to 8 (**Supplementary Table 1**). These
14
15 results indicated that the observational studies were in a reasonable good quality.
16
17

18 19 *Overall meta-analysis*

20
21 **Figure 2** depicted the forest plot of RR estimate with 95% CIs from individual studies
22
23 and overall meta-analysis. In the overall meta-analysis, pooled results showed a
24
25 statistically significant decrease in the liver cancer risk among all statin users (RR
26
27 0.58, 95%CIs 0.51–0.67). Of note, a statistically significant heterogeneity was
28
29 observed ($I^2 = 65%$, $P = 0.0006$). The P -values of Begg's test and Egger's test were
30
31 0.669 and 0.749, respectively, both suggesting there was no evidence of publication
32
33 bias. In the influence analysis, the omission of any individual studies did not alter the
34
35 direction and magnitude of the observed effect (**Supplementary Figure 1**).
36
37
38
39

40 41 *Subgroup analyses and Test for interaction*

42
43 We first performed preplanned subgroup analyses based on study design, baseline risk
44
45 of liver cancer, confounding adjustment, and study location (**Table 3**).
46
47

48
49 The RCT showed there is no significant association between statin use and risk of
50
51 liver cancer (RR 1.06, 0.66–1.71). But the observational studies indicated a significant
52
53 decrease of liver cancer risk among all statin users (RR 0.57, 0.50–0.64; $I^2 = 61%$, $P =$
54
55 0.003) (**Figure 2**). Furthermore, we found a greater risk reduction in the subgroup
56
57
58
59
60

1
2
3
4 analysis of cohort studies (RR 0.51, 0.44–0.58; $I^2 = 18\%$, $P = 0.30$) than in the
5
6 case-control studies (RR 0.63, 0.54–0.73; $I^2 = 46\%$, $P = 0.10$) (**Supplementary**
7
8 **Figure 2**).

9
10 Test for interaction showed significant results between subgroups of the RCT and
11
12 observational studies ($P_{\text{interaction}} = 0.01$, $Z = 2.47$), and between subgroups of the
13
14 cohort and case-control studies ($P_{\text{interaction}} = 0.04$, $Z = -2.03$). These results indicated
15
16 that the difference of the study designs was the part reason that why there was severe
17
18 heterogeneity in the overall analysis (**Table 3**).

19
20 In the subgroup analysis of the four studies with higher baseline risk of liver
21
22 cancer,^{30-32 35} defined as patients with older age, HBV or HCV infection, there was a
23
24 trend toward more decrease of liver cancer risk (RR 0.52, 0.47-0.59; $I^2 = 16\%$, $P =$
25
26 0.31) than in the other eight studies with general population^{19 28 29 33 34 36-38} (RR 0.63,
27
28 0.52–0.75; $I^2 = 59\%$, $P = 0.01$) (**Supplementary Figure 3**).

29
30 We defined the RCT or studies adjusted for at least 4 of 7 important confounders,
31
32 such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD,
33
34 HBV treatment, or HCV treatment,³⁹ were adjusted adequately. Subgroup analysis of
35
36 these six studies^{19 31 32 34-36} found a trend toward less decrease of liver cancer risk (RR
37
38 0.64, 0.53-0.77; $I^2 = 81\%$ $P = 0.0001$) than the other six studies^{28-30 33 37 38} (RR, 0.51,
39
40 0.43-0.60; $I^2 = 3\%$, $P = 0.40$) (**Supplementary Figure 4**).

41
42 Subgroup analyses based on study location found a similar risk reduction of liver
43
44 cancer in the Western countries (RR 0.61, 0.48–0.76; $I^2 = 64\%$, $P = 0.007$) and in the
45
46 Asian countries (RR 0.56, 0.48–0.64; $I^2 = 51\%$, $P = 0.09$). (**Supplementary Figure 5**)
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Besides the overall RR estimates, some studies reported different RR estimate for
5
6 different pharmacokinetic and dosage of statin use (**Supplementary Table 2**). We
7
8 conducted further subgroup analyses based on these available data.
9

10
11 According to the different pharmacokinetic, statins can be classified as lipophilic
12
13 statins (Atorvastatin, Fluvastatin, Lovastatin, and Simvastatin) and hydrophilia statins
14
15 (Pravastatin and Rosuvastatin).²¹ Subgroup analysis of lipophilic statins^{29 31 34-36}
16
17 found a significant decrease of liver cancer risk (RR 0.57, 0.50–0.65; $I^2 = 50%$, $P =$
18
19 0.08). And there was a similar result among users of hydrophilia statins^{31 35 36} (RR
20
21 0.59, 0.41–0.84; $I^2 = 50%$, $P = 0.13$) (**Supplementary Figure 6**).
22
23

24
25 Test for interaction showed non-significant results for subgroups with different
26
27 baseline risk, confounding adjustment, study location, or pharmacokinetic ($P_{\text{interaction}} =$
28
29 0.08, 0.08, 0.54 and 0.86, respectively) (**Table 3**). Therefore, there is no strong
30
31 evidence to support a different preventive effect of statins on liver cancer in these
32
33 subgroups.
34
35

36
37 Subgroup analysis of six studies with higher cumulative dose of statin use, defined as
38
39 statin use more than 180 cumulative defined daily dose (cDDD) or 0.5 years
40
41 (cumulative duration), showed a trend toward more risk reduction of liver cancer (RR
42
43 0.53, 0.36-0.79), but with a high degree of heterogeneity ($I^2 = 90%$, $P < 0.00001$)
44
45 (**Supplementary Figure 7**).
46
47
48
49

50 51 **Discussion**

52
53 This present meta-analysis represents the most comprehensive review to date on the
54
55 association between the statin use and the liver cancer risk, by including 12 studies
56
57
58
59
60

1
2
3
4 (one IPD analysis of 22 RCTs, 5 cohort studies, and 6 case-control studies) and
5
6 involving 5,640,313 participants with 35,756 liver cancer cases. Overall, we found
7
8 that statin use was associated with an over 40% risk reduction in liver cancer
9
10 compared with nonusers (RR 0.58, 95%CI 0.51–0.67). This result was in line with the
11
12 previous three meta-analyses: Singh *et al.* included 10 studies and suggested statin
13
14 users were less likely to develop HCC (OR 0.63, 95%CI 0.52–0.76),¹⁶ Pradelli *et al.*
15
16 and Zhang *et al.* included 5 and 7 observational studies and found a summary RR of
17
18 0.58 (95%CI 0.46–0.74) and 0.61 (95%CI 0.49–0.76), respectively.^{40 41}

19
20 The IPD analysis of 22 RCTs showed there is no significant association between statin
21
22 use and risk of liver cancer. The significant risk reduction of liver cancer among all
23
24 statin users was seen primarily in the observational studies, and this preventive effect
25
26 was relatively convinced in the cohorts than in the case-controls. There were some
27
28 reasons to explain the different findings between RCTs and observational studies.
29
30

31
32 First, the exposure period to statins might be shorter than the period to carcinogenesis
33
34 and the latency to diagnosis in the cohorts and the case-controls. The observational
35
36 studies defined statin use varying in dosage and duration, from patients who received
37
38 ≥ 1 cDDD or >1 Rx of statins to more than 0.5 years (**Table 1**). On the other hand, the
39
40 median period of statin use was 5.1 years in the RCTs. Although there was a trend
41
42 toward more risk reduction of liver cancer with higher cumulative dose of statin use,
43
44 this defect might still result in overestimating the cancer-preventive effect of statins in
45
46 the observational studies.
47
48

49
50 Second, clinical studies demonstrated that higher serum total cholesterol
51
52
53
54
55
56
57
58
59
60

1
2
3
4 concentration was associated with decreased risk of liver cancer (**Supplementary**
5
6 **Table 3**).⁴²⁻⁴⁴ Meanwhile, there were inverse association between use of non-statin
7
8 lipid-lowering drugs and risk of the liver cancer.^{35 38} Meanwhile, because of the
9
10 contraindication, statins might not prescribed to the patients with the chronic liver
11
12 disease, which is known as a risk factor of liver cancer. Unfortunately, the
13
14 observational studies included in this analysis seldom adopted these factors for
15
16 adjustment. Actually, subgroup analysis of studies with adequate adjustment showed a
17
18 trend toward less risk reduction, indicating the potential of overestimate this
19
20 preventive effect by confounders.
21
22
23
24

25
26 Third, the RCTs included lower risk population (patients with cardiovascular disease
27
28 rather than HBV /HCV infection), might not be powerful enough to investigate the
29
30 liver cancer outcomes, which were much rarer than cardiovascular events. In addition,
31
32 subgroup analysis of studies with higher baseline risk showed a trend toward more
33
34 decrease of liver cancer risk.
35
36
37
38

39 These reasons suggested that the observed modulation of cancer incidence cannot be
40
41 ascribable to a direct statin-mediated effect,²⁰ the exposure period, the indication (e.g.
42
43 hyperlipidemia) and contraindication (e.g. chronic liver disease) of statins might
44
45 overestimate its cancer-preventive effect.
46
47
48

49 We found similar results in Western countries and Asian countries, which were
50
51 different from the meta-analysis conducted by Singh *et al.* which concluded that the
52
53 inverse association of statins with HCC was stronger in the Asian population.
54
55 Considering four more studies we included, this difference might be caused by the
56
57
58
59
60

1
2
3
4 insufficient data in their meta-analysis. Based on the pharmacokinetics, it is plausible
5
6 that lipophilic and hydrophilic statins will differ in their liver cancer prevention
7
8 qualities.^{21 22} However, subgroup analysis of lipophilic and hydrophilic statins showed
9
10 similar results.
11

12
13 Besides the limitations described previously, there were some other limitations should
14
15 be noted. First, a significant heterogeneity was observed in the present meta-analysis,
16
17 which might results from the difference in study design. Results of subgroup analyses
18
19 would also be limited by this heterogeneity. Second, the adherence to statin therapy is
20
21 known to be associated with healthy lifestyle, which might affect the cancer
22
23 outcome.⁴⁵ Such information is hard to be captured in databases or medical record in
24
25 the observational studies.⁴⁶ Third, five observational studies were conducted using the
26
27 Taiwanese National Health Insurance Research Database (NHIRD),^{31 32 35-37} although
28
29 they were not in the same period, these studies might contain overlapping groups of
30
31 patients. These limitations mentioned above might lead to confounding of overall
32
33 results from the present study, and should be considered in future studies aiming at
34
35 confirming the protective effects of statins on human cancer risk.
36
37

38
39 The strengths of our meta-analysis were as follows: First, we performed a much more
40
41 comprehensive search and more subgroup analyses, compared with the previous
42
43 meta-analyses; Second, the methodological quality of the included studies were
44
45 reasonable good; Third, publication bias, which due to the tendency of not publishing
46
47 small studies with null results, were not found in our meta-analysis.
48
49

50
51 Of note, preclinical studies have indicated that statins possess synergism with other
52
53
54
55

1
2
3
4 therapeutic agents *in vitro* and *in vivo* for liver cancer.^{47 48} Some clinical studies have
5
6 also demonstrated that statins would prolong survival in patients with advanced liver
7
8 cancer (**Supplementary Table 4**),⁴⁹⁻⁵² and associated with risk reduction of
9
10 recurrence after curative surgery in patients of HBV related HCC.⁵³ Therefore,
11
12 considerable interest exists in adjunctive therapy with statins for liver cancer. In fact,
13
14 there were some RCTs ongoing to determine the effectiveness of pravastatin, when
15
16 used in combination with sorafenib, in the treatment of liver cancer (**Supplementary**
17
18 **Table 5**).

19
20
21
22
23
24 Currently, physicians are less likely to prescribe statins for patients with chronic liver
25
26 disease, based on the concerns about the statin-induced liver injury.³¹ However, there
27
28 were number of studies have demonstrated the safe use, even salutary effects.⁵⁴⁻⁵⁶
29
30
31 Meanwhile, the risk of serious statin-related liver injury appears to be no greater than
32
33 the background incidence of this rare event.⁵⁷ Therefore, considering their benefits for
34
35 cardiovascular event prevention and the potential effect in liver cancer prevention and
36
37 treatment, statins should not be denied to these patients.
38
39

40
41 In conclusion, our results suggest that statin use is associated with a significant risk
42
43 reduction of liver cancer, when taken daily for cardiovascular event prevention.
44
45 However, this preventive effect might be overestimated due to the exposure period,
46
47 indication and contraindication of statins, and other confounders. Statins might be
48
49 considered as an adjuvant in the treatment of liver cancer.
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENT

We thank Medjaden Bioscience Limited and Gui Lv for assisting in the preparation and revision of this manuscript.

CONTRIBUTORSHIP STATEMENT

XB Cui had the original idea, Meng Shi and XB Cui worked together to develop an appropriate theoretical framework and design. XB Cui developed the search, Meng Shi and XB Cui were involved in the selection process. Meng Shi and XB Cui extracted relevant data, XB Cui and Biao Nie performed the statistical analysis and all authors were involved in the data interpretation. Meng Shi and Biao Nie wrote the manuscript draft and revised the draft based on input from the other authors. All authors revised it critically for content and approved the final version.

COMPETING INTERESTS

There are no competing interests

FUNDING

None.

DATA SHARING

No additional data available.

REFERENCES:

1. Baigent C, Keech A, Kearney PM, *et al.* Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;**366**(9493):1267-78.
2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA* 1996;**275**(1):55-60.
3. Demierre MF, Higgins PD, Gruber SB, *et al.* Statins and cancer prevention. *Nat Rev Cancer* 2005;**5**(12):930-42.
4. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. *J Cancer Res Ther* 2012;**8**(2):176-83.
5. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2012;**27**(11):1654-64.
6. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. *Cancer Chemother Pharmacol* 2011;**67**(4):729-39.
7. Dale KM, Coleman CI, Henyan NN, *et al.* Statins and cancer risk: a meta-analysis. *JAMA* 2006;**295**(1):74-80.
8. Browning DRL, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. *Int J Cancer* 2007;**120**(4):833-43.
9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. *Eur J Cancer* 2008;**44**(15):2122-32.
10. Baigent C, Blackwell L, Emberson J, *et al.* Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;**376**(9753):1670-81.
11. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Res Treat* 2012;**135**(1):261-9.
12. Shimoyama S. Statins and gastric cancer risk. *Hepatogastroenterology* 2011;**58**(107-108):1057-61.
13. Cui X, Xie Y, Chen M, *et al.* Statin use and risk of pancreatic cancer: a meta-analysis. *Cancer Causes Control* 2012;**23**(7):1099-111.
14. Bansal D, Undela K, D'Cruz S, *et al.* Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. *PLoS One* 2012;**7**(10):e46691.
15. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. *Gut* 2010;**59**(11):1572-85.
16. Singh S, Singh PP, Singh AG, *et al.* Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. *Gastroenterology* 2013;**144**(2):323-32.
17. Stein EA, Corsini A, Gimpelewicz CR, *et al.* Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract* 2006;**60**(9):1028-34.
18. Matsushita Y, Sugihara M, Kaburagi J, *et al.* Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. *Pharmacoepidemiol Drug Saf* 2010;**19**(2):196-202.
19. Emberson JR, Kearney PM, Blackwell L, *et al.* Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.

- 1
2
3 PLoS One 2012;**7**(1):e29849.
- 4 20. Gazerro P, Bifulco M. Statins and Cancer in Gastroenterology: New Insight? *Gastroenterology*
5 2013;**144**(7):1572-3.
- 6
7 21. Gazerro P, Proto MC, Gangemi G, *et al.* Pharmacological actions of statins: a critical appraisal in
8 the management of cancer. *Pharmacol Rev* 2012;**64**(1):102-46.
- 9
10 22. Gronich N, Rennert G. Beyond aspirin - Cancer prevention with statins, metformin and
11 bisphosphonates. *Nat Rev Clin Oncol* 2013;**10**(11):625-42.
- 12
13 23. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and
14 meta-analyses: the PRISMA statement. *BMJ* 2009;**339**:b2535.
- 15
16 24. GA Wells, B Shea, D O'Connell, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of
17 nonrandomised studies in meta-analyses.
18 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 19
20 25. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ*
21 2003;**327**(7414):557-60.
- 22
23 26. METABIAS: Stata module to test for small-study effects in meta-analysis [program], 2009.
- 24
25 27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*
26 2003;**326**(7382):219.
- 27
28 28. Friis S, Poulsen AH, Johnsen SP, *et al.* Cancer risk among statin users: A population-based cohort
29 study. *Int J Cancer* 2005;**114**(4):643-7.
- 30
31 29. Friedman GD, Flick ED, Udaltsova N, *et al.* Screening statins for possible carcinogenic risk: up to 9
32 years of follow-up of 361,859 recipients. *Pharmacoepidemiol Drug Saf* 2008;**17**(1):27-36.
- 33
34 30. Marelli C, Gunnarsson C, Ross S, *et al.* Statins and Risk of Cancer A Retrospective Cohort Analysis of
35 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult
36 Americans. *J Am Coll Cardiol* 2011;**58**(5):530-7.
- 37
38 31. Tsan YT, Lee CH, Wang JD, *et al.* Statins and the risk of hepatocellular carcinoma in patients with
39 hepatitis B virus infection. *J Clin Oncol* 2012;**30**(6):623-30.
- 40
41 32. Tsan YT, Lee CH, Ho WC, *et al.* Statins and the risk of hepatocellular carcinoma in patients with
42 hepatitis C virus infection. *J Clin Oncol* 2013;**31**(12):1514-21.
- 43
44 33. Khurana V, Saluja A, Caldito G, *et al.* Statins are protective against hepatocellular cancer in patients
45 with hepatitis C virus infection: Half a million US veterans' study. *Gastroenterology*
46 2005;**128**(4, Suppl. 2):A714.
- 47
48 34. El-Serag HB, Johnson ML, Hachem C, *et al.* Statins are associated with a reduced risk of
49 hepatocellular carcinoma in a large cohort of patients with diabetes. *Gastroenterology*
50 2009;**136**(5):1601-8.
- 51
52 35. Chiu HF, Ho SC, Chen CC, *et al.* Statin use and the risk of liver cancer: a population-based
53 case-control study. *Am J Gastroenterol* 2011;**106**(5):894-8.
- 54
55 36. Lai SW, Liao KF, Lai HC, *et al.* Statin use and risk of hepatocellular carcinoma. *Eur J Epidemiol*
56 2013;**28**(6):485-92.
- 57
58 37. Leung HW, Chan AL, Lo D, *et al.* Common cancer risk and statins: a population-based case-control
59 study in a Chinese population. *Expert Opin Drug Saf* 2013;**12**(1):19-27.
- 60
61 38. Chaiteerakij R, Yang JD, Harmsen WS, *et al.* Risk factors for intrahepatic cholangiocarcinoma:
62 association between metformin use and reduced cancer risk. *Hepatology* 2013;**57**(2):648-55.
- 63
64 39. Singh S, Singh PP, Roberts LR, *et al.* Chemopreventive strategies in hepatocellular carcinoma. *Nat*
65 *Rev Gastroenterol Hepatol* 2014;**11**(1):45-54.

- 1
- 2
- 3 40. Pradelli D, Soranna D, Scotti L, *et al.* Statins and primary liver cancer: a meta-analysis of
- 4 observational studies. *Eur J Cancer Prev* 2013;**22**(3):229-34.
- 5
- 6 41. Zhang H, Gao C, Fang L, *et al.* Statin use and risk of liver cancer: A meta-analysis of 7 studies
- 7 involving more than 4.7 million patients. *World J Meta-Anal* 2013;**1**(3):130-7.
- 8
- 9 42. Ahn J, Lim U, Weinstein SJ, *et al.* Prediagnostic total and high-density lipoprotein cholesterol and
- 10 risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2009;**18**(11):2814-21.
- 11
- 12 43. Iso H, Ikeda A, Inoue M, *et al.* Serum cholesterol levels in relation to the incidence of cancer: the
- 13 JPHC study cohorts. *Int J Cancer* 2009;**125**(11):2679-86.
- 14
- 15 44. Kitahara CM, de Gonzalez AB, Freedman ND, *et al.* Total Cholesterol and Cancer Risk in a Large
- 16 Prospective Study in Korea. *J Clin Oncol* 2011;**29**(12):1592-8.
- 17
- 18 45. Brookhart MA, Patrick AR, Dormuth C, *et al.* Adherence to lipid-lowering therapy and the use of
- 19 preventive health services: an investigation of the healthy user effect. *Am J Epidemiol*
- 20 *2007*;**166**(3):348-54.
- 21
- 22 46. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. *Expert Opin*
- 23 *Drug Saf* 2010;**9**(4):603-21.
- 24
- 25 47. Kim W, Yoon JH, Kim JR, *et al.* Synergistic anti-tumor efficacy of lovastatin and protein kinase
- 26 C-beta inhibitor in hepatocellular carcinoma. *Cancer Chemother Pharmacol*
- 27 *2009*;**64**(3):497-507.
- 28
- 29 48. Polo MP, Crespo R, de Bravo MG. Geraniol and simvastatin show a synergistic effect on a human
- 30 hepatocarcinoma cell line. *Cell Biochem Funct* 2011;**29**(6):452-8.
- 31
- 32 49. Kawata S, Yamasaki E, Nagase T, *et al.* Effect of pravastatin on survival in patients with advanced
- 33 hepatocellular carcinoma. A randomized controlled trial. *Br J Cancer* 2001;**84**(7):886-91.
- 34
- 35 50. Lersch C, Schmelz R, Erdmann J, *et al.* Treatment of HCC with pravastatin, octreotide, or
- 36 gemcitabine - A critical evaluation. *Hepatogastroenterology* 2004;**51**(58):1099-103.
- 37
- 38 51. Graf H, Jungst C, Straub G, *et al.* Chemoembolization combined with pravastatin improves survival
- 39 in patients with hepatocellular carcinoma. *Digestion* 2008;**78**(1):34-8.
- 40
- 41 52. Georgescu EF, Badulescu F, Dumitrescu D, *et al.* Lovastatin may enhance cytostatic effects of
- 42 sorafenib in hepatic carcinoma. Primary results of a pilot study. *Hepatol Int* 2011;**5**(1):423.
- 43
- 44 53. Wu CY, Chen YJ, Ho HJ, *et al.* Association between nucleoside analogues and risk of hepatitis B
- 45 virus-related hepatocellular carcinoma recurrence following liver resection. *JAMA*
- 46 *2012*;**308**(18):1906-14.
- 47
- 48 54. Lewis JH, Mortensen ME, Zweig S, *et al.* Efficacy and safety of high-dose pravastatin in
- 49 hypercholesterolemic patients with well-compensated chronic liver disease: Results of a
- 50 prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology*
- 51 *2007*;**46**(5):1453-63.
- 52
- 53 55. Nelson A, Torres DM, Morgan AE, *et al.* A pilot study using simvastatin in the treatment of
- 54 nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol*
- 55 *2009*;**43**(10):990-4.
- 56
- 57 56. Lewis JH. Clinical Perspective: Statins and the Liver-Harmful or Helpful? *Dig Dis Sci*
- 58 *2012*;**57**(7):1754-63.
- 59
- 60 57. Bader T. The myth of statin-induced hepatotoxicity. *Am J Gastroenterol* 2010;**105**(5):978-80.

1
2
3
4
5
6
7
8
9 **Figure legends:**

10
11 **Figure 1.** Flow chart of study selection in the present meta-analysis.

12
13
14 **Figure 2.** Overall meta-analysis of the statin use and the liver cancer risk.

15
16 **Supplementary Figure 1.** Influence analysis.

17
18
19 **Supplementary Figure 2.** Subgroup analyses based on study design.

20
21 **Supplementary Figure 3.** Subgroup analyses based on baseline risk of liver cancer.

22
23
24 **Supplementary Figure 4.** Subgroup analyses based on confounder adjustment.

25
26
27 **Supplementary Figure 5.** Subgroup analyses based on study location.

28
29 **Supplementary Figure 6.** Subgroup analyses based on pharmacokinetic of statins.

30
31
32 **Supplementary Figure 7.** Subgroup analysis of higher cumulative dose of statin use.

Table 1. Study characteristics

Studies	Study design	Patient population	Study period	Cases defined	Follow-up	Statins type	Dosage/Duration of Statin use
Emberson, 2012, UK ¹⁹	RCT	IPD analysis of 22 RCTs	-	ICD-9 155	5.1 years (Me)	A, F, L, P, R, S	5.1 years (Me)
Friis, 2005, North Jutland ²⁸	Cohort	General population (CPR)	1989-2002	ICD-10 C22	3.3 years (M)	Unspecified	≥2 Rx
Friedman, 2008, USA ²⁹	Cohort	General population (KPMCP)	1994-2003	ICD-9-CM 155	> 2 years	A, L, S (97.6%)	≥1 Rx
Marelli, 2011, USA ³⁰	Cohort	General older population (men ≥ 45 and women ≥ 55 years; GE Centricity)	1990-2009	ICD-9 155	4.6 years (M)	Unspecified	≥1 cDDD
Tsan, 2012, Taiwan ³¹	Cohort	Patients with HBV infection (NHIRD)	1997-2008	ICD-9 155	9.9 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Tsan, 2013, Taiwan ³²	Cohort	Patients with HCV infection (NHIRD)	1999-2010	ICD-9 155	10.7 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Khurana, 2005, USA ³³	Case control	General population (VISN)	1997-2002	ICD-9 155	NR	Unspecified	≥1 Rx
El-Serag, 2009, USA ³⁴	Case control	Diabetes patients (VA)	1997-2002	ICD-9-CM 155	2.4 years (M)	A, C, F, L, P, and S	1.6 years (M)
Chiu, 2011, Taiwan ³⁵	Case control	Older patients (≥ 50 years; NHIRD)	2005–2008	ICD-9-CM 155	NR	A, F, L, P, R, and S	≥ 1 cDDD
Lai, 2013, Taiwan ³⁶	Case control	General population (NHIRD)	2000-2009	ICD-9-CM 155	1.4 years (M)	A, F, L, P, R, and S	≥1 Rx
Leung, 2013, Taiwan ³⁷	Case control	General population (NHIRD)	2000-2008	ICD-9-CM 155	4.1 years (M)	Unspecified	> 0.5 years
Chaiteerakij, 2013, USA ³⁸	Case control	Hyperlipidemia patients (Mayo Clinic)	2000-2010	ICD-9-CM 155	>1 years	Unspecified	≥1 Rx

Patients population: IPD = Individual patient data, RCT = randomized controlled trials, CPR = the Central Population Register of Danish citizens, KPMCP = the Kaiser Permanente Medical Care Program in northern California, GE Centricity = the General Electric Centricity database, NHIRD = the Taiwanese National Health Insurance research database, VISN = Veterans Integrated Service Networks 16 Veteran Affairs database, VA = Veterans Affairs national databases, Mayo Clinic = Mayo Clinic (Rochester, MN), HBV = hepatitis B virus; Cases defined: ICD-9 or -10 = International Classification of Diseases, Ninth Revision or Tenth Revision, CM = Clinical Modification; Duration of follow-up: When the follow-up periods of statin user and nonuser were different, only the shorter one was showed, and all periods were transformed to years; Statin type: A = Atorvastatin, C = Cerivastatin, F = Fluvastatin, L = Lovastatin, P = Pravastatin, R = Rosuvastatin, S = Simvastatin, Non-statin = Non-statin cholesterol-lowering drug(s) only; Duration of statin use: M = Mean, Me = Median, ≥1 cDDD = more than 1 cumulative defined daily dose before the diagnosis of liver cancer, Rx = prescriptions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Study data

Studies	Intervention/ Cases		Control		Measurements of effect estimates	Crude RR with 95% CIs	Adjusted RR with 95% CIs	Confounders for adjustment
	No. of event/ No. of exposure	No. of total	No. of event/ No. of exposure	No. of total				
Emberson, 2012, UK ¹⁹	35	67258	33	67279	RR	1.06 (0.66, 1.71)*	1.06 (0.66, 1.71)*	Randomization
Friis, 2005, North Jutland ²⁸	1	12251	166	334754	OR	NA	1.16 (0.46-2.90)	1,2, 16, 21, 23
Friedman(Male), 2008, USA ²⁹	32	192598	NA	1904876	HR	NA	0.49 (0.34-0.70)	16
Friedman(Female), 2008, USA ²⁹	10	169261	NA	1976332	HR	NA	0.40 (0.21-0.75)	
Marelli, 2011, USA ³⁰	13	45857	24	45857	RR	0.31 (0.14-0.68)*	0.31 (0.14-0.68)*	1-5, 14, 16-18, 26, 27
Tsan, 2012, Taiwan ³¹	58	2785	963	30628	HR	0.66 (0.51- 0.86)	0.47 (0.36-0.61)	1, 2, 7, 8, 11, 12
Tsan, 2013, Taiwan ³²	1378	35023	26505	225841	HR	0.42 (0.39-0.46)	0.53 (0.49–0.58)	1, 2, 7, 8, 11, 13
Khurana, 2005, USA ³³	NA	NA	NA	NA	OR	NA	0.52 (0.41- 0.67)	1, 11, 13
El-Serag, 2009, USA ³⁴	447	1303	2766	5212	OR	0.46 (0.40-0.52)	0.74 (0.64-0.87)	1-3, 6, 8, 9, 11-13, 21, 24, 28
Chiu, 2011, Taiwan ³⁵	117	1166	195	1166	OR	0.53 (0.41-0.69)	0.62 (0.45-0.83)	1, 2, 8, 9, 11, 12, 20, 29
Lai, 2013, Taiwan ³⁶	255	3480	1635	13920	OR	0.61 (0.52–0.72)	0.71 (0.56–0.89)	1, 2, 8-13, 22, 24, 25
Leung, 2013, Taiwan ³⁷	26	424	6851	33781	HR	0.45 (0.30-0.67)	0.44 (0.28, 0.72)	1, 2, 11, 15, 20, 21, 23
Chaiteerakij, 2013, USA ³⁸	72	165	165	256	OR	NA	0.6 (0.4-0.9)	1-3, 8, 11, 17, 22, 28, 30

The RR with an asterisk mark (*) was calculated based on the raw data. The others, crude or adjusted, were extracted from the original paper; Confounders for adjustment: 1 = age, 2 = sex, 3 = race, 4 = BMI, 5 = smoking status, 6 = ethanol intake, 7 = socioeconomic status, 8 = cirrhosis, 9 = alcoholic liver disease, 10 = non-alcoholic fatty liver disease, 11 = diabetes mellitus, 12 = HBV infection, 13 = HCV infection, 14 = concomitant diagnoses (unspecified), 15 = Charlson score, 16 = calendar year, 17 = cholesterol (totalcholesterol, VLDL, LDL, or triglycerides), 18 = prostate-specific antigen, 19 = resection extent, 20 = other lipid-lowering agents, 21 = cardiovascular medications (aspirin, nonsteroidal anti-inflammatory medications, or angiotensin-converting enzymes inhibitors), 22 = metformin or thiazolidinedione, 23 = hormone-replacement therapy, 24 = HCV treatment, 25 = HBV treatment, 26 = medications taken (unspecified), 27 = the number of office visits, 28 = propensity to use statins, 29 = hospital stay, 30 = biliary tract diseases

Table 3. Subgroup analyses of included studies

Subgroup	No. of studies (reports)	Summary RR (95% CIs)	Heterogeneity, I ²	Heterogeneity, P value	P _{interaction}	
Study design	RCT	1	1.06 (0.66-1.71)	-	-	<i>P</i> = 0.01
	Observational studies	11(12)	0.57(0.50-0.64)	61%	<i>P</i> = 0.003	
Observational studies	Cohort studies	5 (6)	0.51 (0.44–0.58)	18%	<i>P</i> = 0.30	<i>P</i> = 0.04
	Case-control studies	6	0.63 (0.54–0.73)	46%	<i>P</i> = 0.10	
Baseline risk of liver cancer	Higher baseline risk	4	0.52 (0.47-0.59)	16%	<i>P</i> = 0.31	<i>P</i> = 0.08
	General population	8 (9)	0.63 (0.52–0.75)	59%	<i>P</i> = 0.01	
Confounding adjustment	Adequate adjustment	6	0.64(0.53-0.77)	81%	<i>P</i> = 0.0001	<i>P</i> = 0.08
	Inadequate adjustment	6 (7)	0.51 (0.43-0.60)	3%	<i>P</i> = 0.40	
Study location	Western studies	8 (9)	0.61 (0.48-0.76)	64%	<i>P</i> = 0.007	<i>P</i> = 0.54
	Asian studies	6	0.56 (0.48- 0.64)	51%	<i>P</i> = 0.09	
Pharmacokinetic	Hipophilic statins	5 (6)	0.57 (0.50-0.65)	50%	<i>P</i> = 0.08	<i>P</i> = 0.86
	Hydrophilia statins	3	0.59(0.41–0.84)	50%	<i>P</i> = 0.13	
Higher cumulative dosage of statin		6	0.53 (0.36-0.79)	90%	<i>P</i> <0.0001	-

RR = relative risk; higher baseline risk of liver cancer: patients with older age, HBV or HCV infection. Adequate adjustment: RCT or studies which adjusted for at least 4 of 7 important confounders, such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD, HBV treatment, or HCV treatment; Lipophilic statins: Atorvastatin, Fluvastatin, Lovastatin, or Simvastatin; Hydrophilia statins: Pravastatin or Rosuvastatin; Higher cumulative dosage of statin use: > 180cumulative defined daily dose or Duration of statin use > 0.5 years before the diagnosis of liver cancer.

Statin use and risk of liver cancer: an update meta-analysis

Meng Shi¹, Huiling Zheng¹, Wei Gong¹, **Biao Nie¹** and Xiaobing Cui^{1*}

¹Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Avenue North, Guangzhou 510515, China

***Corresponding author:** Dr. Xiaobing Cui, Tel.: +86-13631312723, Fax: +86-20-87280770, E-mail: xbing119@gmail.com.

Running title: Meta-analysis: statin and liver cancer

Key words: *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*

Abstract

Objective: Statins are commonly prescribed cholesterol-lowering drugs. Preclinical studies suggest that statins may possess cancer preventive properties. **The primary objective of this meta-analysis was to determine the association between the statin use and the risk of liver cancer.**

Design: Meta-analysis.

Setting: International.

Participants: A comprehensive literature search of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO and Cochrane Library was conducted through March 2014. The effect estimate was reported as pooled relative risk (RR) with 95% confidence intervals (CIs), using the random-effects model.

Results: **A total of 12 studies (one individual patient data analysis of 22 randomized controlled trials, 5 cohorts, and 6 case-controls) were qualified for this meta-analysis, involving 5,640,313 participants including 35,756 liver cancer cases.** Our results indicated a significant risk reduction of liver cancer among all statin users (RR 0.58, 95%CIs 0.51–0.67). **The difference of the study designs can partly explained the significant heterogeneity found in the overall analysis ($I^2 = 65%$, $P = 0.0006$).** No evidence of publication bias was observed in this meta-analysis. **Similar risk reductions were found in the subgroups analysis of Western and Asian countries, lipophilic and hydrophilia statins. There was a trend toward more risk reductions in subgroups with higher baseline risk, inadequate adjustment, and higher cumulative dosage of statin use.**

1
2
3
4 **Conclusions:** This meta-analysis suggests that the statin is associated with a
5
6 significant risk reduction of liver cancer, when taken daily for cardiovascular event
7
8 prevention. However, this preventive effect might be overestimated due to the
9
10 exposure period, the indication and contraindication of statins, and other confounders.
11
12
13
14 Statins might be considered as an adjuvant in the treatment of liver cancer.

15
16 **Key words:** *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*
17
18
19

20 21 **Strengths and limitations of this study**

22
23 Statins are commonly prescribed as cholesterol-lowering drugs. In this comprehensive
24
25 meta-analysis, we demonstrate that the statin use is associated with a significant risk
26
27 reduction of liver cancer.
28
29

30
31 The difference of the study designs is the part reason that explained the significant
32
33 heterogeneity found in the overall analysis.
34
35

36
37 However, this preventive effect might be overestimated due to the exposure period,
38
39 the indication and contraindication of statins, and other confounders.
40

41
42 Statins might be considered as an adjuvant in the treatment of liver cancer.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and they are widely used to reduce the plasma cholesterol level and the risk of cardiovascular events.¹ Although there is a concern over their possible carcinogenicity raised in rodent studies,² preclinical studies indicate that statins have anticancer properties *in vitro* and *in vivo*, through inhibiting angiogenesis, inducing apoptosis, and suppressing tumor growth and metastasis.³⁻⁵

However, higher concentrations of statins are typically required to induce these effects, raising questions concerning the therapeutic relevance of statins on cancer.⁶

To date, clinical studies regarding the cancer incidence associated with statin administration have highlighted conflicting results. Moreover, a large number of meta-analyses have concluded that there was no association between statin use and risk of overall cancer,⁷⁻¹⁰ or cancer of breast¹¹, stomach,¹² or pancreas.¹³ There is only a modest protective effect of statins in prostate cancer¹⁴ and colorectal cancer.¹⁵

In contrary, recent studies reported encouraging results for risk reduction of liver cancer among all statin users. Previous meta-analysis, conducted by Singh *et al.* by including 10 studies, found that statin users were less likely to develop hepatocellular carcinoma (HCC) than statin non-users.¹⁶ However, Singh *et al.* included the ALERT, LIPS, and MEGA trials twice, by including three individual patient data (IPD) analysis of randomized controlled trials (RCTs).¹⁷⁻¹⁹ Meanwhile, some factors of stratification were not considered in their analyses, such as dose and timing of exposure to statins, and the selection of controls and confounders, which might limit

1
2
3 the evaluation of cancer risk.²⁰ Furthermore, the lipophilic statins are accompanied by
4 an extensive first-pass effect at the hepatic level.²¹ It is plausible that lipophilic statins
5 may have a better liver cancer preventive qualities than the hydrophilic ones.²²
6
7

8
9 Therefore, we performed this updated meta-analysis to assess the association between
10 the statin use and the risk of liver cancer, involving the recently published studies and
11 conducting more subgroup analyses based on the factors mentioned above. Our results
12 demonstrated that statin use was associated with an over 40% risk reduction in liver
13 cancer, which may have a significant translational potential in the clinical practice.
14
15 However, there were some confounders might overestimate this preventive effect of
16 statins.
17
18
19
20
21
22
23
24
25
26
27

28 **MATERIALS AND METHODS**

29 *Literature Search strategy*

30
31 This meta-analysis was conducted following the PRISMA guidelines.²³
32

33
34 The systematic computerized search for eligible studies were performed on the
35 database of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO, and
36 **Cochrane Library**, covering all studies published from their inception to March 5,
37 2014. The following terms were searched with both the subjects (MeSH terms) and
38 text-word search strategies: “(Statin OR HMG-CoA reductase inhibitors OR
39 Atorvastatin OR Cerivastatin OR Fluvastatin OR Lovastatin OR Pravastatin OR
40 Rosuvastatin OR Simvastatin) AND (Hepatocellular OR Hepatic OR Intrahepatic OR
41 Interlobular OR Liver) AND (Carcinoma OR Sarcomas OR Angiosarcoma OR Cancer
42 OR Neoplasm). Additionally, the relevant reviews and retrieved articles were searched
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 manually for more eligible studies.

5
6 In study searching, only the original researches, published in form of peer review
7
8 article or meeting abstract, were included. No language restrictions were imposed.
9
10
11 However, the studies we included were all published in English.
12

13 ***Study selection***

14
15
16 The inclusion criteria were: (1) randomized controlled trial (RCTs), cohort studies or
17
18 case-control studies; (2) original studies that assessed the effect of statin use on the
19
20 risk of liver cancer, compared with placebo or no treatment; (3) liver cancer cases
21
22 were identified according to the International Classification of Diseases codes (ICD);
23
24 and (4) studies with estimate of relative risk (risk ratio, RR) of liver cancer, or with
25
26 data sufficient to calculate it.
27
28

29
30
31 The exclusion criteria were: (1) study design not meeting the inclusion criteria; (2)
32
33 studies without estimate of RR, or without sufficient data to calculate it; or (3) studies
34
35 with duplicated or overlap reports.
36
37

38 ***Data extraction***

39
40
41 Two independent investigators (M. Shi and X.B. Cui) extracted data from the eligible
42
43 studies using a predefined data collection form. The differences of data extraction
44
45 were resolved by consensus referring back to the original article. The extracted
46
47 information included: (1) Studies: first author, year of publication, study design,
48
49 location, patient populations, period, and follow-up; (2) Statins: type, dosage or
50
51 duration of statin use; (3) liver cancer: case identification, number of liver cancer,
52
53 crude RR with 95% confidence intervals (CIs), adjusted RR reflecting the greatest
54
55
56
57
58
59
60

1
2
3
4 degree of control for confounders, and confounders for adjustment (including
5
6 variables for matching). When the RR were not available, the RR with 95% CIs were
7
8 calculated from the raw data in original studies.
9

10
11 We extracted different measurements of effect estimates from original studies, such as
12
13 Relative Risk (RR), Odds Ratio (OR), Hazard Ratio (HR), and Observed/Expected
14
15 ratio. Due to the fact that the incidence of liver cancer was low in all studies, these
16
17 different measurements can be used to provide similar estimates of RR.
18
19

20 21 *Methodological quality assessment*

22
23 Of note, the included RCT was pooled analysis of other RCTs, therefore, it is
24
25 inappropriate to assess the methodological quality. The methodological quality of
26
27 cohort and case-control studies were assessed on the Newcastle-Ottawa Scale,²⁴
28
29 including eight items that were categorized three categories: selection (four items, one
30
31 star each), comparability (one item, up to two stars), and exposure/outcome (three
32
33 items, one star each). A “star” presents a “high” quality choice of each item.
34
35
36
37
38

39 *Statistical analysis*

40
41 The overall meta-analysis was first performed, followed by the subgroup analyses,
42
43 based on study design, baseline risk of liver cancer, confounding adjustment, study
44
45 location, and pharmacokinetic. Meanwhile, we conducted subgroup analyses based on
46
47 studies which reported RR estimate for higher cumulative dosage of statin use, when
48
49 appropriate data were available.
50
51

52
53 To take into account the heterogeneity and provide a more conservative estimate, the
54
55 inverse variance method was used to estimate the pooled RR and corresponding 95%
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CI, and data were pooled using a random effects model. Heterogeneity was assessed using the Chi-squared statistic (P) together with the Higgins I-squared statistic (I^2), a P value <0.10 was considered statistically significant for heterogeneity; and an I^2 value $> 50\%$ was considered a measure of severe heterogeneity.²⁵

Publication bias was assessed using the Begg's test and the Egger's test.²⁶ Influence analysis was performed to investigate the influence of a single study on the overall meta-analysis estimate, by omitting one study in each turn. Test for interaction was applied to identify the difference between pooled RR from subgroup analysis using the method described by Altman and Bland.²⁷ All statistical tests were two-sided and $P < 0.05$ was considered statistically significant, unless otherwise specified. Software Review Manager (RevMan5.2, Copenhagen) and STATA (Stata 11.2, Texas) were used for the statistical analysis.

Results

Study selection

Figure 1 illustrated the process of study selection for the meta-analysis. Of the 1424 potentially relevant references identified by electric and manual search, 142 were selected for full-text review after screening titles and abstracts. Finally, a total of 12 studies were included, with one IPD analysis,¹⁹ five cohort studies,²⁸⁻³² and six case-control studies.³³⁻³⁸ One case-control study was presented solely in abstract form.³³

Of note, the cohort study conducted by Friedman *et al.* reported RR estimate separately for different gender (male and female),²⁹ we considered these two reports

1
2
3
4 as separate studies. Therefore, a total of thirteen reports were included for the present
5
6 meta-analysis.
7

8 *Study characteristics*

9
10 **Table 1** summarized the characteristics of qualified studies in this meta-analysis. **The**
11
12 **12 studies, involving 5,640,313 participants with 35,756 liver cancer cases,** were
13
14 published between 2005 and 2013. **The “RCT” in the present study was pooled**
15
16 **analysis of 22 clinical trials,¹⁹** which investigated statins therapy in cardiovascular
17
18 event prevention and reported the occurrence of liver cancer as adverse event. The
19
20 observational studies were conducted with the local or national health databases, the
21
22 statin exposure were identified by linkage to prescription databases, and the controls
23
24 were matched mainly by age, sex and index date. Except one cohort adopted ICD-10
25
26 C22,²⁸ all other studies identified liver cancer cases according to the ICD-9 155. Of
27
28 note, **two cohorts were restricted to patients with HBV infection,³¹ and HCV**
29
30 **infection;³² one case-control only included patients with diabetes mellitus;³⁴ two**
31
32 **observational studies included patients aged at least 45 years.^{30 35}**
33
34
35
36
37
38
39
40

41 **Table 2** summarized the data of the included studies. In the RCT¹⁹ and one cohort
42
43 study,³⁰ the RR with 95% CIs were calculated from the 2×2 tables defined by the
44
45 incidence of liver cancer and the statin use status. The observational studies reported
46
47 different measurements of RR estimates with adjustment by confounders. **Several**
48
49 **observational studies adopted the important risk factors of liver cancer for**
50
51 **adjustments^{31 32 34-36},** such as HBV infection, HCV infection, cirrhosis, alcoholic liver
52
53 **disease, or non-alcoholic fatty liver disease (NAFLD).³⁹** Of note, only two studies
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

adjusted for the cholesterol level,^{30 38} and no study adjusted for the metabolic syndrome, which might also influence the risk of liver cancer.³⁹

Methodological quality

For the cohort and case-control studies, the median score was 7 on the Newcastle-Ottawa Scale, with a range of 5 to 8 (Supplementary Table 1). These results indicated that the observational studies were in a reasonable good quality.

Overall meta-analysis

Figure 2 depicted the forest plot of RR estimate with 95% CIs from individual studies and overall meta-analysis. In the overall meta-analysis, pooled results showed a statistically significant decrease in the liver cancer risk among all statin users (RR 0.58, 95% CIs 0.51–0.67). Of note, a statistically significant heterogeneity was observed ($I^2 = 65%$, $P = 0.0006$). The P -values of Begg's test and Egger's test were 0.669 and 0.749, respectively, both suggesting there was no evidence of publication bias. In the influence analysis, the omission of any individual studies did not alter the direction and magnitude of the observed effect (Supplementary Figure 1).

Subgroup analyses and Test for interaction

We first performed preplanned subgroup analyses based on study design, baseline risk of liver cancer, confounding adjustment, and study location (Table 3).

The RCT showed there is no significant association between statin use and risk of liver cancer (RR 1.06, 0.66–1.71). But the observational studies indicated a significant decrease of liver cancer risk among all statin users (RR 0.57, 0.50–0.64; $I^2 = 61%$, $P = 0.003$) (Figure 2). Furthermore, we found a greater risk reduction in the subgroup

1
2
3
4 analysis of cohort studies (RR 0.51, 0.44–0.58; $I^2 = 18\%$, $P = 0.30$) than in the
5
6 case-control studies (RR 0.63, 0.54–0.73; $I^2 = 46\%$, $P = 0.10$) (**Supplementary**
7
8 **Figure 2**).

9
10
11 Test for interaction showed significant results between subgroups of the RCT and
12
13 observational studies ($P_{\text{interaction}} = 0.01$, $Z = 2.47$), and between subgroups of the
14
15 cohort and case-control studies ($P_{\text{interaction}} = 0.04$, $Z = -2.03$). These results indicated
16
17 that the difference of the study designs was the part reason that why there was severe
18
19 heterogeneity in the overall analysis (**Table 3**).

20
21 In the subgroup analysis of the four studies with higher baseline risk of liver
22
23 cancer,^{30-32 35} defined as patients with older age, HBV or HCV infection, there was a
24
25 trend toward more decrease of liver cancer risk (RR 0.52, 0.47-0.59; $I^2 = 16\%$, $P =$
26
27 0.31) than in the other eight studies with general population^{19 28 29 33 34 36-38} (RR 0.63,
28
29 0.52–0.75; $I^2 = 59\%$, $P = 0.01$) (**Supplementary Figure 3**).

30
31 We defined the RCT or studies adjusted for at least 4 of 7 important confounders,
32
33 such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD,
34
35 HBV treatment, or HCV treatment,³⁹ were adjusted adequately. Subgroup analysis of
36
37 these six studies^{19 31 32 34-36} found a trend toward less decrease of liver cancer risk (RR
38
39 0.64, 0.53-0.77; $I^2 = 81\%$ $P = 0.0001$) than the other six studies^{28-30 33 37 38} (RR, 0.51,
40
41 0.43-0.60; $I^2 = 3\%$, $P = 0.40$) (**Supplementary Figure 4**).

42
43 Subgroup analyses based on study location found a similar risk reduction of liver
44
45 cancer in the Western countries (RR 0.61, 0.48–0.76; $I^2 = 64\%$, $P = 0.007$) and in the
46
47 Asian countries (RR 0.56, 0.48–0.64; $I^2 = 51\%$, $P = 0.09$). (**Supplementary Figure 5**)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Besides the overall RR estimates, some studies reported different RR estimate for
5
6 different pharmacokinetic and dosage of statin use (**Supplementary Table 2**). We
7
8 conducted further subgroup analyses based on these available data.
9

10
11 According to the different pharmacokinetic, statins can be classified as lipophilic
12
13 statins (Atorvastatin, Fluvastatin, Lovastatin, and Simvastatin) and hydrophilia statins
14
15 (Pravastatin and Rosuvastatin).²¹ Subgroup analysis of lipophilic statins^{29 31 34-36}
16
17 found a significant decrease of liver cancer risk (RR 0.57, 0.50–0.65; $I^2 = 50\%$, $P =$
18
19 0.08). And there was a similar result among users of hydrophilia statins^{31 35 36} (RR
20
21 0.59, 0.41–0.84; $I^2 = 50\%$, $P = 0.13$) (**Supplementary Figure 6**).
22
23

24
25 Test for interaction showed non-significant results for subgroups with different
26
27 baseline risk, confounding adjustment, study location, or pharmacokinetic ($P_{\text{interaction}} =$
28
29 0.08, 0.08, 0.54 and 0.86, respectively) (**Table 3**). Therefore, there is no strong
30
31 evidence to support a different preventive effect of statins on liver cancer in these
32
33 subgroups.
34
35

36
37 Subgroup analysis of six studies with higher cumulative dose of statin use, defined as
38
39 statin use more than 180 cumulative defined daily dose (cDDD) or 0.5 years
40
41 (cumulative duration), showed a trend toward more risk reduction of liver cancer (RR
42
43 0.53, 0.36-0.79), but with a high degree of heterogeneity ($I^2 = 90\%$, $P < 0.00001$)
44
45 (**Supplementary Figure 7**).
46
47
48
49

50 51 Discussion

52
53 This present meta-analysis represents the most comprehensive review to date on the
54
55 association between the statin use and the liver cancer risk, **by including 12 studies**
56
57
58
59
60

1
2
3
4 (one IPD analysis of 22 RCTs, 5 cohort studies, and 6 case-control studies) and
5
6 involving 5,640,313 participants with 35,756 liver cancer cases. Overall, we found
7
8 that statin use was associated with an over 40% risk reduction in liver cancer
9
10 compared with nonusers (RR 0.58, 95%CI 0.51–0.67). This result was in line with the
11
12 previous three meta-analyses: Singh *et al.* included 10 studies and suggested statin
13
14 users were less likely to develop HCC (OR 0.63, 95%CI 0.52–0.76),¹⁶ Pradelli *et al.*
15
16 and Zhang *et al.* included 5 and 7 observational studies and found a summary RR of
17
18 0.58 (95%CI 0.46–0.74) and 0.61 (95%CI 0.49–0.76), respectively.^{40 41}

19
20
21
22
23
24 The IPD analysis of 22 RCTs showed there is no significant association between statin
25
26 use and risk of liver cancer. The significant risk reduction of liver cancer among all
27
28 statin users was seen primarily in the observational studies, and this preventive effect
29
30 was relatively convinced in the cohorts than in the case-controls. There were some
31
32 reasons to explain the different findings between RCTs and observational studies.
33
34

35
36 First, the exposure period to statins might be shorter than the period to carcinogenesis
37
38 and the latency to diagnosis in the cohorts and the case-controls. The observational
39
40 studies defined statin use varying in dosage and duration, from patients who received
41
42 ≥ 1 cDDD or >1 Rx of statins to more than 0.5 years (**Table 1**). On the other hand, the
43
44 median period of statin use was 5.1 years in the RCTs. Although there was a trend
45
46 toward more risk reduction of liver cancer with higher cumulative dose of statin use,
47
48 this defect might still result in overestimating the cancer-preventive effect of statins in
49
50 the observational studies.
51
52
53
54

55
56 Second, clinical studies demonstrated that higher serum total cholesterol
57
58
59
60

1
2
3
4 concentration was associated with decreased risk of liver cancer (**Supplementary**
5
6 **Table 3**).⁴²⁻⁴⁴ Meanwhile, there were inverse association between use of non-statin
7
8 lipid-lowering drugs and risk of the liver cancer.^{35 38} Meanwhile, because of the
9
10 contraindication, statins might not prescribed to the patients with the chronic liver
11
12 disease, which is known as a risk factor of liver cancer. Unfortunately, the
13
14 observational studies included in this analysis seldom adopted these factors for
15
16 adjustment. Actually, subgroup analysis of studies with adequate adjustment showed a
17
18 trend toward less risk reduction, indicating the potential of overestimate this
19
20 preventive effect by confounders.
21
22
23
24

25
26 Third, the RCTs included lower risk population (patients with cardiovascular disease
27
28 rather than HBV /HCV infection), might not be powerful enough to investigate the
29
30 liver cancer outcomes, which were much rarer than cardiovascular events. In addition,
31
32 subgroup analysis of studies with higher baseline risk showed a trend toward more
33
34 decrease of liver cancer risk.
35
36
37
38

39 These reasons suggested that the observed modulation of cancer incidence cannot be
40
41 ascribable to a direct statin-mediated effect,²⁰ the exposure period, the indication (e.g.
42
43 hyperlipidemia) and contraindication (e.g. chronic liver disease) of statins might
44
45 overestimate its cancer-preventive effect.
46
47
48

49 We found similar results in Western countries and Asian countries, which were
50
51 different from the meta-analysis conducted by Singh *et al.* which concluded that the
52
53 inverse association of statins with HCC was stronger in the Asian population.
54
55

56 **Considering four more studies we included,** this difference might be caused by the
57
58
59
60

1
2
3
4 insufficient data in their meta-analysis. Based on the pharmacokinetics, it is plausible
5
6 that lipophilic and hydrophilic statins will differ in their liver cancer prevention
7
8 qualities.^{21 22} However, subgroup analysis of lipophilic and hydrophilic statins showed
9
10 similar results.
11

12
13 Besides the limitations described previously, there were some other limitations should
14
15 be noted. First, a significant heterogeneity was observed in the present meta-analysis,
16
17 which might results from the difference in study design. Results of subgroup analyses
18
19 would also be limited by this heterogeneity. Second, the adherence to statin therapy is
20
21 known to be associated with healthy lifestyle, which might affect the cancer
22
23 outcome.⁴⁵ Such information is hard to be captured in databases or medical record in
24
25 the observational studies.⁴⁶ Third, five observational studies were conducted using the
26
27 Taiwanese National Health Insurance Research Database (NHIRD),^{31 32 35-37} although
28
29 they were not in the same period, these studies might contain overlapping groups of
30
31 patients. These limitations mentioned above might lead to confounding of overall
32
33 results from the present study, and should be considered in future studies aiming at
34
35 confirming the protective effects of statins on human cancer risk.
36
37
38
39
40
41
42

43
44 The strengths of our meta-analysis were as follows: First, we performed a much more
45
46 comprehensive search and more subgroup analyses, compared with the previous
47
48 meta-analyses; Second, the methodological quality of the included studies were
49
50 reasonable good; Third, publication bias, which due to the tendency of not publishing
51
52 small studies with null results, were not found in our meta-analysis.
53
54

55
56 Of note, preclinical studies have indicated that statins possess synergism with other
57
58
59
60

1
2
3
4 therapeutic agents *in vitro* and *in vivo* for liver cancer.^{47 48} Some clinical studies have
5
6 also demonstrated that statins would prolong survival in patients with advanced liver
7
8 cancer (**Supplementary Table 4**),⁴⁹⁻⁵² and associated with risk reduction of
9
10 recurrence after curative surgery in patients of HBV related HCC.⁵³ Therefore,
11
12 considerable interest exists in adjunctive therapy with statins for liver cancer. In fact,
13
14 there were some RCTs ongoing to determine the effectiveness of pravastatin, when
15
16 used in combination with sorafenib, in the treatment of liver cancer (**Supplementary**
17
18 **Table 5**).

19
20
21
22
23
24 Currently, physicians are less likely to prescribe statins for patients with chronic liver
25
26 disease, based on the concerns about the statin-induced liver injury.³¹ However, there
27
28 were number of studies have demonstrated the safe use, even salutary effects.⁵⁴⁻⁵⁶
29
30
31 Meanwhile, the risk of serious statin-related liver injury appears to be no greater than
32
33 the background incidence of this rare event.⁵⁷ Therefore, considering their benefits for
34
35 cardiovascular event prevention and the potential effect in liver cancer prevention and
36
37 treatment, statins should not be denied to these patients.
38
39

40
41 In conclusion, our results suggest that statin use is associated with a significant risk
42
43 reduction of liver cancer, when taken daily for cardiovascular event prevention.
44
45 However, this preventive effect might be overestimated due to the exposure period,
46
47 indication and contraindication of statins, and other confounders. Statins might be
48
49 considered as an adjuvant in the treatment of liver cancer.
50
51
52

53 54 55 **ACKNOWLEDGEMENT**

56
57 We thank Medjaden Bioscience Limited and Gui Lv for assisting in the preparation
58
59
60

1
2
3 and revision of this manuscript.
4

5 **CONTRIBUTORSHIP STATEMENT**

6
7 XB Cui had the original idea, Meng Shi and XB Cui worked together to develop an
8 appropriate theoretical framework and design. XB Cui developed the search, Meng
9 Shi and XB Cui were involved in the selection process. Meng Shi and XB Cui
10 extracted relevant data, XB Cui and Biao Nie performed the statistical analysis and all
11 authors were involved in the data interpretation. Meng Shi and Biao Nie wrote the
12 manuscript draft and revised the draft based on input from the other authors. All
13 authors revised it critically for content and approved the final version.
14
15
16
17
18
19
20
21
22
23

24 **COMPETING INTERESTS**

25
26 There are no competing interests
27
28

29 **FUNDING**

30
31 None.
32
33

34 **DATA SHARING**

35
36 No additional data available.
37
38
39
40
41
42

43 **REFERENCES:**

- 44
45 1. Baigent C, Keech A, Kearney PM, *et al.* Efficacy and safety of cholesterol-lowering treatment:
46 prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
47 *Lancet* 2005;**366**(9493):1267-78.
48
49 2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA* 1996;**275**(1):55-60.
50
51 3. Demierre MF, Higgins PD, Gruber SB, *et al.* Statins and cancer prevention. *Nat Rev Cancer*
52 2005;**5**(12):930-42.
53
54 4. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the
55 hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. *J*
56 *Cancer Res Ther* 2012;**8**(2):176-83.
57
58 5. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular
59 carcinoma. *J Gastroenterol Hepatol* 2012;**27**(11):1654-64.
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
6. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. *Cancer Chemother Pharmacol* 2011;**67**(4):729-39.
7. Dale KM, Coleman CI, Henyan NN, *et al.* Statins and cancer risk: a meta-analysis. *JAMA* 2006;**295**(1):74-80.
8. Browning DRL, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. *Int J Cancer* 2007;**120**(4):833-43.
9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. *Eur J Cancer* 2008;**44**(15):2122-32.
10. Baigent C, Blackwell L, Emberson J, *et al.* Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;**376**(9753):1670-81.
11. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Res Treat* 2012;**135**(1):261-9.
12. Shimoyama S. Statins and gastric cancer risk. *Hepatogastroenterology* 2011;**58**(107-108):1057-61.
13. Cui X, Xie Y, Chen M, *et al.* Statin use and risk of pancreatic cancer: a meta-analysis. *Cancer Causes Control* 2012;**23**(7):1099-111.
14. Bansal D, Undela K, D'Cruz S, *et al.* Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. *PLoS One* 2012;**7**(10):e46691.
15. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. *Gut* 2010;**59**(11):1572-85.
16. Singh S, Singh PP, Singh AG, *et al.* Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. *Gastroenterology* 2013;**144**(2):323-32.
17. Stein EA, Corsini A, Gimpelewicz CR, *et al.* Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract* 2006;**60**(9):1028-34.
18. Matsushita Y, Sugihara M, Kaburagi J, *et al.* Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. *Pharmacoepidemiol Drug Saf* 2010;**19**(2):196-202.
19. Emberson JR, Kearney PM, Blackwell L, *et al.* Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;**7**(1):e29849.
20. Gazerro P, Bifulco M. Statins and Cancer in Gastroenterology: New Insight? *Gastroenterology* 2013;**144**(7):1572-3.
21. Gazerro P, Proto MC, Gangemi G, *et al.* Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev* 2012;**64**(1):102-46.
22. Gronich N, Rennert G. Beyond aspirin - Cancer prevention with statins, metformin and bisphosphonates. *Nat Rev Clin Oncol* 2013;**10**(11):625-42.
23. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;**339**:b2535.
24. GA Wells, B Shea, D O'Connell, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
25. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

- 1
- 2
- 3 26. METABIAS: Stata module to test for small-study effects in meta-analysis [program], 2009.
- 4 27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*
- 5 2003;**326**(7382):219.
- 6
- 7 28. Friis S, Poulsen AH, Johnsen SP, *et al.* Cancer risk among statin users: A population-based cohort
- 8 study. *Int J Cancer* 2005;**114**(4):643-7.
- 9
- 10 29. Friedman GD, Flick ED, Udaltsova N, *et al.* Screening statins for possible carcinogenic risk: up to 9
- 11 years of follow-up of 361,859 recipients. *Pharmacoepidemiol Drug Saf* 2008;**17**(1):27-36.
- 12 30. Marelli C, Gunnarsson C, Ross S, *et al.* Statins and Risk of Cancer A Retrospective Cohort Analysis of
- 13 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult
- 14 Americans. *J Am Coll Cardiol* 2011;**58**(5):530-7.
- 15 31. Tsan YT, Lee CH, Wang JD, *et al.* Statins and the risk of hepatocellular carcinoma in patients with
- 16 hepatitis B virus infection. *J Clin Oncol* 2012;**30**(6):623-30.
- 17 32. Tsan YT, Lee CH, Ho WC, *et al.* Statins and the risk of hepatocellular carcinoma in patients with
- 18 hepatitis C virus infection. *J Clin Oncol* 2013;**31**(12):1514-21.
- 19 33. Khurana V, Saluja A, Caldito G, *et al.* Statins are protective against hepatocellular cancer in patients
- 20 with hepatitis C virus infection: Half a million US veterans' study. *Gastroenterology*
- 21 2005;**128**(4, Suppl. 2):A714.
- 22 34. El-Serag HB, Johnson ML, Hachem C, *et al.* Statins are associated with a reduced risk of
- 23 hepatocellular carcinoma in a large cohort of patients with diabetes. *Gastroenterology*
- 24 2009;**136**(5):1601-8.
- 25 35. Chiu HF, Ho SC, Chen CC, *et al.* Statin use and the risk of liver cancer: a population-based
- 26 case-control study. *Am J Gastroenterol* 2011;**106**(5):894-8.
- 27 36. Lai SW, Liao KF, Lai HC, *et al.* Statin use and risk of hepatocellular carcinoma. *Eur J Epidemiol*
- 28 2013;**28**(6):485-92.
- 29 37. Leung HW, Chan AL, Lo D, *et al.* Common cancer risk and statins: a population-based case-control
- 30 study in a Chinese population. *Expert Opin Drug Saf* 2013;**12**(1):19-27.
- 31 38. Chaiteerakij R, Yang JD, Harmsen WS, *et al.* Risk factors for intrahepatic cholangiocarcinoma:
- 32 association between metformin use and reduced cancer risk. *Hepatology* 2013;**57**(2):648-55.
- 33 39. Singh S, Singh PP, Roberts LR, *et al.* Chemopreventive strategies in hepatocellular carcinoma. *Nat*
- 34 *Rev Gastroenterol Hepatol* 2014;**11**(1):45-54.
- 35 40. Pradelli D, Soranna D, Scotti L, *et al.* Statins and primary liver cancer: a meta-analysis of
- 36 observational studies. *Eur J Cancer Prev* 2013;**22**(3):229-34.
- 37 41. Zhang H, Gao C, Fang L, *et al.* Statin use and risk of liver cancer: A meta-analysis of 7 studies
- 38 involving more than 4.7 million patients. *World J Meta-Anal* 2013;**1**(3):130-7.
- 39 42. Ahn J, Lim U, Weinstein SJ, *et al.* Prediagnostic total and high-density lipoprotein cholesterol and
- 40 risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2009;**18**(11):2814-21.
- 41 43. Iso H, Ikeda A, Inoue M, *et al.* Serum cholesterol levels in relation to the incidence of cancer: the
- 42 JPHC study cohorts. *Int J Cancer* 2009;**125**(11):2679-86.
- 43 44. Kitahara CM, de Gonzalez AB, Freedman ND, *et al.* Total Cholesterol and Cancer Risk in a Large
- 44 Prospective Study in Korea. *J Clin Oncol* 2011;**29**(12):1592-8.
- 45 45. Brookhart MA, Patrick AR, Dormuth C, *et al.* Adherence to lipid-lowering therapy and the use of
- 46 preventive health services: an investigation of the healthy user effect. *Am J Epidemiol*
- 47 2007;**166**(3):348-54.
- 48 46. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. *Expert Opin*
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 Drug Saf 2010;**9**(4):603-21.
- 4 47. Kim W, Yoon JH, Kim JR, *et al.* Synergistic anti-tumor efficacy of lovastatin and protein kinase
5 C-beta inhibitor in hepatocellular carcinoma. *Cancer Chemother Pharmacol*
6 2009;**64**(3):497-507.
- 7
8 48. Polo MP, Crespo R, de Bravo MG. Geraniol and simvastatin show a synergistic effect on a human
9 hepatocarcinoma cell line. *Cell Biochem Funct* 2011;**29**(6):452-8.
- 10 49. Kawata S, Yamasaki E, Nagase T, *et al.* Effect of pravastatin on survival in patients with advanced
11 hepatocellular carcinoma. A randomized controlled trial. *Br J Cancer* 2001;**84**(7):886-91.
- 12 50. Lersch C, Schmelz R, Erdmann J, *et al.* Treatment of HCC with pravastatin, octreotide, or
13 gemcitabine - A critical evaluation. *Hepatogastroenterology* 2004;**51**(58):1099-103.
- 14 51. Graf H, Jungst C, Straub G, *et al.* Chemoembolization combined with pravastatin improves survival
15 in patients with hepatocellular carcinoma. *Digestion* 2008;**78**(1):34-8.
- 16 52. Georgescu EF, Badulescu F, Dumitrescu D, *et al.* Lovastatin may enhance cytostatic effects of
17 sorafenib in hepatic carcinoma. Primary results of a pilot study. *Hepatol Int* 2011;**5**(1):423.
- 18 53. Wu CY, Chen YJ, Ho HJ, *et al.* Association between nucleoside analogues and risk of hepatitis B
19 virus-related hepatocellular carcinoma recurrence following liver resection. *JAMA*
20 2012;**308**(18):1906-14.
- 21 54. Lewis JH, Mortensen ME, Zweig S, *et al.* Efficacy and safety of high-dose pravastatin in
22 hypercholesterolemic patients with well-compensated chronic liver disease: Results of a
23 prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology*
24 2007;**46**(5):1453-63.
- 25 55. Nelson A, Torres DM, Morgan AE, *et al.* A pilot study using simvastatin in the treatment of
26 nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol*
27 2009;**43**(10):990-4.
- 28 56. Lewis JH. Clinical Perspective: Statins and the Liver-Harmful or Helpful? *Dig Dis Sci*
29 2012;**57**(7):1754-63.
- 30 57. Bader T. The myth of statin-induced hepatotoxicity. *Am J Gastroenterol* 2010;**105**(5):978-80.

Figure legends:

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Flow chart of study selection in the present meta-analysis.

Figure 2. Overall meta-analysis of the statin use and the liver cancer risk.

Supplementary Figure 1. Influence analysis.

Supplementary Figure 2. Subgroup analyses based on study design.

Supplementary Figure 3. Subgroup analyses based on baseline risk of liver cancer.

Supplementary Figure 4. Subgroup analyses based on confounder adjustment.

Supplementary Figure 5. Subgroup analyses based on study location.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 6. Subgroup analyses based on pharmacokinetic of statins.

Supplementary Figure 7. Subgroup analysis of higher cumulative dose of statin use.

For peer review only

Table 1. Study characteristics

Studies	Study design	Patient population	Study period	Cases defined	Follow-up	Statins type	Dosage/Duration of Statin use
Emberson, 2012, UK ¹⁹	RCT	IPD analysis of 22 RCTs	-	ICD-9 155	5.1 years (Me)	A, F, L, P, R, S	5.1 years (Me)
Friis, 2005, North Jutland ²⁸	Cohort	General population (CPR)	1989-2002	ICD-10 C22	3.3 years (M)	Unspecified	≥2 Rx
Friedman, 2008, USA ²⁹	Cohort	General population (KPMCP)	1994-2003	ICD-9-CM 155	> 2 years	A, L, S (97.6%)	≥1 Rx
Marelli, 2011, USA ³⁰	Cohort	General older population (men ≥ 45 and women ≥ 55 years; GE Centricity)	1990-2009	ICD-9 155	4.6 years (M)	Unspecified	≥1 cDDD
Tsan, 2012, Taiwan ³¹	Cohort	Patients with HBV infection (NHIRD)	1997-2008	ICD-9 155	9.9 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Tsan, 2013, Taiwan ³²	Cohort	Patients with HCV infection (NHIRD)	1999-2010	ICD-9 155	10.7 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Khurana, 2005, USA ³³	Case control	General population (VISN)	1997-2002	ICD-9 155	NR	Unspecified	≥1 Rx
El-Serag, 2009, USA ³⁴	Case control	Diabetes patients (VA)	1997-2002	ICD-9-CM 155	2.4 years (M)	A, C, F, L, P, and S	1.6 years (M)
Chiu, 2011, Taiwan ³⁵	Case control	Older patients (≥ 50 years; NHIRD)	2005–2008	ICD-9-CM 155	NR	A, F, L, P, R, and S	≥ 1 cDDD
Lai, 2013, Taiwan ³⁶	Case control	General population (NHIRD)	2000-2009	ICD-9-CM 155	1.4 years (M)	A, F, L, P, R, and S	≥1 Rx
Leung, 2013, Taiwan ³⁷	Case control	General population (NHIRD)	2000-2008	ICD-9-CM 155	4.1 years (M)	Unspecified	> 0.5 years
Chaiteerakij, 2013, USA ³⁸	Case control	Hyperlipidemia patients (Mayo Clinic)	2000-2010	ICD-9-CM 155	>1 years	Unspecified	≥1 Rx

Patients population: IPD = Individual patient data, RCT = randomized controlled trials, CPR = the Central Population Register of Danish citizens, KPMCP = the Kaiser Permanente Medical Care Program in northern California, GE Centricity = the General Electric Centricity database, NHIRD = the Taiwanese National Health Insurance research database, VISN = Veterans Integrated Service Networks 16 Veteran Affairs database, VA = Veterans Affairs national databases, Mayo Clinic = Mayo Clinic (Rochester, MN), HBV = hepatitis B virus; Cases defined: ICD-9 or -10 = International Classification of Diseases, Ninth Revision or Tenth Revision, CM = Clinical Modification; Duration of follow-up: When the follow-up periods of statin user and nonuser were different, only the shorter one was showed, and all periods were transformed to years; Statin type: A = Atorvastatin, C = Cerivastatin, F = Fluvastatin, L = Lovastatin, P = Pravastatin, R = Rosuvastatin, S = Simvastatin, Non-statin = Non-statin cholesterol-lowering drug(s) only; Duration of statin use: M = Mean, Me = Median, ≥1 cDDD = more than 1 cumulative defined daily dose before the diagnosis of liver cancer, Rx = prescriptions.

Table 2. Study data


Studies	Intervention/ Cases		Control		Measurements of effect estimates	Crude RR with 95% CIs	Adjusted RR with 95% CIs	Confounders for adjustment
	No. of event/ No. of exposure	No. of total	No. of event/ No. of exposure	No. of total				
Emberson, 2012, UK ¹⁹	35	67258	33	67279	RR	1.06 (0.66, 1.71)*	1.06 (0.66, 1.71)*	Randomization
Friis, 2005, North Jutland ²⁸	1	12251	166	334754	OR	NA	1.16 (0.46-2.90)	1,2, 16, 21, 23
Friedman(Male), 2008, USA ²⁹	32	192598	NA	1904876	HR	NA	0.49 (0.34-0.70)	16
Friedman(Female), 2008, USA ²⁹	10	169261	NA	1976332	HR	NA	0.40 (0.21-0.75)	
Marelli, 2011, USA ³⁰	13	45857	24	45857	RR	0.31 (0.14-0.68)*	0.31 (0.14-0.68)*	1-5, 14, 16-18, 26, 27
Tsan, 2012, Taiwan ³¹	58	2785	963	30628	HR	0.66 (0.51- 0.86)	0.47 (0.36-0.61)	1, 2, 7, 8, 11, 12
Tsan, 2013, Taiwan ³²	1378	35023	26505	225841	HR	0.42 (0.39-0.46)	0.53 (0.49-0.58)	1, 2, 7, 8, 11, 13
Khurana, 2005, USA ³³	NA	NA	NA	NA	OR	NA	0.52 (0.41- 0.67)	1, 11, 13
El-Serag, 2009, USA ³⁴	447	1303	2766	5212	OR	0.46 (0.40-0.52)	0.74 (0.64-0.87)	1-3, 6, 8, 9, 11-13, 21, 24, 28
Chiu, 2011, Taiwan ³⁵	117	1166	195	1166	OR	0.53 (0.41-0.69)	0.62 (0.45-0.83)	1, 2, 8, 9, 11, 12, 20, 29
Lai, 2013, Taiwan ³⁶	255	3480	1635	13920	OR	0.61 (0.52-0.72)	0.71 (0.56-0.89)	1, 2, 8-13, 22, 24, 25
Leung, 2013, Taiwan ³⁷	26	424	6851	33781	HR	0.45 (0.30-0.67)	0.44 (0.28, 0.72)	1, 2, 11, 15, 20, 21, 23
Chaiteerakij, 2013, USA ³⁸	72	165	165	256	OR	NA	0.6 (0.4-0.9)	1-3, 8, 11, 17, 22, 28, 30

The RR with an asterisk mark (*) was calculated based on the raw data. The others, crude or adjusted, were extracted from the original paper; Confounders for adjustment: 1 = age, 2 = sex, 3 = race, 4 = BMI, 5 = smoking status, 6 = ethanol intake, 7 = socioeconomic status, 8 = cirrhosis, 9 = alcoholic liver disease, 10 = non-alcoholic fatty liver disease, 11 = diabetes mellitus, 12 = HBV infection, 13 = HCV infection, 14 = concomitant diagnoses (unspecified), 15 = Charlson score, 16 = calendar year, 17 = cholesterol (totalcholesterol, VLDL, LDL, or triglycerides), 18 = prostate-specific antigen, 19 = resection extent, 20 = other lipid-lowering agents, 21 = cardiovascular medications (aspirin, nonsteroidal anti-inflammatory medications, or angiotensin-converting enzymes inhibitors), 22 = metformin or thiazolidinedione, 23 = hormone-replacement therapy, 24 = HCV treatment, 25 = HBV treatment, 26 = medications taken (unspecified), 27 = the number of office visits, 28 = propensity to use statins, 29 = hospital stay, 30 = biliary tract diseases

Table 3. Subgroup analyses of included studies


Subgroup	No. of studies (reports)	Summary RR (95% CIs)	Heterogeneity, I ²	Heterogeneity, P value	P _{interaction}	
Study design	RCT	1	1.06 (0.66-1.71)	-	-	P = 0.01
	Observational studies	11(12)	0.57(0.50-0.64)	61%	P = 0.003	
Observational studies	Cohort studies	5 (6)	0.51 (0.44–0.58)	18%	P = 0.30	P = 0.04
	Case-control studies	6	0.63 (0.54–0.73)	46%	P = 0.10	
Baseline risk of liver cancer	Higher baseline risk	4	0.52 (0.47-0.59)	16%	P = 0.31	P = 0.08
	General population	8 (9)	0.63 (0.52–0.75)	59%	P = 0.01	
Confounding adjustment	Adequate adjustment	6	0.64(0.53-0.77)	81%	P = 0.0001	P = 0.08
	Inadequate adjustment	6 (7)	0.51 (0.43-0.60)	3%	P = 0.40	
Study location	Western studies	8 (9)	0.61 (0.48-0.76)	64%	P = 0.007	P = 0.54
	Asian studies	6	0.56 (0.48- 0.64)	51%	P = 0.09	
Pharmacokinetic	Hipophilic statins	5 (6)	0.57 (0.50-0.65)	50%	P = 0.08	P = 0.86
	Hydrophilia statins	3	0.59(0.41–0.84)	50%	P = 0.13	
Higher cumulative dosage of statin		6	0.53 (0.36-0.79)	90%	P<0.0001	-

RR = relative risk; higher baseline risk of liver cancer: patients with older age, HBV or HCV infection. Adequate adjustment: RCT or studies which adjusted for at least 4 of 7 important confounders, such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD, HBV treatment, or HCV treatment; Lipophilic statins: Atorvastatin, Fluvastatin, Lovastatin, or Simvastatin; Hydrophilia statins: Pravastatin or Rosuvastatin; Higher cumulative dosage of statin use: > 180cumulative defined daily dose or Duration of statin use > 0.5 years before the diagnosis of liver cancer.



Flow chart of study selection in the present meta-analysis.
207x224mm (300 x 300 DPI)





Overall meta-analysis of the statin use and the liver cancer risk.
128x80mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

SUPPLEMENTARY TABLES:

Supplementary Table 1. Assessment of methodological quality of the cohort and case-control studies according to the Newcastle–Ottawa Scale

Cohort Studies	Selection			Outcome of present at start of study	Comparability		Outcome		Total Score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure		Control for important factor	Assessment of outcome	Follow-up long enough	Adequacy of follow up	
Friis, 2005 ²⁸	☆	☆	☆	☆	☆	☆	-	☆	7
Friedman, 2008 ²⁹	☆	☆	☆	☆	☆	☆	-	☆	7
Marelli, 2011 ³⁰	☆	☆	☆	☆	☆	☆	☆	☆	8
Tsan, 2012 ³¹	☆	☆	☆	☆	☆	☆	☆	☆	8
Tsan, 2013 ³²	☆	☆	☆	☆	☆	☆	☆	☆	8

Case–Control Studies	Selection			Definition of controls	Comparability		Exposure		Total Score
	Adequate definition of cases	Representativeness of cases	Selection of controls		Control for important factor	Ascertainment of Exposure	Same method for cases and controls	Non-response rate	
Khurana, 2005 ³³	-	☆	☆	☆	☆	☆	☆	-	6
El-Serag, 2009 ³⁴	-	☆	☆	☆	☆☆	☆	☆	-	7
Chiu, 2011 ³⁵	-	☆	☆	☆	☆☆	☆	☆	-	7
Lai, 2013 ³⁶	-	☆	☆	☆	☆☆	☆	☆	-	7
Leung, 2013 ³⁷	☆	☆	☆	☆	☆	☆	☆	☆	8
Chaiteerakij, 2013 ³⁸	-	☆	-	☆	☆	☆	☆	-	5

Control for important factor: ☆Reported relative risk have been adjusted for at least 4 of 7 important factors: HBV infection, HCV infection, cirrhosis, NAFLD, HCV treatment, HBV treatment, anti-diabetic medications; ☆ Study controls for any additional factor. Assessment of outcome: ☆ record linkage. Follow-up long enough: ☆ follow up period ≥ 4 years. Adequate definition of cases: ☆ The case is defined with independent validation. Non-response rate: ☆ Same rate for both groups.

Supplementary Table 2. Studies reporting RR for use of lipophilic or hydrophilic statins, and for higher cumulative dosage of statin use

Studies	Measurements of effect estimates	Statins type	Dosage/Duration of Statin use	Crude RR with 95% CIs	Adjusted RR with 95% CIs
Tsan, 2012, Taiwan ³¹	HR	A, F, L, P, R, and S	>365 cDDD	0.50 (0.26-0.96)	0.34 (0.33-0.59)
	HR	Lipophilia statin	≥28 cDDD	0.62 (0.47-0.83)	0.44 (0.33-0.59)
	HR	Hydrophilic statin	≥28 cDDD	0.65 (0.39-1.09)	0.51 (0.31-0.85)
Tsan, 2013, Taiwan ³²	HR	A, F, L, P, R, and S	>180 cDDD	NA	0.33 (0.25-0.42)
El-Serag, 2009, USA ³⁴	OR	Simvastatin	1.6 years (M)	0.47 (0.41-0.54)	0.64 (0.55-0.75)
	OR	A, F, L, P, R, and S	>215.4 cDDD	0.47 (0.30-0.72)	0.63 (0.37-1.06)
Chiu, 2011, Taiwan ³⁵	OR	Lipophilia statin	≥ 1 cDDD	NA	0.56 (0.45-0.69)*
	OR	Hydrophilic statin	≥ 1 cDDD	NA	0.46 (0.29-0.71)*
Lai, 2013, Taiwan ³⁶	OR	Lipophilia statin	≥1 Rx	0.54 (0.48-0.61)*	0.67 (0.57-0.79)*
	OR	Hydrophilic statin	≥1 Rx	0.63 (0.47-0.83)*	0.80 (0.55-1.16)*

The RR with an asterisk mark (*) was calculated based on the raw data in the original study. The others, crude or adjusted, were extracted from the original paper.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Supplementary Table 3. Published studies of the total cholesterol and the risk of liver cancer

Studies	Study design	cases/ participants	Follow-up	Reference (mg/dL)	Index (mg/dL)	Adjusted HR (95% CIs)		P for trend*	Confounders for adjustment
						Men	Women		
Iso, 2009, Japan ⁴³	Population-based cohort (JPHC Study)	125 /33,368	12.4 years	180–199	<160	2.62 (1.44–4.76)	4.15 (1.70–10.16)	Men < 0.0001 Women < 0.0001	1-10
					160–179	1.04 (0.52–2.07)	1.99 (0.82–4.85)		
					180–199	1	1		
					200–219	0.56 (0.24–1.28)	1.09 (0.44–2.68)		
					200–239	0.49 (0.16–1.44)	0.41 (0.11–1.52)		
Ahn, 2009, Finland ⁴²	Placebo-controlled, double-blinded primary prevention trial in male smokers (ATBC)	191/29,093	18.0 years	< 203.9	< 203.9	1	-	P=0.0007	1-5, 11-17
					203.9-227.6	0.69 (0.46-1.05)	-		
					227.7-249.2	0.63 (0.41-0.97)	-		
					249.3-276.6	0.56 (0.36-0.88)	-		
					> 276.7	0.66 (0.43-1.01)	-		
Kitahara, 2011, Korea ⁴⁴	Prospective study of Korean men and women (Korean NHIC)	10,161/1,189,719	12.7 years	< 160	< 160	1	-	Men < 0.001 Women < 0.001	2-5, 13, 18
					160-179	0.69 (0.65-74)	0.63 (0.54-0.72)		
					180-199	0.62 (0.58-0.66)	0.50 (0.44-0.58)		
					200-239	0.48 (0.45-0.51)	0.37(0.32-0.42)		
					≥ 240	0.42 (0.38-0.45)	0.32 (0.27-0.39)		

JPHC Study = The Japan Public Health Center-based Prospective Study, ATBC = The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Korean NHIC = The Korean National Health Insurance Corporation Medical Evaluation. *Tests for linear trend were conducted by treating the total cholesterol as a continuous variable in the multivariable models. Confounders for adjustment: 1 = age, 2 = BMI, 3 = smoking, 4 = ethanol intake, 5 = hypertension, 6 = diabetes, 7 = hyperlipidemia medication use, 8 = total vegetable intake, 9 = coffee intake, 10 = public health center, 11 = intervention, 12 = level of education, 13 = physical activity, 14 = Saturates fat intake, 15 = polyunsaturated fat intake, 16 = total calorie, 17 = serum HDL cholesterol, 18 = fasting serum glucose.

Supplementary Table 4. Published trials of statin use as adjuvant in treatment of liver cancer


Studies	Study design	Patients population	Intervention	Control	Overall survival of intervention (months)	Overall survival of control (months)	Kaplan-Meier and log-rank test
Kawata, 2001, Japan ⁴⁹	Prospective, randomized, open label study	Patients with advanced liver cancer after TAE procedure, n = 83	Pravastatin 20-40 mg + 5-FU 200 mg QD, n = 41	5-FU 200 mg QD, n = 42	Median 18	Median 9	<i>P</i> = 0.006
Lersch, 2004, Germany ⁵⁰	Prospective study	Patients with advanced liver cancer, n = 58	Pravastatin 40-80 mg QD, n = 20	A: Octreotide, n = 30; B: Gemcitabine, n = 8	Median 7.2 (95% CIs 2.9-11.5)	A: Median 5(95% CIs 2.2-7.8); B: Median 3.5 (95% CIs 2.2-4.9)	A: <i>P</i> = 0.09; B: <i>P</i> = 0.03
Graf, 2008, Germany ⁵¹	Prospective, non-randomized, open label study	Patients with advanced liver cancer after TACE, n = 183	Pravastatin 20-40 mg QD, n = 52	No treatment, n = 131	Median 20.9 (95% CIs 15.5-26.3)	Median 20.9 (95% CIs 15.5-26.3)	<i>P</i> = 0.003
Georgescu, 2011, Romania ⁵²	Prospective, randomized, open label study	Patients with advanced liver cancer, n = 72	Lovastatin 40 mg + Sorafenib 400 mg QD, n = 39	Sorafenib 400 mg QD, n = 33	Mean 12.15±0.76	Mean 10.85±0.82	Non-significant

TAE = Transcatheter Arterial Embolization; TACE = Transhepatic Arterial Chemotherapy and Embolization).


Supplementary Table 5. Ongoing clinical trials of statin use as adjuvant in treatment of liver cancer

Studies	Year	Location	Phase	Study design	Condition	Intervention	Control	Estimated Enrollment	Resist number	Status
ESTAHEP-2010	2011	Spain	II	Multicenter, prospective, randomized, double-blind, placebo-controlled study	Advanced liver cancer	Sorafenib 400 mg BID + Pravastatin 40 mg, QD	Sorafenib 400 mg BID + placebo QD	216	NCT01418729; EUCTR2010-024421-21-ES	Recruiting
PRODIGE 21	2011	France	II	Multicenter, prospective, randomized, open label study	Liver cancer with Child-Pugh B Cirrhosis	A: Sorafenib 400 mg BID; B: Pravastatin 40 mg, QD; C: Sorafenib 400 mg BID + Pravastatin 40 mg, QD	Best supportive care	160	NCT01357486	Recruiting
JOUVE PHRCK 2009	2013	France	III	prospective, randomized, open label study	Liver cancer with Child-Pugh A Cirrhosis	Sorafenib 800 mg BID + Pravastatin 40 mg, QD	Sorafenib 800 mg BID	474	NCT01903694; NCT01075555	Recruiting


SUPPLEMENTARY FIGURES:




Supplementary Figure 1. Influence analysis.




Supplementary Figure 2. Subgroup analyses based on study design.




Supplementary Figure 3. Subgroup analyses based on baseline risk of liver cancer.




Supplementary Figure 4. Subgroup analyses based on confounder adjustment.



Supplementary Figure 5. Subgroup analyses based on study location.



Supplementary Figure 6. Subgroup analyses based on pharmacokinetic of statins.



Supplementary Figure 7. Subgroup analysis of higher cumulative dose of statin use.



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	no
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	7



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9 Table1,2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10, Suppl. Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figure 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	NA

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Statin use and risk of liver cancer: an update meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005399.R2
Article Type:	Research
Date Submitted by the Author:	08-Aug-2014
Complete List of Authors:	Shi, Meng; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Zheng, Huiling; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Nie, Biao; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Gong, Wei; Nanfang Hospital, Southern Medical University, Department of Gastroenterology Cui, Xiaobing; Nanfang Hospital, Southern Medical University, Department of Gastroenterology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Oncology
Keywords:	Gastrointestinal tumours < GASTROENTEROLOGY, Epidemiology < ONCOLOGY, Hepatobiliary tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

only

Statin use and risk of liver cancer: an update meta-analysis

Meng Shi¹, Huiling Zheng¹, Biao Nie¹, Wei Gong^{1*} and Xiaobing Cui^{1*}

¹Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Avenue North, Guangzhou 510515, China

*Correspondence to Dr. Xiaobing Cui, Email: xbing119@gmail.com; and Dr. Wei Gong, Email: drgwei@foxmail.com.

Running title: Meta-analysis: statin and liver cancer

Key words: *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*

Abstract

Objective: Statins are commonly prescribed cholesterol-lowering drugs. Preclinical studies suggest that statins may possess cancer preventive properties. The primary objective of this meta-analysis was to determine the association between the statin use and the risk of liver cancer.

Design: Meta-analysis.

Setting: International.

Participants: A comprehensive literature search of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO and Cochrane Library was conducted through March 2014. The effect estimate was reported as pooled relative risk (RR) with 95% confidence intervals (CIs), using the random-effects model.

Results: A total of 12 studies (one individual patient data analysis of 22 randomized controlled trials, 5 cohorts, and 6 case-controls) were qualified for this meta-analysis, involving 5,640,313 participants including 35,756 liver cancer cases. Our results indicated a significant risk reduction of liver cancer among all statin users (RR 0.58, 95% CIs 0.51–0.67). The difference of the study designs can partly explained the significant heterogeneity found in the overall analysis ($I^2 = 65\%$, $P = 0.0006$). No evidence of publication bias was observed in this meta-analysis. Similar risk reductions were found in the subgroups analysis of Western and Asian countries, lipophilic and hydrophilia statins. There was a trend toward more risk reductions in subgroups with higher baseline risk, inadequate adjustment, and higher cumulative dosage of statin use.

1
2
3
4 **Conclusions:** This meta-analysis suggests that the statin is associated with a
5
6 significant risk reduction of liver cancer, when taken daily for cardiovascular event
7
8 prevention. However, this preventive effect might be overestimated due to the
9
10 exposure period, the indication and contraindication of statins, and other confounders.
11
12
13
14 Statins might be considered as an adjuvant in the treatment of liver cancer.
15
16
17
18

19 **Strengths and limitations of this study**

20
21 Statins are commonly prescribed as cholesterol-lowering drugs. In this comprehensive
22
23 meta-analysis, we demonstrate that the statin use is associated with a significant risk
24
25 reduction of liver cancer.
26
27

28
29 The difference of the study designs is the part reason that explained the significant
30
31 heterogeneity found in the overall analysis.
32

33
34 However, this preventive effect might be overestimated due to the exposure period,
35
36 the indication and contraindication of statins, and other confounders.
37

38
39 Statins might be considered as an adjuvant in the treatment of liver cancer.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and they are widely used to reduce the plasma cholesterol level and the risk of cardiovascular events.¹ Although there is a concern over their possible carcinogenicity raised in rodent studies,² preclinical studies indicate that statins have anticancer properties *in vitro* and *in vivo*, through inhibiting angiogenesis, inducing apoptosis, and suppressing tumor growth and metastasis.³⁻⁵

However, higher concentrations of statins are typically required to induce these effects, raising questions concerning the therapeutic relevance of statins on cancer.⁶

To date, clinical studies regarding the cancer incidence associated with statin administration have highlighted conflicting results. Moreover, a large number of meta-analyses have concluded that there was no association between statin use and risk of overall cancer,⁷⁻¹⁰ or cancer of breast¹¹, stomach,¹² or pancreas.¹³ There is only a modest protective effect of statins in prostate cancer¹⁴ and colorectal cancer.¹⁵

In contrary, recent studies reported encouraging results for risk reduction of liver cancer among all statin users. Previous meta-analysis, conducted by Singh *et al.* by including 10 studies, found that statin users were less likely to develop hepatocellular carcinoma (HCC) than statin non-users.¹⁶ However, Singh *et al.* included the ALERT, LIPS, and MEGA trials twice, by including three individual patient data (IPD) analysis of randomized controlled trials (RCTs).¹⁷⁻¹⁹ Meanwhile, some factors of stratification were not considered in their analyses, such as dose and timing of exposure to statins, and the selection of controls and confounders, which might limit

1
2
3 the evaluation of cancer risk.²⁰ Furthermore, the lipophilic statins are accompanied by
4
5 an extensive first-pass effect at the hepatic level.²¹ It is plausible that lipophilic statins
6
7 may have a better liver cancer preventive qualities than the hydrophilic ones.²²
8
9

10
11 Therefore, we performed this updated meta-analysis to assess the association between
12
13 the statin use and the risk of liver cancer, involving the recently published studies and
14
15 conducting more subgroup analyses based on the factors mentioned above. Our results
16
17 demonstrated that statin use was associated with an over 40% risk reduction in liver
18
19 cancer, which may have a significant translational potential in the clinical practice.
20
21
22 However, there were some confounders might overestimate this preventive effect of
23
24 statins.
25
26
27

28 **MATERIALS AND METHODS**

29 *Literature Search strategy*

30
31 This meta-analysis was conducted following the PRISMA guidelines.²³
32
33

34
35 The systematic computerized search for eligible studies were performed on the
36
37 database of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO, and
38
39 Cochrane Library, covering all studies published from their inception to March 5,
40
41 2014. The following terms were searched with both the subjects (MeSH terms) and
42
43 text-word search strategies: “(Statin OR HMG-CoA reductase inhibitors OR
44
45 Atorvastatin OR Cerivastatin OR Fluvastatin OR Lovastatin OR Pravastatin OR
46
47 Rosuvastatin OR Simvastatin) AND (Hepatocellular OR Hepatic OR Intrahepatic OR
48
49 Interlobular OR Liver) AND (Carcinoma OR Sarcomas OR Angiosarcoma OR Cancer
50
51 OR Neoplasm). Additionally, the relevant reviews and retrieved articles were searched
52
53
54
55
56
57
58
59
60

1
2
3 manually for more eligible studies.
4

5
6 In study searching, only the original researches, published in form of peer review
7
8 article or meeting abstract, were included. No language restrictions were imposed.
9
10
11 However, the studies we included were all published in English.
12

13 ***Study selection***

14
15 The inclusion criteria were: (1) randomized controlled trial (RCTs), cohort studies or
16
17 case-control studies; (2) original studies that assessed the effect of statin use on the
18
19 risk of liver cancer, compared with placebo or no treatment; (3) liver cancer cases
20
21 were identified according to the International Classification of Diseases codes (ICD);
22
23 and (4) studies with estimate of relative risk (risk ratio, RR) of liver cancer, or with
24
25 data sufficient to calculate it.
26
27
28
29

30
31 The exclusion criteria were: (1) study design not meeting the inclusion criteria; (2)
32
33 studies without estimate of RR, or without sufficient data to calculate it; or (3) studies
34
35 with duplicated or overlap reports.
36
37
38

39 ***Data extraction***

40
41 Two independent investigators (M. Shi and X.B. Cui) extracted data from the eligible
42
43 studies using a predefined data collection form. The differences of data extraction
44
45 were resolved by consensus referring back to the original article. The extracted
46
47 information included: (1) Studies: first author, year of publication, study design,
48
49 location, patient populations, period, and follow-up; (2) Statins: type, dosage or
50
51 duration of statin use; (3) liver cancer: case identification, number of liver cancer,
52
53 crude RR with 95% confidence intervals (CIs), adjusted RR reflecting the greatest
54
55
56
57
58
59
60

1
2
3 degree of control for confounders, and confounders for adjustment (including
4 variables for matching). When the RR were not available, the RR with 95% CIs were
5
6
7
8
9 calculated from the raw data in original studies.

10
11 We extracted different measurements of effect estimates from original studies, such as
12
13 Relative Risk (RR), Odds Ratio (OR), Hazard Ratio (HR), and Observed/Expected
14
15 ratio. Due to the fact that the incidence of liver cancer was low in all studies, these
16
17 different measurements can be used to provide similar estimates of RR.
18
19

20 21 ***Methodological quality assessment***

22
23 Of note, the included RCT was pooled analysis of other RCTs, therefore, it is
24
25 inappropriate to assess the methodological quality. The methodological quality of
26
27 cohort and case-control studies were assessed on the Newcastle-Ottawa Scale,²⁴
28
29 including eight items that were categorized three categories: selection (four items, one
30
31 star each), comparability (one item, up to two stars), and exposure/outcome (three
32
33 items, one star each). A “star” presents a “high” quality choice of each item.
34
35
36
37
38

39 ***Statistical analysis***

40
41 The overall meta-analysis was first performed, followed by the subgroup analyses,
42
43 based on study design, baseline risk of liver cancer, confounding adjustment, study
44
45 location, and pharmacokinetic. Meanwhile, we conducted subgroup analyses based on
46
47 studies which reported RR estimate for higher cumulative dosage of statin use, when
48
49 appropriate data were available.
50
51
52

53
54 To take into account the heterogeneity and provide a more conservative estimate, the
55
56 inverse variance method was used to estimate the pooled RR and corresponding 95%
57
58
59
60

1
2
3
4 CIs, and data were pooled using a random effects model. Heterogeneity was assessed
5
6 using the Chi-squared statistic (P) together with the Higgins I-squared statistic (I^2), a
7
8 P value <0.10 was considered statistically significant for heterogeneity; and an I^2
9
10 value $> 50\%$ was considered a measure of severe heterogeneity.²⁵

11
12
13
14 Publication bias was assessed using the Begg's test and the Egger's test.²⁶ Influence
15
16 analysis was performed to investigate the influence of a single study on the overall
17
18 meta-analysis estimate, by omitting one study in each turn. Test for interaction was
19
20 applied to identify the difference between pooled RR from subgroup analysis using
21
22 the method described by Altman and Bland.²⁷ All statistical tests were two-sided and
23
24 $P < 0.05$ was considered statistically significant, unless otherwise specified. Software
25
26 Review Manager (RevMan5.2, Copenhagen) and STATA (Stata 11.2, Texas) were
27
28 used for the statistical analysis.
29
30
31
32

33 34 **Results**

35 36 **Study selection**

37
38 **Figure 1** illustrated the process of study selection for the meta-analysis. Of the 1424
39
40 potentially relevant references identified by electric and manual search, 142 were
41
42 selected for full-text review after screening titles and abstracts. Finally, a total of 12
43
44 studies were included, with one IPD analysis,¹⁹ five cohort studies,²⁸⁻³² and six
45
46 case-control studies.³³⁻³⁸ One case-control study was presented solely in abstract
47
48 form.³³
49
50
51
52

53
54 Of note, the cohort study conducted by Friedman *et al.* reported RR estimate
55
56 separately for different gender (male and female),²⁹ we considered these two reports
57
58
59
60

1
2
3
4 as separate studies. Therefore, a total of thirteen reports were included for the present
5
6 meta-analysis.
7

8 *Study characteristics*

9
10 **Table 1** summarized the characteristics of qualified studies in this meta-analysis. The
11
12 12 studies, involving 5,640,313 participants with 35,756 liver cancer cases, were
13
14 published between 2005 and 2013. The “RCT” in the present study was pooled
15
16 analysis of 22 clinical trials,¹⁹ which investigated statins therapy in cardiovascular
17
18 event prevention and reported the occurrence of liver cancer as adverse event. The
19
20 observational studies were conducted with the local or national health databases, the
21
22 statin exposure were identified by linkage to prescription databases, and the controls
23
24 were matched mainly by age, sex and index date. Except one cohort adopted ICD-10
25
26 C22,²⁸ all other studies identified liver cancer cases according to the ICD-9 155. Of
27
28 note, two cohorts were restricted to patients with HBV infection,³¹ and HCV
29
30 infection;³² one case-control only included patients with diabetes mellitus;³⁴ two
31
32 observational studies included patients aged at least 45 years.^{30 35}
33
34
35
36
37
38
39
40

41 **Table 2** summarized the data of the included studies. In the RCT¹⁹ and one cohort
42
43 study,³⁰ the RR with 95% CIs were calculated from the 2x2 tables defined by the
44
45 incidence of liver cancer and the statin use status. The observational studies reported
46
47 different measurements of RR estimates with adjustment by confounders. Several
48
49 observational studies adopted the important risk factors of liver cancer for
50
51 adjustments^{31 32 34-36}, such as HBV infection, HCV infection, cirrhosis, alcoholic liver
52
53 disease, or non-alcoholic fatty liver disease (NAFLD).³⁹ Of note, only two studies
54
55
56
57
58
59
60

1
2
3 adjusted for the cholesterol level,^{30 38} and no study adjusted for the metabolic
4
5
6 syndrome, which might also influence the risk of liver cancer.³⁹
7

8 9 *Methodological quality*

10
11 For the cohort and case-control studies, the median score was 7 on the
12
13 Newcastle-Ottawa Scale, with a range of 5 to 8 (**Supplementary Table 1**). These
14
15 results indicated that the observational studies were in a reasonable good quality.
16
17

18 19 *Overall meta-analysis*

20
21 **Figure 2** depicted the forest plot of RR estimate with 95% CIs from individual studies
22
23 and overall meta-analysis. In the overall meta-analysis, pooled results showed a
24
25 statistically significant decrease in the liver cancer risk among all statin users (RR
26
27 0.58, 95% CIs 0.51–0.67). Of note, a statistically significant heterogeneity was
28
29 observed ($I^2 = 65%$, $P = 0.0006$). The P -values of Begg's test and Egger's test were
30
31 0.669 and 0.749, respectively, both suggesting there was no evidence of publication
32
33 bias. In the influence analysis, the omission of any individual studies did not alter the
34
35 direction and magnitude of the observed effect (**Supplementary Figure 1**).
36
37
38
39

40 41 *Subgroup analyses and Test for interaction*

42
43 We first performed preplanned subgroup analyses based on study design, baseline risk
44
45 of liver cancer, confounding adjustment, and study location (**Table 3**).
46
47

48
49 The RCT showed there is no significant association between statin use and risk of
50
51 liver cancer (RR 1.06, 0.66–1.71). But the observational studies indicated a significant
52
53 decrease of liver cancer risk among all statin users (RR 0.57, 0.50–0.64; $I^2 = 61%$, $P =$
54
55 0.003) (**Figure 2**). Furthermore, we found a greater risk reduction in the subgroup
56
57
58
59
60

1
2
3
4 analysis of cohort studies (RR 0.51, 0.44–0.58; $I^2 = 18\%$, $P = 0.30$) than in the
5
6 case-control studies (RR 0.63, 0.54–0.73; $I^2 = 46\%$, $P = 0.10$) (**Supplementary**
7
8 **Figure 2**).

9
10
11 Test for interaction showed significant results between subgroups of the RCT and
12
13 observational studies ($P_{\text{interaction}} = 0.01$, $Z = 2.47$), and between subgroups of the
14
15 cohort and case-control studies ($P_{\text{interaction}} = 0.04$, $Z = -2.03$). These results indicated
16
17 that the difference of the study designs was the part reason that why there was severe
18
19 heterogeneity in the overall analysis (**Table 3**).

20
21
22 In the subgroup analysis of the four studies with higher baseline risk of liver
23
24 cancer,^{30-32 35} defined as patients with older age, HBV or HCV infection, there was a
25
26 trend toward more decrease of liver cancer risk (RR 0.52, 0.47-0.59; $I^2 = 16\%$, $P =$
27
28 0.31) than in the other eight studies with general population^{19 28 29 33 34 36-38} (RR 0.63,
29
30 0.52–0.75; $I^2 = 59\%$, $P = 0.01$) (**Supplementary Figure 3**).

31
32
33 We defined the RCT or studies adjusted for at least 4 of 7 important confounders,
34
35 such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD,
36
37 HBV treatment, or HCV treatment,³⁹ were adjusted adequately. Subgroup analysis of
38
39 these six studies^{19 31 32 34-36} found a trend toward less decrease of liver cancer risk (RR
40
41 0.64, 0.53-0.77; $I^2 = 81\%$ $P = 0.0001$) than the other six studies^{28-30 33 37 38} (RR, 0.51,
42
43 0.43-0.60; $I^2 = 3\%$, $P = 0.40$) (**Supplementary Figure 4**).

44
45
46 Subgroup analyses based on study location found a similar risk reduction of liver
47
48 cancer in the Western countries (RR 0.61, 0.48–0.76; $I^2 = 64\%$, $P = 0.007$) and in the
49
50 Asian countries (RR 0.56, 0.48–0.64; $I^2 = 51\%$, $P = 0.09$). (**Supplementary Figure 5**)
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Besides the overall RR estimates, some studies reported different RR estimate for
5
6 different pharmacokinetic and dosage of statin use (**Supplementary Table 2**). We
7
8 conducted further subgroup analyses based on these available data.
9

10
11 According to the different pharmacokinetic, statins can be classified as lipophilic
12
13 statins (Atorvastatin, Fluvastatin, Lovastatin, and Simvastatin) and hydrophilia statins
14
15 (Pravastatin and Rosuvastatin).²¹ Subgroup analysis of lipophilic statins^{29 31 34-36}
16
17 found a significant decrease of liver cancer risk (RR 0.57, 0.50–0.65; $I^2 = 50%$, $P =$
18
19 0.08). And there was a similar result among users of hydrophilia statins^{31 35 36} (RR
20
21 0.59, 0.41–0.84; $I^2 = 50%$, $P = 0.13$) (**Supplementary Figure 6**).
22
23

24
25 Test for interaction showed non-significant results for subgroups with different
26
27 baseline risk, confounding adjustment, study location, or pharmacokinetic ($P_{\text{interaction}} =$
28
29 0.08, 0.08, 0.54 and 0.86, respectively) (**Table 3**). Therefore, there is no strong
30
31 evidence to support a different preventive effect of statins on liver cancer in these
32
33 subgroups.
34
35

36
37 Subgroup analysis of six studies with higher cumulative dose of statin use, defined as
38
39 statin use more than 180 cumulative defined daily dose (cDDD) or 0.5 years
40
41 (cumulative duration), showed a trend toward more risk reduction of liver cancer (RR
42
43 0.53, 0.36-0.79), but with a high degree of heterogeneity ($I^2 = 90%$, $P < 0.00001$)
44
45 (**Supplementary Figure 7**).
46
47
48
49

50 51 Discussion

52
53 This present meta-analysis represents the most comprehensive review to date on the
54
55 association between the statin use and the liver cancer risk, by including 12 studies
56
57
58
59
60

1
2
3
4 (one IPD analysis of 22 RCTs, 5 cohort studies, and 6 case-control studies) and
5
6 involving 5,640,313 participants with 35,756 liver cancer cases. Overall, we found
7
8 that statin use was associated with an over 40% risk reduction in liver cancer
9
10 compared with nonusers (RR 0.58, 95%CI 0.51–0.67). This result was in line with the
11
12 previous three meta-analyses: Singh *et al.* included 10 studies and suggested statin
13
14 users were less likely to develop HCC (OR 0.63, 95%CI 0.52–0.76),¹⁶ Pradelli *et al.*
15
16 and Zhang *et al.* included 5 and 7 observational studies and found a summary RR of
17
18 0.58 (95%CI 0.46–0.74) and 0.61 (95%CI 0.49–0.76), respectively.^{40 41}

19
20
21
22
23
24 The IPD analysis of 22 RCTs showed there is no significant association between statin
25
26 use and risk of liver cancer. The significant risk reduction of liver cancer among all
27
28 statin users was seen primarily in the observational studies, and this preventive effect
29
30 was relatively convinced in the cohorts than in the case-controls. There were some
31
32 reasons to explain the different findings between RCTs and observational studies.
33
34

35
36 First, the exposure period to statins might be shorter than the period to carcinogenesis
37
38 and the latency to diagnosis in the cohorts and the case-controls. The observational
39
40 studies defined statin use varying in dosage and duration, from patients who received
41
42 ≥ 1 cDDD or >1 Rx of statins to more than 0.5 years (**Table 1**). On the other hand, the
43
44 median period of statin use was 5.1 years in the RCTs. Although there was a trend
45
46 toward more risk reduction of liver cancer with higher cumulative dose of statin use,
47
48 this defect might still result in overestimating the cancer-preventive effect of statins in
49
50 the observational studies.
51
52
53
54

55
56 Second, clinical studies demonstrated that higher serum total cholesterol
57
58
59
60

1
2
3
4 concentration was associated with decreased risk of liver cancer (**Supplementary**
5
6 **Table 3**).⁴²⁻⁴⁴ Meanwhile, there were inverse association between use of non-statin
7
8 lipid-lowering drugs and risk of the liver cancer.^{35 38} Meanwhile, because of the
9
10 contraindication, statins might not prescribed to the patients with the chronic liver
11
12 disease, which is known as a risk factor of liver cancer. Unfortunately, the
13
14 observational studies included in this analysis seldom adopted these factors for
15
16 adjustment. Actually, subgroup analysis of studies with adequate adjustment showed a
17
18 trend toward less risk reduction, indicating the potential of overestimate this
19
20 preventive effect by confounders.

21
22
23
24
25
26 Third, the RCTs included lower risk population (patients with cardiovascular disease
27
28 rather than HBV /HCV infection), might not be powerful enough to investigate the
29
30 liver cancer outcomes, which were much rarer than cardiovascular events. In addition,
31
32 subgroup analysis of studies with higher baseline risk showed a trend toward more
33
34 decrease of liver cancer risk.

35
36
37
38
39 These reasons suggested that the observed modulation of cancer incidence cannot be
40
41 ascribable to a direct statin-mediated effect,²⁰ the exposure period, the indication (e.g.
42
43 hyperlipidemia) and contraindication (e.g. chronic liver disease) of statins might
44
45 overestimate its cancer-preventive effect.

46
47
48
49 We found similar results in Western countries and Asian countries, which were
50
51 different from the meta-analysis conducted by Singh *et al.* which concluded that the
52
53 inverse association of statins with HCC was stronger in the Asian population.
54
55 Considering four more studies we included, this difference might be caused by the
56
57
58
59
60

1
2
3
4 insufficient data in their meta-analysis. Based on the pharmacokinetics, it is plausible
5
6 that lipophilic and hydrophilic statins will differ in their liver cancer prevention
7
8 qualities.^{21 22} However, subgroup analysis of lipophilic and hydrophilic statins showed
9
10 similar results.
11

12
13 Besides the limitations described previously, there were some other limitations should
14
15 be noted. First, a significant heterogeneity was observed in the present meta-analysis,
16
17 which might results from the difference in study design. Results of subgroup analyses
18
19 would also be limited by this heterogeneity. Second, the adherence to statin therapy is
20
21 known to be associated with healthy lifestyle, which might affect the cancer
22
23 outcome.⁴⁵ Such information is hard to be captured in databases or medical record in
24
25 the observational studies.⁴⁶ Third, five observational studies were conducted using the
26
27 Taiwanese National Health Insurance Research Database (NHIRD),^{31 32 35-37} although
28
29 they were not in the same period, these studies might contain overlapping groups of
30
31 patients. These limitations mentioned above might lead to confounding of overall
32
33 results from the present study, and should be considered in future studies aiming at
34
35 confirming the protective effects of statins on human cancer risk.
36
37

38
39 The strengths of our meta-analysis were as follows: First, we performed a much more
40
41 comprehensive search and more subgroup analyses, compared with the previous
42
43 meta-analyses; Second, the methodological quality of the included studies were
44
45 reasonable good; Third, publication bias, which due to the tendency of not publishing
46
47 small studies with null results, were not found in our meta-analysis.
48
49

50
51 Of note, preclinical studies have indicated that statins possess synergism with other
52
53
54
55

1
2
3
4 therapeutic agents *in vitro* and *in vivo* for liver cancer.^{47 48} Some clinical studies have
5
6 also demonstrated that statins would prolong survival in patients with advanced liver
7
8 cancer (**Supplementary Table 4**),⁴⁹⁻⁵² and associated with risk reduction of
9
10 recurrence after curative surgery in patients of HBV related HCC.⁵³ Therefore,
11
12 considerable interest exists in adjunctive therapy with statins for liver cancer. In fact,
13
14 there were some RCTs ongoing to determine the effectiveness of pravastatin, when
15
16 used in combination with sorafenib, in the treatment of liver cancer (**Supplementary**
17
18 **Table 5**).

19
20
21
22
23
24 Currently, physicians are less likely to prescribe statins for patients with chronic liver
25
26 disease, based on the concerns about the statin-induced liver injury.³¹ However, there
27
28 were number of studies have demonstrated the safe use, even salutary effects.⁵⁴⁻⁵⁶
29
30
31 Meanwhile, the risk of serious statin-related liver injury appears to be no greater than
32
33 the background incidence of this rare event.⁵⁷ Therefore, considering their benefits for
34
35 cardiovascular event prevention and the potential effect in liver cancer prevention and
36
37 treatment, statins should not be denied to these patients.
38
39

40
41 In conclusion, our results suggest that statin use is associated with a significant risk
42
43 reduction of liver cancer, when taken daily for cardiovascular event prevention.
44
45 However, this preventive effect might be overestimated due to the exposure period,
46
47 indication and contraindication of statins, and other confounders. Statins might be
48
49 considered as an adjuvant in the treatment of liver cancer.
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENT

We thank Medjaden Bioscience Limited and Gui Lv for assisting in the preparation and revision of this manuscript.

CONTRIBUTORSHIP STATEMENT

XB Cui had the original idea, M Shi, XB Cui and W Gong worked together to develop an appropriate theoretical framework and design. XB Cui developed the search, M Shi and XB Cui were involved in the selection process. M Shi and XB Cui extracted relevant data, XB Cui and W Gong performed the statistical analysis and all authors were involved in the data interpretation. M Shi and B Nie wrote the manuscript draft and revised the draft based on input from the other authors. All authors revised it critically for content and approved the final version.

COMPETING INTERESTS

There are no competing interests

FUNDING

None.

DATA SHARING

No additional data available.

REFERENCES:

1. Baigent C, Keech A, Kearney PM, *et al.* Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;**366**(9493):1267-78.
2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA* 1996;**275**(1):55-60.
3. Demierre MF, Higgins PD, Gruber SB, *et al.* Statins and cancer prevention. *Nat Rev Cancer* 2005;**5**(12):930-42.
4. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. *J Cancer Res Ther* 2012;**8**(2):176-83.
5. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2012;**27**(11):1654-64.
6. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. *Cancer Chemother Pharmacol* 2011;**67**(4):729-39.
7. Dale KM, Coleman CI, Henyan NN, *et al.* Statins and cancer risk: a meta-analysis. *JAMA* 2006;**295**(1):74-80.
8. Browning DRL, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. *Int J Cancer* 2007;**120**(4):833-43.
9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. *Eur J Cancer* 2008;**44**(15):2122-32.
10. Baigent C, Blackwell L, Emberson J, *et al.* Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;**376**(9753):1670-81.
11. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Res Treat* 2012;**135**(1):261-9.
12. Shimoyama S. Statins and gastric cancer risk. *Hepatogastroenterology* 2011;**58**(107-108):1057-61.
13. Cui X, Xie Y, Chen M, *et al.* Statin use and risk of pancreatic cancer: a meta-analysis. *Cancer Causes Control* 2012;**23**(7):1099-111.
14. Bansal D, Undela K, D'Cruz S, *et al.* Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. *PLoS One* 2012;**7**(10):e46691.
15. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. *Gut* 2010;**59**(11):1572-85.
16. Singh S, Singh PP, Singh AG, *et al.* Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. *Gastroenterology* 2013;**144**(2):323-32.
17. Stein EA, Corsini A, Gimpelewicz CR, *et al.* Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract* 2006;**60**(9):1028-34.
18. Matsushita Y, Sugihara M, Kaburagi J, *et al.* Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. *Pharmacoepidemiol Drug Saf* 2010;**19**(2):196-202.
19. Emberson JR, Kearney PM, Blackwell L, *et al.* Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.

- 1
2
3 PLoS One 2012;**7**(1):e29849.
- 4 20. Gazerro P, Bifulco M. Statins and Cancer in Gastroenterology: New Insight? *Gastroenterology*
5 2013;**144**(7):1572-3.
- 6 21. Gazerro P, Proto MC, Gangemi G, *et al.* Pharmacological actions of statins: a critical appraisal in
7 the management of cancer. *Pharmacol Rev* 2012;**64**(1):102-46.
- 8 22. Gronich N, Rennert G. Beyond aspirin - Cancer prevention with statins, metformin and
9 bisphosphonates. *Nat Rev Clin Oncol* 2013;**10**(11):625-42.
- 10 23. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and
11 meta-analyses: the PRISMA statement. *BMJ* 2009;**339**:b2535.
- 12 24. GA Wells, B Shea, D O'Connell, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of
13 nonrandomised studies in meta-analyses.
14 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 15 25. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ*
16 2003;**327**(7414):557-60.
- 17 26. METABIAS: Stata module to test for small-study effects in meta-analysis [program], 2009.
- 18 27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*
19 2003;**326**(7382):219.
- 20 28. Friis S, Poulsen AH, Johnsen SP, *et al.* Cancer risk among statin users: A population-based cohort
21 study. *Int J Cancer* 2005;**114**(4):643-7.
- 22 29. Friedman GD, Flick ED, Udaltsova N, *et al.* Screening statins for possible carcinogenic risk: up to 9
23 years of follow-up of 361,859 recipients. *Pharmacoepidemiol Drug Saf* 2008;**17**(1):27-36.
- 24 30. Marelli C, Gunnarsson C, Ross S, *et al.* Statins and Risk of Cancer A Retrospective Cohort Analysis of
25 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult
26 Americans. *J Am Coll Cardiol* 2011;**58**(5):530-7.
- 27 31. Tsan YT, Lee CH, Wang JD, *et al.* Statins and the risk of hepatocellular carcinoma in patients with
28 hepatitis B virus infection. *J Clin Oncol* 2012;**30**(6):623-30.
- 29 32. Tsan YT, Lee CH, Ho WC, *et al.* Statins and the risk of hepatocellular carcinoma in patients with
30 hepatitis C virus infection. *J Clin Oncol* 2013;**31**(12):1514-21.
- 31 33. Khurana V, Saluja A, Caldito G, *et al.* Statins are protective against hepatocellular cancer in patients
32 with hepatitis C virus infection: Half a million US veterans' study. *Gastroenterology*
33 2005;**128**(4, Suppl. 2):A714.
- 34 34. El-Serag HB, Johnson ML, Hachem C, *et al.* Statins are associated with a reduced risk of
35 hepatocellular carcinoma in a large cohort of patients with diabetes. *Gastroenterology*
36 2009;**136**(5):1601-8.
- 37 35. Chiu HF, Ho SC, Chen CC, *et al.* Statin use and the risk of liver cancer: a population-based
38 case-control study. *Am J Gastroenterol* 2011;**106**(5):894-8.
- 39 36. Lai SW, Liao KF, Lai HC, *et al.* Statin use and risk of hepatocellular carcinoma. *Eur J Epidemiol*
40 2013;**28**(6):485-92.
- 41 37. Leung HW, Chan AL, Lo D, *et al.* Common cancer risk and statins: a population-based case-control
42 study in a Chinese population. *Expert Opin Drug Saf* 2013;**12**(1):19-27.
- 43 38. Chaiteerakij R, Yang JD, Harmsen WS, *et al.* Risk factors for intrahepatic cholangiocarcinoma:
44 association between metformin use and reduced cancer risk. *Hepatology* 2013;**57**(2):648-55.
- 45 39. Singh S, Singh PP, Roberts LR, *et al.* Chemopreventive strategies in hepatocellular carcinoma. *Nat*
46 *Rev Gastroenterol Hepatol* 2014;**11**(1):45-54.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
- 2
- 3 40. Pradelli D, Soranna D, Scotti L, *et al.* Statins and primary liver cancer: a meta-analysis of
- 4 observational studies. *Eur J Cancer Prev* 2013;**22**(3):229-34.
- 5
- 6 41. Zhang H, Gao C, Fang L, *et al.* Statin use and risk of liver cancer: A meta-analysis of 7 studies
- 7 involving more than 4.7 million patients. *World J Meta-Anal* 2013;**1**(3):130-7.
- 8
- 9 42. Ahn J, Lim U, Weinstein SJ, *et al.* Prediagnostic total and high-density lipoprotein cholesterol and
- 10 risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2009;**18**(11):2814-21.
- 11
- 12 43. Iso H, Ikeda A, Inoue M, *et al.* Serum cholesterol levels in relation to the incidence of cancer: the
- 13 JPHC study cohorts. *Int J Cancer* 2009;**125**(11):2679-86.
- 14
- 15 44. Kitahara CM, de Gonzalez AB, Freedman ND, *et al.* Total Cholesterol and Cancer Risk in a Large
- 16 Prospective Study in Korea. *J Clin Oncol* 2011;**29**(12):1592-8.
- 17
- 18 45. Brookhart MA, Patrick AR, Dormuth C, *et al.* Adherence to lipid-lowering therapy and the use of
- 19 preventive health services: an investigation of the healthy user effect. *Am J Epidemiol*
- 20 2007;**166**(3):348-54.
- 21
- 22 46. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. *Expert Opin*
- 23 *Drug Saf* 2010;**9**(4):603-21.
- 24
- 25 47. Kim W, Yoon JH, Kim JR, *et al.* Synergistic anti-tumor efficacy of lovastatin and protein kinase
- 26 C-beta inhibitor in hepatocellular carcinoma. *Cancer Chemother Pharmacol*
- 27 2009;**64**(3):497-507.
- 28
- 29 48. Polo MP, Crespo R, de Bravo MG. Geraniol and simvastatin show a synergistic effect on a human
- 30 hepatocarcinoma cell line. *Cell Biochem Funct* 2011;**29**(6):452-8.
- 31
- 32 49. Kawata S, Yamasaki E, Nagase T, *et al.* Effect of pravastatin on survival in patients with advanced
- 33 hepatocellular carcinoma. A randomized controlled trial. *Br J Cancer* 2001;**84**(7):886-91.
- 34
- 35 50. Lersch C, Schmelz R, Erdmann J, *et al.* Treatment of HCC with pravastatin, octreotide, or
- 36 gemcitabine - A critical evaluation. *Hepatogastroenterology* 2004;**51**(58):1099-103.
- 37
- 38 51. Graf H, Jungst C, Straub G, *et al.* Chemoembolization combined with pravastatin improves survival
- 39 in patients with hepatocellular carcinoma. *Digestion* 2008;**78**(1):34-8.
- 40
- 41 52. Georgescu EF, Badulescu F, Dumitrescu D, *et al.* Lovastatin may enhance cytostatic effects of
- 42 sorafenib in hepatic carcinoma. Primary results of a pilot study. *Hepatol Int* 2011;**5**(1):423.
- 43
- 44 53. Wu CY, Chen YJ, Ho HJ, *et al.* Association between nucleoside analogues and risk of hepatitis B
- 45 virus-related hepatocellular carcinoma recurrence following liver resection. *JAMA*
- 46 2012;**308**(18):1906-14.
- 47
- 48 54. Lewis JH, Mortensen ME, Zweig S, *et al.* Efficacy and safety of high-dose pravastatin in
- 49 hypercholesterolemic patients with well-compensated chronic liver disease: Results of a
- 50 prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology*
- 51 2007;**46**(5):1453-63.
- 52
- 53 55. Nelson A, Torres DM, Morgan AE, *et al.* A pilot study using simvastatin in the treatment of
- 54 nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol*
- 55 2009;**43**(10):990-4.
- 56
- 57 56. Lewis JH. Clinical Perspective: Statins and the Liver-Harmful or Helpful? *Dig Dis Sci*
- 58 2012;**57**(7):1754-63.
- 59
- 60 57. Bader T. The myth of statin-induced hepatotoxicity. *Am J Gastroenterol* 2010;**105**(5):978-80.

Figure legends:

Figure 1. Flow chart of study selection in the present meta-analysis.

Figure 2. Overall meta-analysis of the statin use and the liver cancer risk.

Supplementary Figure 1. Influence analysis.

Supplementary Figure 2. Subgroup analyses based on study design.

Supplementary Figure 3. Subgroup analyses based on baseline risk of liver cancer.

Supplementary Figure 4. Subgroup analyses based on confounder adjustment.

Supplementary Figure 5. Subgroup analyses based on study location.

Supplementary Figure 6. Subgroup analyses based on pharmacokinetic of statins.

Supplementary Figure 7. Subgroup analysis of higher cumulative dose of statin use.

Table 1. Study characteristics

Studies	Study design	Patient population	Study period	Cases defined	Follow-up	Statins type	Dosage/Duration of Statin use
Emberson, 2012, UK ¹⁹	RCT	IPD analysis of 22 RCTs	-	ICD-9 155	5.1 years (Me)	A, F, L, P, R, S	5.1 years (Me)
Friis, 2005, North Jutland ²⁸	Cohort	General population (CPR)	1989-2002	ICD-10 C22	3.3 years (M)	Unspecified	≥2 Rx
Friedman, 2008, USA ²⁹	Cohort	General population (KPMCP)	1994-2003	ICD-9-CM 155	> 2 years	A, L, S (97.6%)	≥1 Rx
Marelli, 2011, USA ³⁰	Cohort	General older population (men ≥ 45 and women ≥ 55 years; GE Centricity)	1990-2009	ICD-9 155	4.6 years (M)	Unspecified	≥1 cDDD
Tsan, 2012, Taiwan ³¹	Cohort	Patients with HBV infection (NHIRD)	1997-2008	ICD-9 155	9.9 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Tsan, 2013, Taiwan ³²	Cohort	Patients with HCV infection (NHIRD)	1999-2010	ICD-9 155	10.7 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Khurana, 2005, USA ³³	Case control	General population (VISN)	1997-2002	ICD-9 155	NR	Unspecified	≥1 Rx
El-Serag, 2009, USA ³⁴	Case control	Diabetes patients (VA)	1997-2002	ICD-9-CM 155	2.4 years (M)	A, C, F, L, P, and S	1.6 years (M)
Chiu, 2011, Taiwan ³⁵	Case control	Older patients (≥ 50 years; NHIRD)	2005–2008	ICD-9-CM 155	NR	A, F, L, P, R, and S	≥ 1 cDDD
Lai, 2013, Taiwan ³⁶	Case control	General population (NHIRD)	2000-2009	ICD-9-CM 155	1.4 years (M)	A, F, L, P, R, and S	≥1 Rx
Leung, 2013, Taiwan ³⁷	Case control	General population (NHIRD)	2000-2008	ICD-9-CM 155	4.1 years (M)	Unspecified	> 0.5 years
Chaiteerakij, 2013, USA ³⁸	Case control	Hyperlipidemia patients (Mayo Clinic)	2000-2010	ICD-9-CM 155	>1 years	Unspecified	≥1 Rx

Patients population: IPD = Individual patient data, RCT = randomized controlled trials, CPR = the Central Population Register of Danish citizens, KPMCP = the Kaiser Permanente Medical Care Program in northern California, GE Centricity = the General Electric Centricity database, NHIRD = the Taiwanese National Health Insurance research database, VISN = Veterans Integrated Service Networks 16 Veteran Affairs database, VA = Veterans Affairs national databases, Mayo Clinic = Mayo Clinic (Rochester, MN), HBV = hepatitis B virus; Cases defined: ICD-9 or -10 = International Classification of Diseases, Ninth Revision or Tenth Revision, CM = Clinical Modification; Duration of follow-up: When the follow-up periods of statin user and nonuser were different, only the shorter one was showed, and all periods were transformed to years; Statin type: A = Atorvastatin, C = Cerivastatin, F = Fluvastatin, L = Lovastatin, P = Pravastatin, R = Rosuvastatin, S = Simvastatin, Non-statin = Non-statin cholesterol-lowering drug(s) only; Duration of statin use: M = Mean, Me = Median, ≥1 cDDD = more than 1 cumulative defined daily dose before the diagnosis of liver cancer, Rx = prescriptions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Study data

Studies	Intervention/ Cases		Control		Measurements of effect estimates	Crude RR with 95% CIs	Adjusted RR with 95% CIs	Confounders for adjustment
	No. of event/ No. of exposure	No. of total	No. of event/ No. of exposure	No. of total				
Emberson, 2012, UK ¹⁹	35	67258	33	67279	RR	1.06 (0.66, 1.71)*	1.06 (0.66, 1.71)*	Randomization
Friis, 2005, North Jutland ²⁸	1	12251	166	334754	OR	NA	1.16 (0.46-2.90)	1,2, 16, 21, 23
Friedman(Male), 2008, USA ²⁹	32	192598	NA	1904876	HR	NA	0.49 (0.34-0.70)	16
Friedman(Female), 2008, USA ²⁹	10	169261	NA	1976332	HR	NA	0.40 (0.21-0.75)	
Marelli, 2011, USA ³⁰	13	45857	24	45857	RR	0.31 (0.14-0.68)*	0.31 (0.14-0.68)*	1-5, 14, 16-18, 26, 27
Tsan, 2012, Taiwan ³¹	58	2785	963	30628	HR	0.66 (0.51- 0.86)	0.47 (0.36-0.61)	1, 2, 7, 8, 11, 12
Tsan, 2013, Taiwan ³²	1378	35023	26505	225841	HR	0.42 (0.39-0.46)	0.53 (0.49–0.58)	1, 2, 7, 8, 11, 13
Khurana, 2005, USA ³³	NA	NA	NA	NA	OR	NA	0.52 (0.41- 0.67)	1, 11, 13
El-Serag, 2009, USA ³⁴	447	1303	2766	5212	OR	0.46 (0.40-0.52)	0.74 (0.64-0.87)	1-3, 6, 8, 9, 11-13, 21, 24, 28
Chiu, 2011, Taiwan ³⁵	117	1166	195	1166	OR	0.53 (0.41-0.69)	0.62 (0.45-0.83)	1, 2, 8, 9, 11, 12, 20, 29
Lai, 2013, Taiwan ³⁶	255	3480	1635	13920	OR	0.61 (0.52–0.72)	0.71 (0.56–0.89)	1, 2, 8-13, 22, 24, 25
Leung, 2013, Taiwan ³⁷	26	424	6851	33781	HR	0.45 (0.30-0.67)	0.44 (0.28, 0.72)	1, 2, 11, 15, 20, 21, 23
Chaiteerakij, 2013, USA ³⁸	72	165	165	256	OR	NA	0.6 (0.4-0.9)	1-3, 8, 11, 17, 22, 28, 30

The RR with an asterisk mark (*) was calculated based on the raw data. The others, crude or adjusted, were extracted from the original paper; Confounders for adjustment: 1 = age, 2 = sex, 3 = race, 4 = BMI, 5 = smoking status, 6 = ethanol intake, 7 = socioeconomic status, 8 = cirrhosis, 9 = alcoholic liver disease, 10 = non-alcoholic fatty liver disease, 11 = diabetes mellitus, 12 = HBV infection, 13 = HCV infection, 14 = concomitant diagnoses (unspecified), 15 = Charlson score, 16 = calendar year, 17 = cholesterol (totalcholesterol, VLDL, LDL, or triglycerides), 18 = prostate-specific antigen, 19 = resection extent, 20 = other lipid-lowering agents, 21 = cardiovascular medications (aspirin, nonsteroidal anti-inflammatory medications, or angiotensin-converting enzymes inhibitors), 22 = metformin or thiazolidinedione, 23 = hormone-replacement therapy, 24 = HCV treatment, 25 = HBV treatment, 26 = medications taken (unspecified), 27 = the number of office visits, 28 = propensity to use statins, 29 = hospital stay, 30 = biliary tract diseases

Table 3. Subgroup analyses of included studies

Subgroup	No. of studies (reports)	Summary RR (95% CIs)	Heterogeneity, I ²	Heterogeneity, P value	P _{interaction}	
Study design	RCT	1	1.06 (0.66-1.71)	-	-	P = 0.01
	Observational studies	11(12)	0.57(0.50-0.64)	61%	P = 0.003	
Observational studies	Cohort studies	5 (6)	0.51 (0.44–0.58)	18%	P = 0.30	P = 0.04
	Case-control studies	6	0.63 (0.54–0.73)	46%	P = 0.10	
Baseline risk of liver cancer	Higher baseline risk	4	0.52 (0.47-0.59)	16%	P = 0.31	P = 0.08
	General population	8 (9)	0.63 (0.52–0.75)	59%	P = 0.01	
Confounding adjustment	Adequate adjustment	6	0.64(0.53-0.77)	81%	P = 0.0001	P = 0.08
	Inadequate adjustment	6 (7)	0.51 (0.43-0.60)	3%	P = 0.40	
Study location	Western studies	7 (8)	0.61 (0.48-0.76)	64%	P = 0.007	P = 0.54
	Asian studies	5	0.56 (0.48-0.64)	51%	P = 0.09	
Pharmacokinetic	Hipophilic statins	5 (6)	0.57 (0.50-0.65)	50%	P = 0.08	P = 0.86
	Hydrophilia statins	3	0.59(0.41–0.84)	50%	P = 0.13	
Higher cumulative dosage of statin		6	0.53 (0.36-0.79)	90%	P<0.0001	-

RR = relative risk; higher baseline risk of liver cancer: patients with older age, HBV or HCV infection. Adequate adjustment: RCT or studies which adjusted for at least 4 of 7 important confounders, such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD, HBV treatment, or HCV treatment; Lipophilic statins: Atorvastatin, Fluvastatin, Lovastatin, or Simvastatin; Hydrophilia statins: Pravastatin or Rosuvastatin; Higher cumulative dosage of statin use: > 180cumulative defined daily dose or Duration of statin use > 0.5 years before the diagnosis of liver cancer.

Statin use and risk of liver cancer: an update meta-analysis

Meng Shi¹, Huiling Zheng¹, Biao Nie¹, Wei Gong^{1*} and Xiaobing Cui^{1*}

¹Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Avenue North, Guangzhou 510515, China

*Correspondence to Dr. Xiaobing Cui, Email: xbing119@gmail.com; and Dr. Wei Gong, Email: drgwei@foxmail.com.

Running title: Meta-analysis: statin and liver cancer

Key words: *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*

Abstract

Objective: Statins are commonly prescribed cholesterol-lowering drugs. Preclinical studies suggest that statins may possess cancer preventive properties. The primary objective of this meta-analysis was to determine the association between the statin use and the risk of liver cancer.

Design: Meta-analysis.

Setting: International.

Participants: A comprehensive literature search of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO and Cochrane Library was conducted through March 2014. The effect estimate was reported as pooled relative risk (RR) with 95% confidence intervals (CIs), using the random-effects model.

Results: A total of 12 studies (one individual patient data analysis of 22 randomized controlled trials, 5 cohorts, and 6 case-controls) were qualified for this meta-analysis, involving 5,640,313 participants including 35,756 liver cancer cases. Our results indicated a significant risk reduction of liver cancer among all statin users (RR 0.58, 95%CIs 0.51–0.67). The difference of the study designs can partly explained the significant heterogeneity found in the overall analysis ($I^2 = 65%$, $P = 0.0006$). No evidence of publication bias was observed in this meta-analysis. Similar risk reductions were found in the subgroups analysis of Western and Asian countries, lipophilic and hydrophilia statins. There was a trend toward more risk reductions in subgroups with higher baseline risk, inadequate adjustment, and higher cumulative dosage of statin use.

1
2
3
4 **Conclusions:** This meta-analysis suggests that the statin is associated with a
5
6 significant risk reduction of liver cancer, when taken daily for cardiovascular event
7
8 prevention. However, this preventive effect might be overestimated due to the
9
10 exposure period, the indication and contraindication of statins, and other confounders.
11
12
13
14 Statins might be considered as an adjuvant in the treatment of liver cancer.

15
16 **Key words:** *Statin; Liver cancer; Cancer Prevention; Meta-analysis.*
17
18
19
20

21 **Strengths and limitations of this study**

22
23 Statins are commonly prescribed as cholesterol-lowering drugs. In this comprehensive
24
25 meta-analysis, we demonstrate that the statin use is associated with a significant risk
26
27 reduction of liver cancer.
28
29

30
31 The difference of the study designs is the part reason that explained the significant
32
33 heterogeneity found in the overall analysis.
34
35

36
37 However, this preventive effect might be overestimated due to the exposure period,
38
39 the indication and contraindication of statins, and other confounders.

40
41 Statins might be considered as an adjuvant in the treatment of liver cancer.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and they are widely used to reduce the plasma cholesterol level and the risk of cardiovascular events.¹ Although there is a concern over their possible carcinogenicity raised in rodent studies,² preclinical studies indicate that statins have anticancer properties *in vitro* and *in vivo*, through inhibiting angiogenesis, inducing apoptosis, and suppressing tumor growth and metastasis.³⁻⁵

However, higher concentrations of statins are typically required to induce these effects, raising questions concerning the therapeutic relevance of statins on cancer.⁶

To date, clinical studies regarding the cancer incidence associated with statin administration have highlighted conflicting results. Moreover, a large number of meta-analyses have concluded that there was no association between statin use and risk of overall cancer,⁷⁻¹⁰ or cancer of breast¹¹, stomach,¹² or pancreas.¹³ There is only a modest protective effect of statins in prostate cancer¹⁴ and colorectal cancer.¹⁵

In contrary, recent studies reported encouraging results for risk reduction of liver cancer among all statin users. Previous meta-analysis, conducted by Singh *et al.* by including 10 studies, found that statin users were less likely to develop hepatocellular carcinoma (HCC) than statin non-users.¹⁶ However, Singh *et al.* included the ALERT, LIPS, and MEGA trials twice, by including three individual patient data (IPD) analysis of randomized controlled trials (RCTs).¹⁷⁻¹⁹ Meanwhile, some factors of stratification were not considered in their analyses, such as dose and timing of exposure to statins, and the selection of controls and confounders, which might limit

1
2
3 the evaluation of cancer risk.²⁰ Furthermore, the lipophilic statins are accompanied by
4
5 an extensive first-pass effect at the hepatic level.²¹ It is plausible that lipophilic statins
6
7 may have a better liver cancer preventive qualities than the hydrophilic ones.²²
8
9

10
11 Therefore, we performed this updated meta-analysis to assess the association between
12
13 the statin use and the risk of liver cancer, involving the recently published studies and
14
15 conducting more subgroup analyses based on the factors mentioned above. Our results
16
17 demonstrated that statin use was associated with an over 40% risk reduction in liver
18
19 cancer, which may have a significant translational potential in the clinical practice.
20
21
22 However, there were some confounders might overestimate this preventive effect of
23
24 statins.
25
26
27

28 **MATERIALS AND METHODS**

29 *Literature Search strategy*

30
31 This meta-analysis was conducted following the PRISMA guidelines.²³
32
33

34
35 The systematic computerized search for eligible studies were performed on the
36
37 database of PubMed, BIOSIS Previews, Web of Science, EMBASE, EBSCO, and
38
39 Cochrane Library, covering all studies published from their inception to March 5,
40
41 2014. The following terms were searched with both the subjects (MeSH terms) and
42
43 text-word search strategies: “(Statin OR HMG-CoA reductase inhibitors OR
44
45 Atorvastatin OR Cerivastatin OR Fluvastatin OR Lovastatin OR Pravastatin OR
46
47 Rosuvastatin OR Simvastatin) AND (Hepatocellular OR Hepatic OR Intrahepatic OR
48
49 Interlobular OR Liver) AND (Carcinoma OR Sarcomas OR Angiosarcoma OR Cancer
50
51 OR Neoplasm). Additionally, the relevant reviews and retrieved articles were searched
52
53
54
55
56
57
58
59
60

1
2
3
4 manually for more eligible studies.

5
6 In study searching, only the original researches, published in form of peer review
7
8 article or meeting abstract, were included. No language restrictions were imposed.
9
10
11 However, the studies we included were all published in English.
12

13 ***Study selection***

14
15 The inclusion criteria were: (1) randomized controlled trial (RCTs), cohort studies or
16
17 case-control studies; (2) original studies that assessed the effect of statin use on the
18
19 risk of liver cancer, compared with placebo or no treatment; (3) liver cancer cases
20
21 were identified according to the International Classification of Diseases codes (ICD);
22
23 and (4) studies with estimate of relative risk (risk ratio, RR) of liver cancer, or with
24
25 data sufficient to calculate it.
26
27
28
29

30
31 The exclusion criteria were: (1) study design not meeting the inclusion criteria; (2)
32
33 studies without estimate of RR, or without sufficient data to calculate it; or (3) studies
34
35 with duplicated or overlap reports.
36
37
38

39 ***Data extraction***

40
41 Two independent investigators (M. Shi and X.B. Cui) extracted data from the eligible
42
43 studies using a predefined data collection form. The differences of data extraction
44
45 were resolved by consensus referring back to the original article. The extracted
46
47 information included: (1) Studies: first author, year of publication, study design,
48
49 location, patient populations, period, and follow-up; (2) Statins: type, dosage or
50
51 duration of statin use; (3) liver cancer: case identification, number of liver cancer,
52
53 crude RR with 95% confidence intervals (CIs), adjusted RR reflecting the greatest
54
55
56
57
58
59
60

1
2
3
4 degree of control for confounders, and confounders for adjustment (including
5
6 variables for matching). When the RR were not available, the RR with 95% CIs were
7
8 calculated from the raw data in original studies.
9

10
11 We extracted different measurements of effect estimates from original studies, such as
12
13 Relative Risk (RR), Odds Ratio (OR), Hazard Ratio (HR), and Observed/Expected
14
15 ratio. Due to the fact that the incidence of liver cancer was low in all studies, these
16
17 different measurements can be used to provide similar estimates of RR.
18
19

20 21 ***Methodological quality assessment*** 22

23
24 Of note, the included RCT was pooled analysis of other RCTs, therefore, it is
25
26 inappropriate to assess the methodological quality. The methodological quality of
27
28 cohort and case-control studies were assessed on the Newcastle-Ottawa Scale,²⁴
29
30 including eight items that were categorized three categories: selection (four items, one
31
32 star each), comparability (one item, up to two stars), and exposure/outcome (three
33
34 items, one star each). A “star” presents a “high” quality choice of each item.
35
36
37
38

39 ***Statistical analysis*** 40

41
42 The overall meta-analysis was first performed, followed by the subgroup analyses,
43
44 based on study design, baseline risk of liver cancer, confounding adjustment, study
45
46 location, and pharmacokinetic. Meanwhile, we conducted subgroup analyses based on
47
48 studies which reported RR estimate for higher cumulative dosage of statin use, when
49
50 appropriate data were available.
51
52

53
54 To take into account the heterogeneity and provide a more conservative estimate, the
55
56 inverse variance method was used to estimate the pooled RR and corresponding 95%
57
58
59
60

1
2
3
4 CIs, and data were pooled using a random effects model. Heterogeneity was assessed
5
6 using the Chi-squared statistic (P) together with the Higgins I-squared statistic (I^2), a
7
8 P value <0.10 was considered statistically significant for heterogeneity; and an I^2
9
10 value $> 50\%$ was considered a measure of severe heterogeneity.²⁵

11
12
13
14 Publication bias was assessed using the Begg's test and the Egger's test.²⁶ Influence
15
16 analysis was performed to investigate the influence of a single study on the overall
17
18 meta-analysis estimate, by omitting one study in each turn. Test for interaction was
19
20 applied to identify the difference between pooled RR from subgroup analysis using
21
22 the method described by Altman and Bland.²⁷ All statistical tests were two-sided and
23
24 $P < 0.05$ was considered statistically significant, unless otherwise specified. Software
25
26 Review Manager (RevMan5.2, Copenhagen) and STATA (Stata 11.2, Texas) were
27
28 used for the statistical analysis.
29
30
31
32

33 34 **Results**

35 36 **Study selection**

37
38 **Figure 1** illustrated the process of study selection for the meta-analysis. Of the 1424
39
40 potentially relevant references identified by electric and manual search, 142 were
41
42 selected for full-text review after screening titles and abstracts. Finally, a total of 12
43
44 studies were included, with one IPD analysis,¹⁹ five cohort studies,²⁸⁻³² and six
45
46 case-control studies.³³⁻³⁸ One case-control study was presented solely in abstract
47
48 form.³³
49
50

51
52
53
54 Of note, the cohort study conducted by Friedman *et al.* reported RR estimate
55
56 separately for different gender (male and female),²⁹ we considered these two reports
57
58
59
60

1
2
3
4 as separate studies. Therefore, a total of thirteen reports were included for the present
5
6 meta-analysis.
7

8 *Study characteristics*

9
10 **Table 1** summarized the characteristics of qualified studies in this meta-analysis. The
11
12 12 studies, involving 5,640,313 participants with 35,756 liver cancer cases, were
13
14 published between 2005 and 2013. The “RCT” in the present study was pooled
15
16 analysis of 22 clinical trials,¹⁹ which investigated statins therapy in cardiovascular
17
18 event prevention and reported the occurrence of liver cancer as adverse event. The
19
20 observational studies were conducted with the local or national health databases, the
21
22 statin exposure were identified by linkage to prescription databases, and the controls
23
24 were matched mainly by age, sex and index date. Except one cohort adopted ICD-10
25
26 C22,²⁸ all other studies identified liver cancer cases according to the ICD-9 155. Of
27
28 note, two cohorts were restricted to patients with HBV infection,³¹ and HCV
29
30 infection;³² one case-control only included patients with diabetes mellitus;³⁴ two
31
32 observational studies included patients aged at least 45 years.^{30 35}
33
34
35
36
37
38
39
40

41 **Table 2** summarized the data of the included studies. In the RCT¹⁹ and one cohort
42
43 study,³⁰ the RR with 95% CIs were calculated from the 2×2 tables defined by the
44
45 incidence of liver cancer and the statin use status. The observational studies reported
46
47 different measurements of RR estimates with adjustment by confounders. Several
48
49 observational studies adopted the important risk factors of liver cancer for
50
51 adjustments^{31 32 34-36}, such as HBV infection, HCV infection, cirrhosis, alcoholic liver
52
53 disease, or non-alcoholic fatty liver disease (NAFLD).³⁹ Of note, only two studies
54
55
56
57
58
59
60

1
2
3 adjusted for the cholesterol level,^{30 38} and no study adjusted for the metabolic
4
5
6 syndrome, which might also influence the risk of liver cancer.³⁹
7

8 9 *Methodological quality*

10
11 For the cohort and case-control studies, the median score was 7 on the
12
13 Newcastle-Ottawa Scale, with a range of 5 to 8 (**Supplementary Table 1**). These
14
15 results indicated that the observational studies were in a reasonable good quality.
16
17

18 19 *Overall meta-analysis*

20
21 **Figure 2** depicted the forest plot of RR estimate with 95% CIs from individual studies
22
23 and overall meta-analysis. In the overall meta-analysis, pooled results showed a
24
25 statistically significant decrease in the liver cancer risk among all statin users (RR
26
27 0.58, 95%CIs 0.51–0.67). Of note, a statistically significant heterogeneity was
28
29 observed ($I^2 = 65\%$, $P = 0.0006$). The P -values of Begg's test and Egger's test were
30
31 0.669 and 0.749, respectively, both suggesting there was no evidence of publication
32
33 bias. In the influence analysis, the omission of any individual studies did not alter the
34
35 direction and magnitude of the observed effect (**Supplementary Figure 1**).
36
37
38
39

40 41 *Subgroup analyses and Test for interaction*

42
43 We first performed preplanned subgroup analyses based on study design, baseline risk
44
45 of liver cancer, confounding adjustment, and study location (**Table 3**).
46
47

48
49 The RCT showed there is no significant association between statin use and risk of
50
51 liver cancer (RR 1.06, 0.66–1.71). But the observational studies indicated a significant
52
53 decrease of liver cancer risk among all statin users (RR 0.57, 0.50–0.64; $I^2 = 61\%$, $P =$
54
55 0.003) (**Figure 2**). Furthermore, we found a greater risk reduction in the subgroup
56
57
58
59
60

1
2
3
4 analysis of cohort studies (RR 0.51, 0.44–0.58; $I^2 = 18\%$, $P = 0.30$) than in the
5
6 case-control studies (RR 0.63, 0.54–0.73; $I^2 = 46\%$, $P = 0.10$) (**Supplementary**
7
8 **Figure 2**).

9
10
11 Test for interaction showed significant results between subgroups of the RCT and
12
13 observational studies ($P_{\text{interaction}} = 0.01$, $Z = 2.47$), and between subgroups of the
14
15 cohort and case-control studies ($P_{\text{interaction}} = 0.04$, $Z = -2.03$). These results indicated
16
17 that the difference of the study designs was the part reason that why there was severe
18
19 heterogeneity in the overall analysis (**Table 3**).

20
21
22 In the subgroup analysis of the four studies with higher baseline risk of liver
23
24 cancer,^{30-32 35} defined as patients with older age, HBV or HCV infection, there was a
25
26 trend toward more decrease of liver cancer risk (RR 0.52, 0.47-0.59; $I^2 = 16\%$, $P =$
27
28 0.31) than in the other eight studies with general population^{19 28 29 33 34 36-38} (RR 0.63,
29
30 0.52–0.75; $I^2 = 59\%$, $P = 0.01$) (**Supplementary Figure 3**).

31
32
33 We defined the RCT or studies adjusted for at least 4 of 7 important confounders,
34
35 such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD,
36
37 HBV treatment, or HCV treatment,³⁹ were adjusted adequately. Subgroup analysis of
38
39 these six studies^{19 31 32 34-36} found a trend toward less decrease of liver cancer risk (RR
40
41 0.64, 0.53-0.77; $I^2 = 81\%$ $P = 0.0001$) than the other six studies^{28-30 33 37 38} (RR, 0.51,
42
43 0.43-0.60; $I^2 = 3\%$, $P = 0.40$) (**Supplementary Figure 4**).

44
45
46 Subgroup analyses based on study location found a similar risk reduction of liver
47
48 cancer in the Western countries (RR 0.61, 0.48–0.76; $I^2 = 64\%$, $P = 0.007$) and in the
49
50 Asian countries (RR 0.56, 0.48–0.64; $I^2 = 51\%$, $P = 0.09$). (**Supplementary Figure 5**)
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Besides the overall RR estimates, some studies reported different RR estimate for
5
6 different pharmacokinetic and dosage of statin use (**Supplementary Table 2**). We
7
8 conducted further subgroup analyses based on these available data.
9

10
11 According to the different pharmacokinetic, statins can be classified as lipophilic
12
13 statins (Atorvastatin, Fluvastatin, Lovastatin, and Simvastatin) and hydrophilia statins
14
15 (Pravastatin and Rosuvastatin).²¹ Subgroup analysis of lipophilic statins^{29 31 34-36}
16
17 found a significant decrease of liver cancer risk (RR 0.57, 0.50–0.65; $I^2 = 50\%$, $P =$
18
19 0.08). And there was a similar result among users of hydrophilia statins^{31 35 36} (RR
20
21 0.59, 0.41–0.84; $I^2 = 50\%$, $P = 0.13$) (**Supplementary Figure 6**).
22
23
24

25
26 Test for interaction showed non-significant results for subgroups with different
27
28 baseline risk, confounding adjustment, study location, or pharmacokinetic ($P_{\text{interaction}} =$
29
30 0.08, 0.08, 0.54 and 0.86, respectively) (**Table 3**). Therefore, there is no strong
31
32 evidence to support a different preventive effect of statins on liver cancer in these
33
34 subgroups.
35
36

37
38 Subgroup analysis of six studies with higher cumulative dose of statin use, defined as
39
40 statin use more than 180 cumulative defined daily dose (cDDD) or 0.5 years
41
42 (cumulative duration), showed a trend toward more risk reduction of liver cancer (RR
43
44 0.53, 0.36-0.79), but with a high degree of heterogeneity ($I^2 = 90\%$, $P < 0.00001$)
45
46
47
48 (**Supplementary Figure 7**).
49

50 51 Discussion

52
53 This present meta-analysis represents the most comprehensive review to date on the
54
55 association between the statin use and the liver cancer risk, by including 12 studies
56
57
58
59
60

1
2
3
4 (one IPD analysis of 22 RCTs, 5 cohort studies, and 6 case-control studies) and
5
6 involving 5,640,313 participants with 35,756 liver cancer cases. Overall, we found
7
8 that statin use was associated with an over 40% risk reduction in liver cancer
9
10 compared with nonusers (RR 0.58, 95%CI 0.51–0.67). This result was in line with the
11
12 previous three meta-analyses: Singh *et al.* included 10 studies and suggested statin
13
14 users were less likely to develop HCC (OR 0.63, 95%CI 0.52–0.76),¹⁶ Pradelli *et al.*
15
16 and Zhang *et al.* included 5 and 7 observational studies and found a summary RR of
17
18 0.58 (95%CI 0.46–0.74) and 0.61 (95%CI 0.49–0.76), respectively.^{40 41}

19
20 The IPD analysis of 22 RCTs showed there is no significant association between statin
21
22 use and risk of liver cancer. The significant risk reduction of liver cancer among all
23
24 statin users was seen primarily in the observational studies, and this preventive effect
25
26 was relatively convinced in the cohorts than in the case-controls. There were some
27
28 reasons to explain the different findings between RCTs and observational studies.
29
30

31
32 First, the exposure period to statins might be shorter than the period to carcinogenesis
33
34 and the latency to diagnosis in the cohorts and the case-controls. The observational
35
36 studies defined statin use varying in dosage and duration, from patients who received
37
38 ≥ 1 cDDD or >1 Rx of statins to more than 0.5 years (**Table 1**). On the other hand, the
39
40 median period of statin use was 5.1 years in the RCTs. Although there was a trend
41
42 toward more risk reduction of liver cancer with higher cumulative dose of statin use,
43
44 this defect might still result in overestimating the cancer-preventive effect of statins in
45
46 the observational studies.
47
48

49
50 Second, clinical studies demonstrated that higher serum total cholesterol
51
52
53
54
55
56
57
58
59
60

1
2
3
4 concentration was associated with decreased risk of liver cancer (**Supplementary**
5
6 **Table 3**).⁴²⁻⁴⁴ Meanwhile, there were inverse association between use of non-statin
7
8 lipid-lowering drugs and risk of the liver cancer.^{35 38} Meanwhile, because of the
9
10 contraindication, statins might not prescribed to the patients with the chronic liver
11
12 disease, which is known as a risk factor of liver cancer. Unfortunately, the
13
14 observational studies included in this analysis seldom adopted these factors for
15
16 adjustment. Actually, subgroup analysis of studies with adequate adjustment showed a
17
18 trend toward less risk reduction, indicating the potential of overestimate this
19
20 preventive effect by confounders.

21
22
23
24
25
26 Third, the RCTs included lower risk population (patients with cardiovascular disease
27
28 rather than HBV /HCV infection), might not be powerful enough to investigate the
29
30 liver cancer outcomes, which were much rarer than cardiovascular events. In addition,
31
32 subgroup analysis of studies with higher baseline risk showed a trend toward more
33
34 decrease of liver cancer risk.

35
36
37
38
39 These reasons suggested that the observed modulation of cancer incidence cannot be
40
41 ascribable to a direct statin-mediated effect,²⁰ the exposure period, the indication (e.g.
42
43 hyperlipidemia) and contraindication (e.g. chronic liver disease) of statins might
44
45 overestimate its cancer-preventive effect.

46
47
48
49 We found similar results in Western countries and Asian countries, which were
50
51 different from the meta-analysis conducted by Singh *et al.* which concluded that the
52
53 inverse association of statins with HCC was stronger in the Asian population.
54
55 Considering four more studies we included, this difference might be caused by the
56
57
58
59
60

1
2
3
4 insufficient data in their meta-analysis. Based on the pharmacokinetics, it is plausible
5
6 that lipophilic and hydrophilic statins will differ in their liver cancer prevention
7
8 qualities.^{21 22} However, subgroup analysis of lipophilic and hydrophilic statins showed
9
10 similar results.
11

12
13 Besides the limitations described previously, there were some other limitations should
14
15 be noted. First, a significant heterogeneity was observed in the present meta-analysis,
16
17 which might results from the difference in study design. Results of subgroup analyses
18
19 would also be limited by this heterogeneity. Second, the adherence to statin therapy is
20
21 known to be associated with healthy lifestyle, which might affect the cancer
22
23 outcome.⁴⁵ Such information is hard to be captured in databases or medical record in
24
25 the observational studies.⁴⁶ Third, five observational studies were conducted using the
26
27 Taiwanese National Health Insurance Research Database (NHIRD),^{31 32 35-37} although
28
29 they were not in the same period, these studies might contain overlapping groups of
30
31 patients. These limitations mentioned above might lead to confounding of overall
32
33 results from the present study, and should be considered in future studies aiming at
34
35 confirming the protective effects of statins on human cancer risk.
36
37
38
39
40
41
42

43 The strengths of our meta-analysis were as follows: First, we performed a much more
44
45 comprehensive search and more subgroup analyses, compared with the previous
46
47 meta-analyses; Second, the methodological quality of the included studies were
48
49 reasonable good; Third, publication bias, which due to the tendency of not publishing
50
51 small studies with null results, were not found in our meta-analysis.
52
53
54

55
56 Of note, preclinical studies have indicated that statins possess synergism with other
57
58
59
60

1
2
3
4 therapeutic agents *in vitro* and *in vivo* for liver cancer.^{47 48} Some clinical studies have
5
6 also demonstrated that statins would prolong survival in patients with advanced liver
7
8 cancer (**Supplementary Table 4**),⁴⁹⁻⁵² and associated with risk reduction of
9
10 recurrence after curative surgery in patients of HBV related HCC.⁵³ Therefore,
11
12 considerable interest exists in adjunctive therapy with statins for liver cancer. In fact,
13
14 there were some RCTs ongoing to determine the effectiveness of pravastatin, when
15
16 used in combination with sorafenib, in the treatment of liver cancer (**Supplementary**
17
18 **Table 5**).

19
20
21
22
23
24 Currently, physicians are less likely to prescribe statins for patients with chronic liver
25
26 disease, based on the concerns about the statin-induced liver injury.³¹ However, there
27
28 were number of studies have demonstrated the safe use, even salutary effects.⁵⁴⁻⁵⁶
29
30
31 Meanwhile, the risk of serious statin-related liver injury appears to be no greater than
32
33 the background incidence of this rare event.⁵⁷ Therefore, considering their benefits for
34
35 cardiovascular event prevention and the potential effect in liver cancer prevention and
36
37 treatment, statins should not be denied to these patients.
38
39

40
41 In conclusion, our results suggest that statin use is associated with a significant risk
42
43 reduction of liver cancer, when taken daily for cardiovascular event prevention.
44
45 However, this preventive effect might be overestimated due to the exposure period,
46
47 indication and contraindication of statins, and other confounders. Statins might be
48
49 considered as an adjuvant in the treatment of liver cancer.
50
51
52

53 54 55 **ACKNOWLEDGEMENT**

56
57 We thank Medjaden Bioscience Limited and Gui Lv for assisting in the preparation
58
59
60

1
2
3 and revision of this manuscript.
4
5
6

7 **CONTRIBUTORSHIP STATEMENT**

8
9 XB Cui had the original idea, M Shi, XB Cui and W Gong worked together to
10 develop an appropriate theoretical framework and design. XB Cui developed the
11 search, M Shi and XB Cui were involved in the selection process. M Shi and XB Cui
12 extracted relevant data, XB Cui and W Gong performed the statistical analysis and all
13 authors were involved in the data interpretation. M Shi and B Nie wrote the
14 manuscript draft and revised the draft based on input from the other authors. All
15 authors revised it critically for content and approved the final version.
16
17
18
19
20
21
22
23
24
25

26 **COMPETING INTERESTS**

27
28 There are no competing interests
29
30
31

32 **FUNDING**

33
34 None.
35
36

37 **DATA SHARING**

38
39 No additional data available.
40
41
42
43

44 **REFERENCES:**

- 45
46 1. Baigent C, Keech A, Kearney PM, *et al.* Efficacy and safety of cholesterol-lowering treatment:
47 prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
48 *Lancet* 2005;**366**(9493):1267-78.
49
50 2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA* 1996;**275**(1):55-60.
51
52 3. Demierre MF, Higgins PD, Gruber SB, *et al.* Statins and cancer prevention. *Nat Rev Cancer*
53 2005;**5**(12):930-42.
54
55 4. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the
56 hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. *J*
57 *Cancer Res Ther* 2012;**8**(2):176-83.
58
59 5. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular
60

- carcinoma. *J Gastroenterol Hepatol* 2012;**27**(11):1654-64.
6. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. *Cancer Chemother Pharmacol* 2011;**67**(4):729-39.
 7. Dale KM, Coleman CI, Henyan NN, *et al.* Statins and cancer risk: a meta-analysis. *JAMA* 2006;**295**(1):74-80.
 8. Browning DRL, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. *Int J Cancer* 2007;**120**(4):833-43.
 9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. *Eur J Cancer* 2008;**44**(15):2122-32.
 10. Baigent C, Blackwell L, Emberson J, *et al.* Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;**376**(9753):1670-81.
 11. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Res Treat* 2012;**135**(1):261-9.
 12. Shimoyama S. Statins and gastric cancer risk. *Hepatogastroenterology* 2011;**58**(107-108):1057-61.
 13. Cui X, Xie Y, Chen M, *et al.* Statin use and risk of pancreatic cancer: a meta-analysis. *Cancer Causes Control* 2012;**23**(7):1099-111.
 14. Bansal D, Undela K, D'Cruz S, *et al.* Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. *PLoS One* 2012;**7**(10):e46691.
 15. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. *Gut* 2010;**59**(11):1572-85.
 16. Singh S, Singh PP, Singh AG, *et al.* Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. *Gastroenterology* 2013;**144**(2):323-32.
 17. Stein EA, Corsini A, Gimpelewicz CR, *et al.* Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract* 2006;**60**(9):1028-34.
 18. Matsushita Y, Sugihara M, Kaburagi J, *et al.* Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. *Pharmacoepidemiol Drug Saf* 2010;**19**(2):196-202.
 19. Emberson JR, Kearney PM, Blackwell L, *et al.* Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;**7**(1):e29849.
 20. Gazerro P, Bifulco M. Statins and Cancer in Gastroenterology: New Insight? *Gastroenterology* 2013;**144**(7):1572-3.
 21. Gazerro P, Proto MC, Gangemi G, *et al.* Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev* 2012;**64**(1):102-46.
 22. Gronich N, Rennert G. Beyond aspirin - Cancer prevention with statins, metformin and bisphosphonates. *Nat Rev Clin Oncol* 2013;**10**(11):625-42.
 23. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;**339**:b2535.
 24. GA Wells, B Shea, D O'Connell, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
 25. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ*

- 2003;**327**(7414):557-60.
26. METABIAS: Stata module to test for small-study effects in meta-analysis [program], 2009.
27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;**326**(7382):219.
28. Friis S, Poulsen AH, Johnsen SP, *et al.* Cancer risk among statin users: A population-based cohort study. *Int J Cancer* 2005;**114**(4):643-7.
29. Friedman GD, Flick ED, Udaltsova N, *et al.* Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. *Pharmacoepidemiol Drug Saf* 2008;**17**(1):27-36.
30. Marelli C, Gunnarsson C, Ross S, *et al.* Statins and Risk of Cancer A Retrospective Cohort Analysis of 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult Americans. *J Am Coll Cardiol* 2011;**58**(5):530-7.
31. Tsan YT, Lee CH, Wang JD, *et al.* Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. *J Clin Oncol* 2012;**30**(6):623-30.
32. Tsan YT, Lee CH, Ho WC, *et al.* Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. *J Clin Oncol* 2013;**31**(12):1514-21.
33. Khurana V, Saluja A, Caldito G, *et al.* Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: Half a million US veterans' study. *Gastroenterology* 2005;**128**(4, Suppl. 2):A714.
34. El-Serag HB, Johnson ML, Hachem C, *et al.* Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. *Gastroenterology* 2009;**136**(5):1601-8.
35. Chiu HF, Ho SC, Chen CC, *et al.* Statin use and the risk of liver cancer: a population-based case-control study. *Am J Gastroenterol* 2011;**106**(5):894-8.
36. Lai SW, Liao KF, Lai HC, *et al.* Statin use and risk of hepatocellular carcinoma. *Eur J Epidemiol* 2013;**28**(6):485-92.
37. Leung HW, Chan AL, Lo D, *et al.* Common cancer risk and statins: a population-based case-control study in a Chinese population. *Expert Opin Drug Saf* 2013;**12**(1):19-27.
38. Chaiteerakij R, Yang JD, Harmsen WS, *et al.* Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. *Hepatology* 2013;**57**(2):648-55.
39. Singh S, Singh PP, Roberts LR, *et al.* Chemopreventive strategies in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2014;**11**(1):45-54.
40. Pradelli D, Soranna D, Scotti L, *et al.* Statins and primary liver cancer: a meta-analysis of observational studies. *Eur J Cancer Prev* 2013;**22**(3):229-34.
41. Zhang H, Gao C, Fang L, *et al.* Statin use and risk of liver cancer: A meta-analysis of 7 studies involving more than 4.7 million patients. *World J Meta-Anal* 2013;**1**(3):130-7.
42. Ahn J, Lim U, Weinstein SJ, *et al.* Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2009;**18**(11):2814-21.
43. Iso H, Ikeda A, Inoue M, *et al.* Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. *Int J Cancer* 2009;**125**(11):2679-86.
44. Kitahara CM, de Gonzalez AB, Freedman ND, *et al.* Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea. *J Clin Oncol* 2011;**29**(12):1592-8.
45. Brookhart MA, Patrick AR, Dormuth C, *et al.* Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. *Am J Epidemiol* 2007;**166**(3):348-54.

- 1
2
3 46. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. *Expert Opin*
4 *Drug Saf* 2010;**9**(4):603-21.
- 5
6 47. Kim W, Yoon JH, Kim JR, *et al.* Synergistic anti-tumor efficacy of lovastatin and protein kinase
7 C-beta inhibitor in hepatocellular carcinoma. *Cancer Chemother Pharmacol*
8 2009;**64**(3):497-507.
- 9
10 48. Polo MP, Crespo R, de Bravo MG. Geraniol and simvastatin show a synergistic effect on a human
11 hepatocarcinoma cell line. *Cell Biochem Funct* 2011;**29**(6):452-8.
- 12
13 49. Kawata S, Yamasaki E, Nagase T, *et al.* Effect of pravastatin on survival in patients with advanced
14 hepatocellular carcinoma. A randomized controlled trial. *Br J Cancer* 2001;**84**(7):886-91.
- 15
16 50. Lersch C, Schmelz R, Erdmann J, *et al.* Treatment of HCC with pravastatin, octreotide, or
17 gemcitabine - A critical evaluation. *Hepatogastroenterology* 2004;**51**(58):1099-103.
- 18
19 51. Graf H, Jungst C, Straub G, *et al.* Chemoembolization combined with pravastatin improves survival
20 in patients with hepatocellular carcinoma. *Digestion* 2008;**78**(1):34-8.
- 21
22 52. Georgescu EF, Badulescu F, Dumitrescu D, *et al.* Lovastatin may enhance cytostatic effects of
23 sorafenib in hepatic carcinoma. Primary results of a pilot study. *Hepatol Int* 2011;**5**(1):423.
- 24
25 53. Wu CY, Chen YJ, Ho HJ, *et al.* Association between nucleoside analogues and risk of hepatitis B
26 virus-related hepatocellular carcinoma recurrence following liver resection. *JAMA*
27 2012;**308**(18):1906-14.
- 28
29 54. Lewis JH, Mortensen ME, Zweig S, *et al.* Efficacy and safety of high-dose pravastatin in
30 hypercholesterolemic patients with well-compensated chronic liver disease: Results of a
31 prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology*
32 2007;**46**(5):1453-63.
- 33
34 55. Nelson A, Torres DM, Morgan AE, *et al.* A pilot study using simvastatin in the treatment of
35 nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol*
36 2009;**43**(10):990-4.
- 37
38 56. Lewis JH. Clinical Perspective: Statins and the Liver-Harmful or Helpful? *Dig Dis Sci*
39 2012;**57**(7):1754-63.
- 40
41 57. Bader T. The myth of statin-induced hepatotoxicity. *Am J Gastroenterol* 2010;**105**(5):978-80.

Figure legends:

42
43
44 **Figure 1.** Flow chart of study selection in the present meta-analysis.

45
46
47 **Figure 2.** Overall meta-analysis of the statin use and the liver cancer risk.

48
49 **Supplementary Figure 1.** Influence analysis.

50
51
52 **Supplementary Figure 2.** Subgroup analyses based on study design.

53
54
55 **Supplementary Figure 3.** Subgroup analyses based on baseline risk of liver cancer.

56
57
58 **Supplementary Figure 4.** Subgroup analyses based on confounder adjustment.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 5. Subgroup analyses based on study location.

Supplementary Figure 6. Subgroup analyses based on pharmacokinetic of statins.

Supplementary Figure 7. Subgroup analysis of higher cumulative dose of statin use.

For peer review only

Table 1. Study characteristics

Studies	Study design	Patient population	Study period	Cases defined	Follow-up	Statins type	Dosage/Duration of Statin use
Emberson, 2012, UK ¹⁹	RCT	IPD analysis of 22 RCTs	-	ICD-9 155	5.1 years (Me)	A, F, L, P, R, S	5.1 years (Me)
Friis, 2005, North Jutland ²⁸	Cohort	General population (CPR)	1989-2002	ICD-10 C22	3.3 years (M)	Unspecified	≥2 Rx
Friedman, 2008, USA ²⁹	Cohort	General population (KPMCP)	1994-2003	ICD-9-CM 155	> 2 years	A, L, S (97.6%)	≥1 Rx
Marelli, 2011, USA ³⁰	Cohort	General older population (men ≥ 45 and women ≥ 55 years; GE Centricity)	1990-2009	ICD-9 155	4.6 years (M)	Unspecified	≥1 cDDD
Tsan, 2012, Taiwan ³¹	Cohort	Patients with HBV infection (NHIRD)	1997-2008	ICD-9 155	9.9 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Tsan, 2013, Taiwan ³²	Cohort	Patients with HCV infection (NHIRD)	1999-2010	ICD-9 155	10.7 years (M)	A, F, L, P, R, and S	≥28 cDDDs
Khurana, 2005, USA ³³	Case control	General population (VISN)	1997-2002	ICD-9 155	NR	Unspecified	≥1 Rx
El-Serag, 2009, USA ³⁴	Case control	Diabetes patients (VA)	1997-2002	ICD-9-CM 155	2.4 years (M)	A, C, F, L, P, and S	1.6 years (M)
Chiu, 2011, Taiwan ³⁵	Case control	Older patients (≥ 50 years; NHIRD)	2005–2008	ICD-9-CM 155	NR	A, F, L, P, R, and S	≥ 1 cDDD
Lai, 2013, Taiwan ³⁶	Case control	General population (NHIRD)	2000-2009	ICD-9-CM 155	1.4 years (M)	A, F, L, P, R, and S	≥1 Rx
Leung, 2013, Taiwan ³⁷	Case control	General population (NHIRD)	2000-2008	ICD-9-CM 155	4.1 years (M)	Unspecified	> 0.5 years
Chaiteerakij, 2013, USA ³⁸	Case control	Hyperlipidemia patients (Mayo Clinic)	2000-2010	ICD-9-CM 155	>1 years	Unspecified	≥1 Rx

Patients population: IPD = Individual patient data, RCT = randomized controlled trials, CPR = the Central Population Register of Danish citizens, KPMCP = the Kaiser Permanente Medical Care Program in northern California, GE Centricity = the General Electric Centricity database, NHIRD = the Taiwanese National Health Insurance research database, VISN = Veterans Integrated Service Networks 16 Veteran Affairs database, VA = Veterans Affairs national databases, Mayo Clinic = Mayo Clinic (Rochester, MN), HBV = hepatitis B virus; Cases defined: ICD-9 or -10 = International Classification of Diseases, Ninth Revision or Tenth Revision, CM = Clinical Modification; Duration of follow-up: When the follow-up periods of statin user and nonuser were different, only the shorter one was showed, and all periods were transformed to years; Statin type: A = Atorvastatin, C = Cerivastatin, F = Fluvastatin, L = Lovastatin, P = Pravastatin, R = Rosuvastatin, S = Simvastatin, Non-statin = Non-statin cholesterol-lowering drug(s) only; Duration of statin use: M = Mean, Me = Median, ≥1 cDDD = more than 1 cumulative defined daily dose before the diagnosis of liver cancer, Rx = prescriptions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Study data

Studies	Intervention/ Cases		Control		Measurements of effect estimates	Crude RR with 95% CIs	Adjusted RR with 95% CIs	Confounders for adjustment
	No. of event/ No. of exposure	No. of total	No. of event/ No. of exposure	No. of total				
Emberson, 2012, UK ¹⁹	35	67258	33	67279	RR	1.06 (0.66, 1.71)*	1.06 (0.66, 1.71)*	Randomization
Friis, 2005, North Jutland ²⁸	1	12251	166	334754	OR	NA	1.16 (0.46-2.90)	1,2, 16, 21, 23
Friedman(Male), 2008, USA ²⁹	32	192598	NA	1904876	HR	NA	0.49 (0.34-0.70)	16
Friedman(Female), 2008, USA ²⁹	10	169261	NA	1976332	HR	NA	0.40 (0.21-0.75)	
Marelli, 2011, USA ³⁰	13	45857	24	45857	RR	0.31 (0.14-0.68)*	0.31 (0.14-0.68)*	1-5, 14, 16-18, 26, 27
Tsan, 2012, Taiwan ³¹	58	2785	963	30628	HR	0.66 (0.51- 0.86)	0.47 (0.36-0.61)	1, 2, 7, 8, 11, 12
Tsan, 2013, Taiwan ³²	1378	35023	26505	225841	HR	0.42 (0.39-0.46)	0.53 (0.49-0.58)	1, 2, 7, 8, 11, 13
Khurana, 2005, USA ³³	NA	NA	NA	NA	OR	NA	0.52 (0.41- 0.67)	1, 11, 13
El-Serag, 2009, USA ³⁴	447	1303	2766	5212	OR	0.46 (0.40-0.52)	0.74 (0.64-0.87)	1-3, 6, 8, 9, 11-13, 21, 24, 28
Chiu, 2011, Taiwan ³⁵	117	1166	195	1166	OR	0.53 (0.41-0.69)	0.62 (0.45-0.83)	1, 2, 8, 9, 11, 12, 20, 29
Lai, 2013, Taiwan ³⁶	255	3480	1635	13920	OR	0.61 (0.52-0.72)	0.71 (0.56-0.89)	1, 2, 8-13, 22, 24, 25
Leung, 2013, Taiwan ³⁷	26	424	6851	33781	HR	0.45 (0.30-0.67)	0.44 (0.28, 0.72)	1, 2, 11, 15, 20, 21, 23
Chaiteerakij, 2013, USA ³⁸	72	165	165	256	OR	NA	0.6 (0.4-0.9)	1-3, 8, 11, 17, 22, 28, 30


The RR with an asterisk mark (*) was calculated based on the raw data. The others, crude or adjusted, were extracted from the original paper; Confounders for adjustment: 1 = age, 2 = sex, 3 = race, 4 = BMI, 5 = smoking status, 6 = ethanol intake, 7 = socioeconomic status, 8 = cirrhosis, 9 = alcoholic liver disease, 10 = non-alcoholic fatty liver disease, 11 = diabetes mellitus, 12 = HBV infection, 13 = HCV infection, 14 = concomitant diagnoses (unspecified), 15 = Charlson score, 16 = calendar year, 17 = cholesterol (totalcholesterol, VLDL, LDL, or triglycerides), 18 = prostate-specific antigen, 19 = resection extent, 20 = other lipid-lowering agents, 21 = cardiovascular medications (aspirin, nonsteroidal anti-inflammatory medications, or angiotensin-converting enzymes inhibitors), 22 = metformin or thiazolidinedione, 23 = hormone-replacement therapy, 24 = HCV treatment, 25 = HBV treatment, 26 = medications taken (unspecified), 27 = the number of office visits, 28 = propensity to use statins, 29 = hospital stay, 30 = biliary tract diseases

Table 3. Subgroup analyses of included studies

Subgroup	No. of studies (reports)	Summary RR (95% CIs)	Heterogeneity, I ²	Heterogeneity, P value	P _{interaction}	
Study design	RCT	1	1.06 (0.66-1.71)	-	-	P = 0.01
	Observational studies	11(12)	0.57(0.50-0.64)	61%	P = 0.003	
Observational studies	Cohort studies	5 (6)	0.51 (0.44–0.58)	18%	P = 0.30	P = 0.04
	Case-control studies	6	0.63 (0.54–0.73)	46%	P = 0.10	
Baseline risk of liver cancer	Higher baseline risk	4	0.52 (0.47-0.59)	16%	P = 0.31	P = 0.08
	General population	8 (9)	0.63 (0.52–0.75)	59%	P = 0.01	
Confounding adjustment	Adequate adjustment	6	0.64(0.53-0.77)	81%	P = 0.0001	P = 0.08
	Inadequate adjustment	6 (7)	0.51 (0.43-0.60)	3%	P = 0.40	
Study location	Western studies	7 (8)	0.61 (0.48-0.76)	64%	P = 0.007	P = 0.54
	Asian studies	5	0.56 (0.48-0.64)	51%	P = 0.09	
Pharmacokinetic	Hipophilic statins	5 (6)	0.57 (0.50-0.65)	50%	P = 0.08	P = 0.86
	Hydrophilia statins	3	0.59(0.41–0.84)	50%	P = 0.13	
Higher cumulative dosage of statin		6	0.53 (0.36-0.79)	90%	P<0.0001	-


RR = relative risk; higher baseline risk of liver cancer: patients with older age, HBV or HCV infection. Adequate adjustment: RCT or studies which adjusted for at least 4 of 7 important confounders, such as HBV infection, HCV infection, cirrhosis, alcoholic liver disease, NAFLD, HBV treatment, or HCV treatment; Lipophilic statins: Atorvastatin, Fluvastatin, Lovastatin, or Simvastatin; Hydrophilia statins: Pravastatin or Rosuvastatin; Higher cumulative dosage of statin use: > 180cumulative defined daily dose or Duration of statin use > 0.5 years before the diagnosis of liver cancer.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Flow chart of study selection in the present meta-analysis.
207x224mm (300 x 300 DPI)







Overall meta-analysis of the statin use and the liver cancer risk.
128x80mm (300 x 300 DPI)

Review only


SUPPLEMENTARY FIGURES:




Supplementary Figure 1. Influence analysis.




Supplementary Figure 2. Subgroup analyses based on study design.




Supplementary Figure 3. Subgroup analyses based on baseline risk of liver cancer.




Supplementary Figure 4. Subgroup analyses based on confounder adjustment.



Supplementary Figure 5. Subgroup analyses based on study location.



Supplementary Figure 6. Subgroup analyses based on pharmacokinetic of statins.



Supplementary Figure 7. Subgroup analysis of higher cumulative dose of statin use.

SUPPLEMENTARY TABLES:

Supplementary Table 1. Assessment of methodological quality of the cohort and case-control studies according to the Newcastle–Ottawa Scale

Cohort Studies	Selection			Comparability			Outcome		Total Score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Outcome of present at start of study	Control for important factor	Assessment of outcome	Follow-up long enough	Adequacy of follow up	
Friis, 2005 ²⁸	☆	☆	☆	☆	☆	☆	-	☆	7
Friedman, 2008 ²⁹	☆	☆	☆	☆	☆	☆	-	☆	7
Marelli, 2011 ³⁰	☆	☆	☆	☆	☆	☆	☆	☆	8
Tsan, 2012 ³¹	☆	☆	☆	☆	☆	☆	☆	☆	8
Tsan, 2013 ³²	☆	☆	☆	☆	☆	☆	☆	☆	8

Case–Control Studies	Selection			Comparability			Exposure		Total Score
	Adequate definition of cases	Representativeness of cases	Selection of controls	Definition of controls	Control for important factor	Ascertainment of Exposure	Same method for cases and controls	Non-response rate	
Khurana, 2005 ³³	-	☆	☆	☆	☆	☆	☆	-	6
El-Serag, 2009 ³⁴	-	☆	☆	☆	☆☆	☆	☆	-	7
Chiu, 2011 ³⁵	-	☆	☆	☆	☆☆	☆	☆	-	7
Lai, 2013 ³⁶	-	☆	☆	☆	☆☆	☆	☆	-	7
Leung, 2013 ³⁷	☆	☆	☆	☆	☆	☆	☆	☆	8
Chaiteerakij, 2013 ³⁸	-	☆	-	☆	☆	☆	☆	-	5

Control for important factor: ☆ Reported relative risk have been adjusted for at least 4 of 7 important factors: HBV infection, HCV infection, cirrhosis, NAFLD, HCV treatment, HBV treatment, anti-diabetic medications; ☆ Study controls for any additional factor. Assessment of outcome: ☆ record linkage. Follow-up long enough: ☆ follow up period ≥ 4 years. Adequate definition of cases: ☆ The case is defined with independent validation. Non-response rate: ☆ Same rate for both groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplementary Table 2. Studies reporting RR for use of lipophilic or hydrophilia statins, and for higher cumulative dosage of statin use

Studies	Measurements of effect estimates	Statins type	Dosage/Duration of Statin use	Crude RR with 95% CIs	Adjusted RR with 95% CIs
Tsan, 2012, Taiwan ³¹	HR	A, F, L, P, R, and S	>365 cDDD	0.50 (0.26-0.96)	0.34 (0.33-0.59)
	HR	Lipophilia statin	≥28 cDDD	0.62 (0.47-0.83)	0.44 (0.33-0.59)
	HR	Hydrophilia statin	≥28 cDDD	0.65 (0.39 -1.09)	0.51 (0.31-0.85)
Tsan, 2013, Taiwan ³²	HR	A, F, L, P, R, and S	>180 cDDD	NA	0.33 (0.25–0.42)
El-Serag, 2009, USA ³⁴	OR	Simvastatin	1.6 years (M)	0.47 (0.41- 0.54)	0.64 (0.55-0.75)
	OR	A, F, L, P, R, and S	>215.4 cDDD	0.47 (0.30-0.72)	0.63 (0.37-1.06)
Chiu, 2011, Taiwan ³⁵	OR	Lipophilia statin	≥ 1 cDDD	NA	0.56 (0.45–0.69)*
	OR	Hydrophilia statin	≥ 1 cDDD	NA	0.46 (0.29–0.71)*
	OR	Lipophilia statin	≥1 Rx	0.54 (0.48–0.61)*	0.67 (0.57–0.79)*
Lai, 2013, Taiwan ³⁶	OR	Hydrophilia statin	≥1 Rx	0.63 (0.47–0.83)*	0.80 (0.55–1.16)*

The RR with an asterisk mark (*) was calculated based on the raw data in the original study. The others, crude or adjusted, were extracted from the original paper.

Supplementary Table 3. Published studies of the total cholesterol and the risk of liver cancer

Studies	Study design	cases/ participants	Follow-up	Reference (mg/dL)	Index (mg/dL)	Adjusted HR (95% CIs)		P for trend*	Confounders for adjustment
						Men	Women		
Iso, 2009, Japan ⁴³	Population-based cohort (JPHC Study)	125 /33,368	12.4 years	180–199	<160	2.62 (1.44–4.76)	4.15 (1.70–10.16)	Men < 0.0001 Women < 0.0001	1-10
					160–179	1.04 (0.52–2.07)	1.99 (0.82–4.85)		
					180–199	1	1		
					200–219	0.56 (0.24–1.28)	1.09 (0.44–2.68)		
					200–239	0.49 (0.16–1.44)	0.41 (0.11–1.52)		
					> 240	-	0.80 (0.28–2.27)		
Ahn, 2009, Finland ⁴²	Placebo-controlled, double-blinded primary prevention trial in male smokers (ATBC)	191/29,093	18.0 years	< 203.9	< 203.9	1	-	P=0.0007	1-5, 11-17
					203.9-227.6	0.69 (0.46-1.05)	-		
					227.7-249.2	0.63 (0.41-0.97)	-		
					249.3-276.6	0.56 (0.36-0.88)	-		
					> 276.7	0.66 (0.43-1.01)	-		
Kitahara, 2011, Korea ⁴⁴	Prospective study of Korean men and women (Korean NHIC)	10,161/1,189,719	12.7 years	< 160	< 160	1	-	Men < 0.001 Women < 0.001	2-5, 13, 18
					160-179	0.69 (0.65-0.74)	0.63 (0.54-0.72)		
					180-199	0.62 (0.58-0.66)	0.50 (0.44-0.58)		
					200-239	0.48 (0.45-0.51)	0.37(0.32-0.42)		
					≥ 240	0.42 (0.38-0.45)	0.32 (0.27-0.39)		

JPHC Study = The Japan Public Health Center-based Prospective Study, ATBC = The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Korean NHIC = The Korean National Health Insurance Corporation Medical Evaluation. *Tests for linear trend were conducted by treating the total cholesterol as a continuous variable in the multivariable models. Confounders for adjustment: 1 = age, 2 = BMI, 3 = smoking, 4 = ethanol intake, 5 = hypertension, 6 = diabetes, 7 = hyperlipidemia medication use, 8 = total vegetable intake, 9 = coffee intake, 10 = public health center, 11 = intervention, 12 = level of education, 13 = physical activity, 14 = Saturated fat intake, 15 = polyunsaturated fat intake, 16 = total calorie, 17 = serum HDL cholesterol, 18 = fasting serum glucose.

Supplementary Table 4. Published trials of statin use as adjuvant in treatment of liver cancer

Studies	Study design	Patients population	Intervention	Control	Overall survival of intervention (months)	Overall survival of control (months)	Kaplan-Meier and log-rank test
Kawata, 2001, Japan ⁴⁹	Prospective, randomized, open label study	Patients with advanced liver cancer after TAE procedure, n = 83	Pravastatin 20-40 mg + 5-FU 200 mg QD, n = 41	5-FU 200 mg QD, n = 42	Median 18	Median 9	<i>P</i> = 0.006
Lersch, 2004, Germany ⁵⁰	Prospective study	Patients with advanced liver cancer, n = 58	Pravastatin 40-80 mg QD, n = 20	A: Octreotide, n = 30; B: Gemcitabine, n = 8	Median 7.2 (95% CIs 2.9-11.5)	A: Median 5(95% CIs 2.2-7.8); B: Median 3.5 (95% CIs 2.2-4.9)	A: <i>P</i> = 0.09; B: <i>P</i> = 0.03
Graf, 2008, Germany ⁵¹	Prospective, non-randomized, open label study	Patients with advanced liver cancer after TACE, n = 183	Pravastatin 20-40 mg QD, n = 52	No treatment, n = 131	Median 20.9 (95% CIs 15.5-26.3)	Median 20.9 (95% CIs 15.5-26.3)	<i>P</i> = 0.003
Georgescu, 2011, Romania ⁵²	Prospective, randomized, open label study	Patients with advanced liver cancer, n = 72	Lovastatin 40 mg + Sorafenib 400 mg QD, n = 39	Sorafenib 400 mg QD, n = 33	Mean 12.15±0.76	Mean 10.85±0.82	Non-significant

TAE = Transcatheter Arterial Embolization; TACE = Transhepatic Arterial Chemotherapy and Embolization).

Supplementary Table 5. Ongoing clinical trials of statin use as adjuvant in treatment of liver cancer

Studies	Year	Location	Phase	Study design	Condition	Intervention	Control	Estimated Enrollment	Resist number	Status
ESTAHEP-2010	2011	Spain	II	Multicenter, prospective, randomized, double-blind, placebo-controlled study	Advanced liver cancer	Sorafenib 400 mg BID + Pravastatin 40 mg, QD	Sorafenib 400 mg BID + placebo QD	216	NCT01418729; EUCTR2010-024421-21-ES	Recruiting
PRODIGE 21	2011	France	II	Multicenter, prospective, randomized, open label study	Liver cancer with Child-Pugh B Cirrhosis	A: Sorafenib 400 mg BID; B: Pravastatin 40 mg, QD; C: Sorafenib 400 mg BID + Pravastatin 40 mg, QD	Best supportive care	160	NCT01357486	Recruiting
JOUVE PHRCK 2009	2013	France	III	prospective, randomized, open label study	Liver cancer with Child-Pugh A Cirrhosis	Sorafenib 800 mg BID + Pravastatin 40 mg, QD	Sorafenib 800 mg BID	474	NCT01903694; NCT01075555	Recruiting



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	no
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	7



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9 Table1,2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10, Suppl. Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figure 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	NA

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>